2008 Full Report

Comments

Transcription

2008 Full Report
Financial Highlights
Boehringer Ingelheim group of companies
2008
2007
change
11,595
10,952
6 %
Europe
33 %
33 %
Americas
48 %
50 %
Asia, Australasia, Africa
19 %
17 %
96 %
96 %
4 %
4 %
Research and development
2,109
1,900
11 %
Personnel costs
3,004
2,886
4 %
41,300
39,800
4 %
Operating income
1,980
2,100
- 6 %
Operating income as % of sales
17.1%
19.2 %
Amounts in millions of EUR, unless otherwise indicated
Net sales
by region
by business
Human Pharmaceuticals
Boehringer Ingelheim
Animal Health
Annual Report 2008
Income after taxes
Annual Report 2008
www.boehringer-ingelheim.com
Average number of employees
1,428
1,812
12.3 %
16.5 %
4,703
3,372
42.2 %
35.0 %
1,997
2,392
-17 %
Investments in tangible assets
665
654
2 %
Depreciation of tangible assets
453
432
5 %
Income after taxes as % of sales
Shareholders’ equity
Return on shareholders’ equity
Cash flow
-21 %
39 %
Value through Innovation
Value through Innovation
Top 5 products — Prescription Medicines
30234/03/09
Net sales 2008
nopq
Top 5 products — Consumer Health Care
in millions of EUR
change
Net sales 2008
in millions of EUR
change
spiriva®
2,070
+16 %
micardis®
1,219
+15 %
dulcolax®
134
+7 %
mucosolvan®
125
+7 %
flomax®/alna®
pharmaton®
1,075
+5 %
115
+21 %
mirapex®/sifrol®
752
+17 %
buscopan®
99
+24 %
combivent®
553
-15 %
zantac®
92
-17 %
Financial Highlights
Boehringer Ingelheim group of companies
2008
2007
change
11,595
10,952
6 %
Europe
33 %
33 %
Americas
48 %
50 %
Asia, Australasia, Africa
19 %
17 %
96 %
96 %
4 %
4 %
Research and development
2,109
1,900
11 %
Personnel costs
3,004
2,886
4 %
41,300
39,800
4 %
Operating income
1,980
2,100
- 6 %
Operating income as % of sales
17.1%
19.2 %
Amounts in millions of EUR, unless otherwise indicated
Net sales
by region
by business
Human Pharmaceuticals
Boehringer Ingelheim
Animal Health
Annual Report 2008
Income after taxes
Annual Report 2008
www.boehringer-ingelheim.com
Average number of employees
1,428
1,812
12.3 %
16.5 %
4,703
3,372
42.2 %
35.0 %
1,997
2,392
-17 %
Investments in tangible assets
665
654
2 %
Depreciation of tangible assets
453
432
5 %
Income after taxes as % of sales
Shareholders’ equity
Return on shareholders’ equity
Cash flow
-21 %
39 %
Value through Innovation
Value through Innovation
Top 5 products — Prescription Medicines
30234/03/09
Net sales 2008
nopq
Top 5 products — Consumer Health Care
in millions of EUR
change
Net sales 2008
in millions of EUR
change
spiriva®
2,070
+16 %
micardis®
1,219
+15 %
dulcolax®
134
+7 %
mucosolvan®
125
+7 %
flomax®/alna®
pharmaton®
1,075
+5 %
115
+21 %
mirapex®/sifrol®
752
+17 %
buscopan®
99
+24 %
combivent®
553
-15 %
zantac®
92
-17 %
Contents
2 The shareholders’ perspective
4 Key aspects 2008
8 Corporate bodies
Corporate
Responsibility
The ethical principles that guide
our company have created a
culture of corporate responsibility
and commitment. page 28
10 Group Management Report
Comparison of balance sheets/
financial data 1999—2008 (in millions of EUR)
30 Corporate Responsibility
30 Caring for our neighbours – “We care”
32 Environmental protection and occupational safety
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
400
344
322
302
242
267
233
554
547
539
1,992
2,217
2,467
2,840
2,767
2,712
2,900
2,886
2,972
3,177
849
1,135
1,008
1,689
2,462
2,756
3,396
3,043
1,638
1,739
3,241
3,696
3,797
4,831
5,471
5,735
6,529
6,483
5,157
5,455
944
1,021
1,014
971
1,000
1,085
1,229
1,280
1,387
1,561
1,870
1,938
2,314
2,360
2,537
2,477
3,013
3,137
2,912
3,496
459
477
1,002
1,055
1,134
1,333
1,247
945
1,015
1,312
Current assets
3,273
3,436
4,330
4,386
4,671
4,895
5,489
5,362
5,314
6,369
Total assets
6,514
7,132
8,127
9,217
10,142
10,630
12,018
11,845
10,471
11,824
Liabilities and equity (as of 31.12.)
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
Financial assets
Fixed assets
Inventories
Accounts receivable (incl. deferred charges and deferred taxes)
Our own research and
development continues to be
the major driver of innovative,
new medicines. page 44
30 Caring for patients – The viramune® Donation Programme
Intangible assets
Tangible assets
Research & Development
Corporate Responsibility
Assets (as of 31.12.)
Cash and cash equivalents (incl. securities)
39 Our people
Research & Development
46 Our R&D strategy
48 Our R&D sites
51 Non-clinical research and development
53 From test tube to bioreactor – A seamless path for biopharmaceuticals
53 Clinical development
56 2008 – The year of landmark trials
58 Bridge to academia
Human
Pharmaceuticals
Shareholders’ capital
332
211
200
178
178
178
178
178
178
178
1,982
2,362
2,753
2,818
3,139
3,297
2,940
3,275
1,385
3,101
Net income
320
379
401
537
529
888
1,491
1,722
1,809
1,424
Total equity
2,634
2,952
3,354
3,533
3,846
4,363
4,609
5,175
3,372
4,703
0
0
1
203
188
193
216
188
167
190
Group equity
2,634
2,952
3,355
3,736
4,034
4,556
4,825
5,363
3,539
4,893
Provisions (incl. deferred taxes)
2,631
2,932
3,150
3,568
3,963
4,172
4,958
4,641
4,726
5,120
Reserves (incl. currency conversion difference)
We are committed to the goal
of serving humankind through
new drugs and therapies. page 62
Minority interests
60 Our business
Human Pharmaceuticals
64 Highlights Branded Prescription Medicines*
67 Highlights Generic Prescription Medicines
68 Highlights Consumer Health Care
Liabilities (incl. deferred charges)
1,249
1,248
1,622
1,913
2,145
1,902
2,235
1,841
2,206
1,811
Total liabilities
3,880
4,180
4,772
5,481
6,108
6,074
7,193
6,482
6,932
6,931
Total liabilities and equity
6,514
7,132
8,127
9,217
10,142
10,630
12,018
11,845
10,471
11,824
Product Supply and Industrial Customer
74 Biopharmaceuticals
Product supply and
Industrial Customer
76 Pharmaceuticals Production
78 Pharma Chemicals
79 Manufacturing excellence in our centre for global animal health vaccines
Animal Health
81 Highlights Animal Health
84 Samples of the product portfolio
106 Consolidated Financial Statements 2008
108 Overview of the major consolidated companies
110 Consolidated balance sheet
Animal Health
With innovative veterinary
medicines that accommodate the
needs of both man and animal,
we are a reliable partner for ­animal
owners and veterinarians. page 80
We produce drugs for our own Human
­Pharmaceuticals business in a globally
coordinated production network.
Furthermore we offer customised
manufacturing services to our indus­trial
customers. page 70
Summary of selected financial data
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
Net sales
5,086
6,188
6,694
7,580
7,382
8,157
9,535
10,574
10,952
11,595
Operating income
655
800
980
1,082
901
1,372
1,923
2,140
2,100
1,980
Operating income as % of net sales
12.9
12.9
14.6
14.3
12.2
16.8
20.2
20.2
19.2
17.1
Income after taxes
320
379
401
551
537
908
1,514
1,729
1,812
1,428
Income after taxes as % of net sales
6.3
6.1
6.0
7.3
7.3
11.1
15.9
16.4
16.5
12.3
Return on shareholders’ equity (in %)
13.8
14.4
13.6
16.0
15.0
23.1
34.2
37.4
35.0
42.2
Equity ratio (in %)
40.4
41.4
41.3
38.3
37.9
41.0
38.4
43.7
32.2
39.8
Cash flow
111 Consolidated profit and loss statement
737
791
1,117
1,049
1,059
1,430
2,069
2,317
2,392
1,997
Financial funds
1,055
1,094
1,645
2,645
3,516
4,015
4,585
3,934
2,581
2,932
Personnel costs
1,527
1,749
1,916
2,175
2,252
2,443
2,671
2,836
2,886
3,004
30.5
29.9
28.0
26.8
26.4
25.9
34,221 35,529
37,406
38,428
39,800
41,300
112 Cash flow statement
Personnel costs as % of net sales
113 Statement of changes in group equity
Average number of employees
114 Notes to the consolidated financial statements
Research and development costs*
132 Auditor’s Report
R&D as % of net sales
Flap Comparison of balance sheets / financial data 1999–2008
* The patient reports are authentic reports which refer to personal
experience only. Please note that other patients may experience
different treatment results. Individual treatment regimes have always
to be discussed between patient and physician case by case.
28.3
28.6
28.7
27,325
27,980
31,843
826
968
1,019
1,304
1,176
1,232
1,360
1,574
1,900
2,109
16.2
15.6
15.2
17.2
15.9
15.1
14.3
14.9
17.3
18.2
Investments in tangible assets
377
497
548
634
516
427
532
596
654
665
Depreciation of tangible assets
256
288
305
340
354
377
439
419
432
453
* As���������������������������������������
of the year 2008, costs for phase IV clinical
����������������
trials
are included in R&D costs, among other expenses.
The 2007 figure was adjusted accordingly.
please turn over
30.0
26,448
Our core principles – Leitbild shareholders’
perspective
Boehringer Ingelheim has been a successful, familyowned business for more than 100 years and intends
to remain so for the second century of its existence.
Although it is impossible to predict the future precisely,
we are actively and creatively facing the changing
tasks and challenges, building on our experiences and
achievements. This gives us the strength, direction
and confidence to shape our future. We have committed
ourselves to the goal of serving humankind through
research into diseases and the development of new
drugs and therapies. In this endeavour the future of
our company will depend on its innovative capability.
In all our activities we safeguard our employees,
facilities and the environment from harmful influences,
conserve natural resources and promote environmental
awareness. Parallel to pursuing these goals we seek
to foster economic and social well-being in the countries
and communities where we do business. In order
to realise our goals, we must be financially successful,
be willing to make the necessary changes, and be
critically receptive to new ideas and developments.
Maintaining and improving the performance of the
company take precedence over maximising earnings
in the short term.
The shareholders’ perspective
We, the shareholders of Boehringer Ingelheim, regard ourselves as being actively engaged in the
corporation and its future development as an independent, family-owned company. And we have
the goal that drives us: we want to serve humankind through research into diseases and the
development of new drugs and therapies. The future of our company thus depends directly on its
innovative capability. Our employees are the guarantors of this capability and our most important
corporate asset. They form the core of our unique corporate culture as a family-owned company,
which we wish to preserve.
Continual and sustained further development of our company offers the potential for Boehringer
Ingelheim to secure and extend our position as a global, independent company with a business
model based on organic growth. Its basis will be established, on the one hand, by a strong pipeline
of innovative products from our own research and development and, on the other hand, by selling
the products successfully in a market characterised by intense competition.
We shareholders have provided both the financial means and a stable strategic framework for this
continuous growth and sustainable alignment of the company. And, as shareholders, we note
with appreciation and satisfaction that our company has also realised our ambitious goals and
expectations for 2008.
Given our long personal cooperation, it is a matter of importance to us to express our special
gratitude to the members of the Board of Managing Directors, who were in charge until the end
of 2008. They hand on a successful company that is well-equipped for the future.
The good results of the past are both motivation and mission for the fourth generation of shareholders. We regard ourselves as stewards of sustainable success.
Safeguarding the sustainability of our company is also a challenge we face, and the company must
assert itself in an increasingly volatile business environment. Last year, 2008, stands for the start
of a period in which the general business environment is undergoing significant change. The
internal preconditions exist to continue our successful growth in the years ahead. However, for us
too, the impact of the financial crisis and the consequent economic crisis cannot be assessed.
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Christian Boehringer
In the medium-term future, a challenge confronting our company will arise from the expiry of
patent protection for several drugs, which will have a negative impact on our revenues. At the same
time, however, we are justifiably confident of being in the favourable position to bring new and
innovative drugs to the market. However, the investment necessary for this will also reduce our
earnings. And with weakening growth rates and increased cost control over healthcare budgets in
the traditionally most important pharmaceutical markets, we must concentrate more on the
growing markets and their specific requirements.
This prospect represents the basis of a new chapter in Boehringer Ingelheim’s company history that
we will now open with the Board of Managing Directors.
As shareholders, we wish to look ahead together with the members of the Board of Managing
Directors and, appreciative of the current success, to identify future challenges and jointly
commit to continually developing our way of working and our business model in order to remain
­sustainable. At the same time, we are determined to preserve our company’s fundamental values.
Christian Boehringer
Chairman of the Shareholders’ Committee
The shareholders’ perspective
Key aspects 2008
2008 was again a successful year for Boehringer Ingelheim. Despite the changing global pharmaceutical market and the crisis of the international financial system, we continued to stay on a
growth path.
The success of Boehringer Ingelheim as an independent and dynamically growing pharmaceutical
company was maintained, and in 2008 we also grew above average and outpaced the world market
for the ninth consecutive year. And of greatest importance is that our innovative medicines help
millions of patients.
As in previous years, in 2008 we also advanced our projects in late stage clinical development with
continuously increasing investments in research and development and thereby securing our future.
Our business results
Our corporation-wide net sales in 2008 amounted to EUR 11,595 million. In local currency terms,
we posted growth of 9.5 %. In euro terms, growth was 5.9 %.
In our prime business area, Human Pharmaceuticals, Prescription Medicines’ sales rose by 9.1 %
in local currency terms to EUR 11,128 million (5.5 % in euro terms). We are one of the fastest
growing pharmaceutical companies worldwide. We have achieved a 2 % share (according to the IMS
Health database) of the world market, thereby further consolidating our position among the leading
international pharmaceutical companies.
As foreseen, our R&D expenditure increased disproportionately in 2008 (+11% compared to the
previous year). Hence, our operating income of EUR 1,980 million decreased by – 5.7 % compared
to the previous year. This corresponds to a return on sales of 17.1 %. We are pleased that all our
core products achieved good growth in 2008 and once again improved their market position.
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Wolfram Carius, Andreas Barner, Engelbert Tjeenk Willink, Hubertus von Baumbach
(from left to right)
Our blockbuster products each with net sales of more than USD 1 billion, spiriva®, micardis®,
flomax®/alna® and mirapex®/sifrol®, together posted net sales of more than EUR 5 billion,
resulting in average growth of more than 10 % compared to the previous year.
Our self-medication business segment Consumer Health Care (CHC) also developed positively
in 2008, with growth of 5.4 % in local currencies (4.3 % in euro terms) to EUR 1,190 million.
This business contributed 10.3 % to the company’s net sales.
Our business segment Industrial Customer posted gratifying growth (12.3 % in local currencies,
10.8 % in euro terms), with net sales of EUR 819 million, and contributed 7 % to the company’s
net sales. Biopharmaceuticals contributed the biggest share, with net sales increasing by
22.8 % to EUR 569 million. Boehringer Ingelheim is a leading company in the development
and ­manufacture of biopharmaceuticals.
Besides Human Pharmaceuticals, our important business area, Animal Health, posted
­extraordinary growth in net sales of 19.5 % in local currencies (14.4 % in euro terms) to EUR 467
million, making Boehringer Ingelheim one of the fastest growing animal health companies.
Our landmark trials
In 2008, Boehringer Ingelheim published the results of the landmark trials ontarget™, profess®,
transcend®, uplift® and ecass 3™.
We have provided evidence-based answers to some of the most challenging questions in medicine
today. Our trials will improve medical knowledge and management of three common causes
of death: heart disease, stroke and chronic obstructive pulmonary disease (COPD). These currently
claim the lives of over 20 million people each year and will be the three leading causes of death
by 2020.
Key aspects 2008
People are key
We are proud of our employees and very grateful for their achievements. The work climate in our
company is very good, and the attractiveness of Boehringer Ingelheim as an employer of choice
is widely acknowledged and was again confirmed last year in highly regarded, independent surveys.
In 2008, we succeeded for the seventh consecutive year in coming first in the VAA (Verband
angestellter Akademiker und leitender Angestellter in der Chemischen Industrie) most preferred
employer survey of executives in the German chemical and pharmaceutical industries.
Value through Innovation – our late stage development compounds
We conduct research and develop innovative medicines and therapies for the benefit of patients.
Our compounds in late stage clinical development made good progress in 2008, giving us the
confidence that we will soon be able to launch further new compounds from our own research
and development on the market.
In our pipeline in the area of metabolism we have convincing oral anti-diabetic compounds,
establishing the company in the field of medications for the treatment of type 2 diabetes.
Our oncology pipeline has also developed favourably and, with four compounds in development,
is well-filled.
New product launches
In 2008, Boehringer Ingelheim was granted marketing authorisation for pradaxa® in the
indication prevention of venous thrombo-embolic events in adults who have undergone total hip
or knee replacement surgery. We continue to evaluate the efficacy and safety of pradaxa® in
a range of thrombo-embolic disease conditions, including stroke prevention in patients with atrial
fibrillation (SPAF), in the treatment of acute venous thrombo-embolism (VTE), the secondary
prevention of venous thrombo-embolism and prevention of cardiac events in patients with acute
coronary syndrome (ACS).
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Outlook and commitment
We, the members of the Board of Managing Directors, together with all of the corporation’s
employees, want to reinforce the future viability of Boehringer Ingelheim in order to master
the challenges that will arise for the company. As anticipated, our earnings will in the medium-term
be burdened by patent expiries. At the same time, we will make investments for preparing the launch
of our new compounds, which will secure the long-term growth of the company. Furthermore, we
expect significant changes and increased volatility in the general business environment and we will
continuously monitor and actively counteract their potential impact on the company.
Our goal is to successfully position the company in a dynamic and changing business environment
in order to continue to offer patients the best possible medications for treating their conditions.
Andreas Barner
Hubertus von Baumbach
Wolfram Carius
Engelbert Tjeenk Willink
Key aspects 2008
Corporate bodies
Shareholders’ Committee
Board of Managing Directors
(until 31.12.2008)
Christian Boehringer
Chairman of the Shareholders’ Committee
Dr Alessandro Banchi
Chairman of the Board
Albert Boehringer
Corporate Board Division Chairman of the Board
Corporate Board Division Pharma Marketing
Christoph Boehringer
and Sales
Erich von Baumbach Jr.
Prof.* Dr Dr Andreas Barner
Vice-Chairman of the Board
Ferdinand von Baumbach
Corporate Board Division Pharma Research,
Development and Medicine
Dr Mathias Boehringer
Dr Hans-Jürgen Leuchs
Corporate Board Division Operations
Advisory Board
Corporate Board Division Animal Health
Prof. Dr Michael Hoffmann-Becking
Prof. Dr Marbod Muff
Attorney at Law, Düsseldorf
Corporate Board Division Finance
Chairman of the Advisory Board
Corporate Board Division Human Resources
Egbert Appel
Trustee, Martin Hilti Family Trust;
Board of Managing Directors
Member of the Board and
(from 01.01.2009)
Managing Director, Hilti Foundation
(from 01.01.2009)
Prof.* Dr Dr Andreas Barner
Chairman of the Board
Dr Rolf-E. Breuer
Corporate Board Division Chairman of the Board
Frankfurt (Main)
and Pharma Research, Development and Medicine
(until 31.12.2008)
Hubertus von Baumbach
Dr Andreas Kreimeyer
Corporate Board Division Finance and
Member of the Board of
Animal Health
Executive Directors and
Research Executive Director BASF SE
Prof. h. c. Dr Wolfram Carius
(from 01.08.2008)
Corporate Board Division Human Resources
and Operations
Prof. Dr Fredmund Malik
Chairman of the Board
Engelbert Tjeenk Willink
Malik Management Zentrum St. Gallen AG
Corporate Board Division Marketing
and Sales Human Pharma
* Republic of Austria
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Our corporate vision – “Value through Innovation”
The objectives and beliefs of Boehringer Ingelheim
can be summed up in a single phrase: Value through
Innovation. This vision has helped us to build on
our strengths and make the most of our distinctive
character. In a competitive and fast-changing world,
the value of products, services and companies is
constantly changing. Real customer value today can
only be created by constantly developing new solutions
and doing what we already do better.
Our company
We are a research-driven company dedicated to research­
ing and developing, manufacturing and marketing
pharmaceuticals that improve health and quality
of life. Our business areas consist of Human
Pharmaceuticals and Animal Health. We have 41,300
employees in 138 affiliated companies worldwide,
research and development (R&D) facilities in ten
countries and production plants in 16 countries.
R&D expenditure in Prescription Medicines corresponds
to more than 22% of net sales in this segment. Our
headquarters is at Ingelheim, the German town where
the family-owned company was founded in 1885.
Group Management Report
Business and operating
environment
for industrial countries. The situation on the
­financial markets has worsened severely. At the
same time, there has been a noticeable reduction
in worldwide consumer prices since the middle
Overview
of the year. Raw material prices, which had pre-
The economic environment deteriorated signifi-
viously caused the steep rise in inflation, fell
cantly in 2008. The problems on the US mort-
sharply as demand was decreased because of the
gage market that were already indicated in the
economy. On the foreign exchange market, the
year before, have since developed into a world-
US dollar reached an historic low against the
wide financial crisis. The expansion phase of the
euro in mid-2008, but stabilised at a much
­world­wide economy ceased ­ toward the end of
higher level at the end of the year. The Japanese
the third quarter of 2008 and was replaced by
yen also increased in value significantly against
an unusually sharp downward trend.
the euro. At the end of 2008, the exchange rate
After the worldwide economy grew by 3.7 % in
2002.
of the euro to the yen was at its lowest level since
2007, current estimates for 2008 are for growth
of only 2.5 %. Forecasts for 2009 predict that the
In Germany, the economic momentum slowed
economic situation will be further aggravated;
down considerably from the middle of the year
negative growth has already been predicted
onwards as a result of the turbulences on the
Net
Netsales
salesbybybusinesses
businesses2008
2008
(in(in
millions
millions
ofEUR)
EUR)
Net
sales byof
business
Net
Netsales
salesbybyregion
region2008
2008
(in(inmillions
EUR)
millions
EUR)
Net sales
by
regionofof
(in millions of EUR)
(in millions of EUR)
Medicines
Prescription
Medicines
Prescription
8,660
8,660
Care
Health
Consumer
Care
Health
Consumer
1,141
1,141
9,111
9,111
5,560
5,560
Europe
Europe
3,578
3,578
3,877
3,877
1,190
1,190
Biopharmaceuticals
Biopharmaceuticals
463
463
569
569
and
Chemicals
Pharma
and
Chemicals
Pharma
Production
Pharmaceuticals
Production
Pharmaceuticals
276
276
250
250
Health
Animal
Health
Animal
408
408
467
467
07070808
10
Americas
Americas
5,463
5,463
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Total
Total
Africa
Australasia,
Asia,
Africa
Australasia,
Asia,
1,911
1,911
10,952
10,952
2,158
2,158
07070808
11,595
11,595
worldwide financial markets. The gross ­domestic
industry. So far, no extraordinary risks to our
product, adjusted for price, grew by only 1.3 %
company have been identified. In this situation,
compared with the previous year, which was
we anticipate changes in the pharmaceutical in-
well below the level of growth for 2007 (2.5 %).
dustry, but no short-term intervention, owing to
The number of unemployed ­ people dropped to
the complex legislative procedures.
an average of 3.3 million for the year and is
thus still strongly marked by the positive devel-
The group sales of Boehringer Ingelheim ­totalled
opments in the first three quarters. Develop-
EUR 11,595 million (+5.9 %) in the reporting
ments at the end of the year have ­already shown,
­period. Unfavourable developments in exchange
however, that the economic slowdown will also
rates compared with the previous year placed a
become more apparent on the German employ-
burden of approximately EUR 365 million on
ment market.
the group sales. With adjustments for these negative exchange rate effects, worldwide sales of
In a market environment shaped by the turbu-
almost EUR 12 billion would have been achieved.
lences on the international financial markets,
This means that, on the worldwide pharmaceu-
worldwide pharmaceutical activities recorded
tical market, we achieved stronger growth than
growth in sales. Growth rates for the worldwide
the market for the ninth consecutive year. We
pharmaceutical market, adjusted for currency
were pleased that demand for our products
effects, fell again, however, according to the
­remained high, particularly in view of the finan-
­latest market data from market research insti-
cial crisis.
tutes for the last financial year. The reasons for
this development are partly the state regulation
Growth in the group of companies was once
of pharmaceutical activities and partly the
again supported by all three regions. The highest
­expiry of patent rights for some products. Like
percentage of growth was recorded in the
all other pharmaceutical companies, Boehringer
region Asia, Australasia and Africa (AAA), with
Ingelheim is also affected by this. Cost pressure
an ­increase in sales of around 13 %. Europe saw
on health systems leads to increased prescrip-
­virtually identical growth to 2007 (+8.4 %),
tion of generic drugs and tighter regulation of
while sales in the Americas region were only
the price of medicines. In addition, the patent
slightly higher than in the previous year (+1.8 %).
rights of profitable products are being attacked
The negative impact of the currency effects
increasingly early. The considerably lower prices
­mentioned above was felt strongly here.
of generic products that are subsequently produced impede the capital-intensive development
of innovative medicines. Despite these chang­es
Net sales by region
(in millions of EUR)
2008
2007
in overall conditions, Boehringer Ingelheim
Americas
5,560
5,463
will remain committed to research into new and
Europe
3,877
3,578
innovative pharmaceuticals.
Asia, Australasia, Africa
2,158
1,911
At present, there are only limited signs of the
Business with Prescription Medicines accounts
­effects that the turbulences on the international
for around 79 % of group sales at Boehringer
financial markets are having on worldwide eco-
Ingel­heim. This makes it the most important
nomic systems and thus on the pharmaceutical
business segment within the group of compa-
11
Group Management Report
nies. With adjustments for currency effects,
the results of the ontarget™ study. With
growth of more than 9 % was achieved in the
­f lomax®, used in the treatment of benign pros-
2008 financial year, thereby following up on the
tatic hyperplasia (BPH), sales increased by 5 %.
positive development of the previous years.
The share of this medication in the US market
was once again around 60 %. We obtained
Net sales
(in millions of EUR)
­market approval for pradaxa® (dabigatran
2008
2007 Change
Prescription Medicines
9,111
8,660
+5.2 %
Consumer Health Care
1,190
1,141
+4.3 %
Biopharmaceuticals
569
463 +22.8 %
Pharma Chemicals
etexilate), our new oral direct thrombin inhibitor. Initial sales in 2008 fulfilled our expectations for the medicine, which was developed by
us, and allow us to be optimistic for the future.
Our Consumer Health Care business achieved
and Pharmaceuticals
Production
250
276
-9.4 %
Animal Health
467
408 +14.4 %
further growth last year and recorded total sales
of around EUR 1.2 billion. On a local basis, this
corresponded to growth in sales of 5.4 %. The
most important brands, each of which achieved
The development of sales in the Prescription
sales of over EUR 100 million, were once again
Medicines segment was driven by the pleasing
dulcolax®, mucosolvan® and pharmaton®.
development of our strategic products, as in
buscopan® showed excellent growth in the
the preceding years. Our blockbuster products
2008 calendar year and almost reached sales of
that each generate sales of over USD 1 billion,
EUR 100 million. Overall, the core CHC brands
spiriva®, micardis®, flomax® and sifrol®/
showed very pleasing development.
mirapex®, achieved sales of more than EUR 5
billion in 2008 and grew on average by more
than 10 % compared with the previous year.
After our Animal Health business already
achieved ­excellent growth in 2007, the previous
year’s figures were significantly exceeded once
Our innovative COPD medication spiriva®
again in 2008. With growth in sales of 14.4 %
­increased its worldwide sales by 16 % to EUR
(19.5 % based on local currencies), we strength-
2,070 million in 2008 and thus achieved sales
ened our position on the market further and are
of more than EUR 2 billion for the first time.
in eighth place with a (provisional) worldwide
This means that it is once again the product with
market share of 3.5 %. The growth engine in the
the highest sales at Boehringer Ingelheim. The
Animal Health segment was our own develop-
­results published from the COPD milestone
ment ­ ingelvac circoflex®. Sales of the vac-
study uplift® will further strengthen the mar-
cine for pigs grew by more than 140 % to around
ket position of the anticholinergic. The primary
EUR 90 million.
growth engine within the group of products
considered to be the most important by the
In our Biopharmaceuticals business, sales ­ in-
group was sifrol®/mirapex®, with growth in
creased following a decline in 2007, owing to
sales of 17 %. In an intensely competitive market
alterations and extensions at our production site
segment, ­ micardis®, a medicine for the treat-
in Biberach. With growth of over 20 % to EUR
ment of high blood pressure, increased its sales.
569 million, the best sales in the history of this
Further growth is also expected here following
business segment were achieved in 2008.
12
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
In 2008, we were able to build on the success of
ents, which represents around 18.2 % of group
previous years, which confirms our strategic
sales (2007: 17.4 %). A total of EUR 2,016 ­million
­orientation. With innovative products, supple-
was spent in 2008 on research and development
mented by an extensive pipeline with promising
in the Prescription Medicines segment, the focus
new developments and motivated staff, we are
of our R&D activities (22.1 %).
ready for the challenges ahead and look to the
future with confidence.
Our own research forms the basis for our R&D
strategy. In addition, our portfolio is extended
Operating income decreased in the last financial
through targeted in-licensing and cooperations.
year. This was essentially due to the dispropor-
One important addition in the last financial year
tionately large increase in R&D costs (+11 %) and
was the partial acquisition of the biopharmaceu-
burdens caused by the unfavourable develop-
tical company Actimis Pharmaceuticals, Inc,
ment of the US dollar in 2008.
based in San Diego (California), USA. The com-
The most important earnings figures for 2008
for the treatment of asthma, AP768, which is
pany owns a leading active ingredient candidate
are as follows:
currently in phase I of clinical development.
Even before the current clinical trial, AP768 had
(in millions of EUR)
Net sales
Operating income
2008
2007
Change
11,595 10,952
+5.9 %
1,980
2,100
17.1
19.2
Return on net sales (as %)
-5.7 %
been proven to possess the potential for more
­effective mechanisms of action than the leukotriene receptor antagonists currently available on
the market. We continued our successful partnerships with the Belgian biotechnology company Ablynx NV, for research into Nanobodies®,
Research and development
the US company Xencor, Inc. (biological active
In line with our vision as a pharmaceutical
ingredients), the British company Vectura (pow-
­research company, we are firmly convinced that
der inhaler) and the US company Vitae Pharma-
innovation will also in future continue to be an
ceuticals (11beta-HSD1 inhibitors).
important driving force behind our growth. Our
personal and financial commitment is therefore
In accordance with our current strategy, we carry
to research into new and innovative active ingre-
out drug discovery and development at the four
dients for the treatment of diseases for which
previously mentioned R&D sites in seven major
only inadequate medical therapies are current-
therapeutic areas:
­ly available. We are therefore intent on both
strength­ening our core business and to pressing
• cardiovascular diseases
ahead with the optimisation of our current prod-
• respiratory diseases
uct portfolio.
• central nervous system diseases
• metabolic diseases
In the last financial year, an average of 6,788
• virological diseases
persons were employed at our R&D sites in
• oncology
Germany, the USA, Austria and Canada. In total,
• immunology and inflammation
over EUR 2.1 billion were invested here in the
­development and research of new active ingredi-
13
Group Management Report
In the field of the treatment and prevention of
thrombo-embolic diseases, we achieved crucial
­alteplase (actilyse®) is safe and effective even
success, confirming our commitment to R&D.
after the end of the permitted 3-hour window.
pradaxa® (dabigatran etexilate), our new oral
According to the study, patients can benefit from
direct thrombin inhibitor, an active ingredient
­alteplase up to 4.5 hours after the first symp-
developed by Boehringer Ingelheim and the first
toms of stroke begin. We are therefore aiming to
with a new kind of mechanism of action, has
extend the approval for actilyse®. The signifi-
­obtained market ­approval for Europe and for a
cance of this result is emphasized by the fact that
growing number of countries outside Europe.
the international medical journal The Lancet
Approval was ­ initially granted for the preven-
has chosen the publication of this study as
tion of venous thrombo-embolism (VTE) fol-
­“Paper of the Year 2008 (editors’ choice).”
lowing hip and knee ­replacement surgery. With
the re-­volution® clinical trial programme, in
In profess®, the largest study so far into the
which over 30,000 patients are participating
secondary prevention of stroke, the effectiveness
worldwide, we are aiming to obtain approval for
of the fixed combination of delayed dipyrida-
further indications. These include the preven-
mole/ASA (aggrenox®) was compared with
tion of strokes in patients with atrial fibrillation
clopidogrel. The results of the study showed that
(re-ly™: over 18,000 patients worldwide), the
the risk of a further stroke is comparable for the
treatment of acute VTE (re-cover™) and the
two treatment options. The combined risk of
secondary prevention of ­ VTE (re-medy™) as
stroke, myocardial infarction and death due to
well as acute coronary syndrome (re-deem™).
vascular diseases was also comparable.
In 2008, several major trials for the indications
With the results of the ontarget™ study we
of central nervous system diseases and cardio-
were able to prove that telmisartan (micardis®),
vascular diseases were concluded.
our angiotensin II receptor blocker (ARB), protects high-risk patients against cardiovascular
The ecass 3™ study proved that in the treatment
events just as well as the current gold standard,
of acute ischaemic stroke, thrombolysis with
ramipril. In a direct comparison, telmisartan
Research and development
2008*
2007
2006
2005
2004
Expenditure in millions of EUR
2,109
1,900
1,574
1,360
1,232
18.2
17.4
14.9
14.3
15.1
2,016
1,818
1,501
1,293
1,173
- as % of net sales
Prescription Medicines expenditure
in millions of EUR
- as % of Prescription Medicines net sales
Average number of employees
22.1
21.0
18.1
17.8
19.0
6,788
6,405
6,003
5,678
5,471
145
157
125
116
97
Investments in tangible assets (without
investments in infrastructure) in millions of EUR
*As of the year under review, costs for phase IV clinical trials are included in R&D costs, among other expenses.
The previous year’s figure was adjusted accordingly.
14
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
also proved to be significantly better tolerated.
Production
The results were confirmed by transcend®, a
Boehringer Ingelheim has a worldwide network
parallel study to ontarget™, in which almost
of 23 production sites for Human Pharmaceuti-
6,000 patients from 40 countries participated.
cals. Pharmaceuticals Production is the main
transcend® is the first milestone study in
focus with 18 sites. There are also additional
which the cardiovascular protective effects of an
production sites for Pharma Chemicals and Bio­
angiotensin II receptor blocker were tested and
pharmaceutical Production.
proved against a placebo in addition to standard
treatment in high-risk patients with intolerance
Pharmaceuticals Production is ­ re­spon­sible for
to angiotensin-converting enzyme (ACE) in­
the manufacture of our own products in the
hibitors.
­Human Pharmaceuticals business. Boehringer
Ingelheim has also established itself as a con-
In the field of respiratory diseases, the beta-
tract manufacturer for external partners through
­agonist bi 1744 successfully completed clinical
its excellent quality of service. In 2008, the oral
phase II. A large-scale phase III trial has been
thrombin inhibitor pradaxa® was successfully
commenced. A supplementary phase II trial is
launched by our Pharmaceuticals Production
also underway for the fixed combination of
­division in Ingelheim. The introduction of inno-
bi 1744 and tiotropium (spiriva®) in ­r espimat®,
vative products makes particular demands on
our already very successful long-acting anti-
the quality of processes. At our launch sites in
cholinergic for the treatment of chronic obstruc-
the USA and Germany we have the specialist
tive pulmonary disease (COPD). We expect the
knowledge needed to ensure that products are
combined programme to enter clinical phase III
made just in time. The LogiPack-Center at the
in 2009.
Ingelheim site in Germany will make a significant contribution to this in future. Through an
In 2008, we also received the results of our
investment of EUR 49 million, we have created a
COPD milestone study uplift®. These show that
highly modern and extremely ­ efficient packag-
treatment with tiotropium leads to a lasting ­ im­-
ing centre, which will give us further competi-
provement in lung function over four years and
tive advantages. In addition, around EUR 65
increased survival rate. 5,993 male and female
million has been invested in a first module for
patients with COPD took part in the study.
the production of pradaxa®. We will continue
In the field of diabetes treatment, our compound
for the expansion of our capacity, in order to
to make funds available in the next few years
bi 1356 (ondero®), a DPP-4 inhibitor, success-
­guarantee the supply of the market and to fulfil
fully entered clinical phase III. All the necessary
increasing regulatory conditions.
studies for approval for the indication of type 2
diabetes were commenced worldwide. Our
We aim to improve efficiency and flexibility
­development programmes in the field of oncol-
within our production network in order to
ogy are also on schedule. Further progress ­
­remain competitive in future. Our product costs
has been made here with the preparation and
are competitive and at a low level compared
commencement of phase III trials for the two
with the rest of the industry. The results of a
compounds bibw 2992 and bibf 1120 (desig-
business process excellence initiative and
nated brands ­tovok® and vargatef®).
­insights gained from tried and tested methods
15
Group Management Report
such as lean manufacturing support our ­actions.
guarantee the practical implementation of our
In connection with this, we sold our production
principles. The minimum standards for this are
site in Reims, France. Our decision will ensure
the legal requirements of the respective coun-
future growth for the site and will guarantee
tries in which we operate, which we naturally
Boehringer Ingelheim a long-term supply of
respect and observe. With issues that we regard
high-quality products.
as meaningful and essential, we even aim to ex-
At Pharma Chemicals, we continued with the
Compliance with our principles and their suc-
ceed the requirements defined by legislators.
expansion of capacity at our sites in Fornovo,
cessful implementation is ensured through es-
Italy, and Petersburg, USA, especially for the
tablished processes in the Environmental, Health
production of captive active ingredients. Invest-
& Safety (EHS) division. In 2008, for example,
ment projects at the two sites with a total ­volume
11 audits were carried out in which various sites
of around EUR 160 million will be completed in
were checked to ensure their compliance with
2009. In the next few years, further investments
the guidelines issued and the correct function-
in chemical production totalling over EUR 490
ing of the systems. Along with statutory and
million are planned.
­internal regulations, Boehringer Ingelheim has
also committed itself to following the principles
Boehringer Ingelheim has been involved in the
that apply as part of the worldwide “Responsible
development and manufacture of biopharma-
Care” initiative in the chemical industry.
ceutical products for over 20 years. Our sites in
Vienna, Austria, and Biberach, Germany, have
One of Boehringer Ingelheim’s major projects in
since then developed 14 new biological entities
the field of energy efficiency in 2008 was the
(NBEs) into marketable products. This makes
­inauguration of the cold water storage facility at
us one of the most experienced contract manu-
our site in Biberach. This is one of the largest
facturers in biopharmaceuticals. ­ Total invest-
of its kind in Europe and makes a lasting contri-
ments of approximately EUR 60 million in 2008
bution to the protection of the environment. In
and planned investments of over EUR 400 mil-
addition to the economic advantages, around
lion for the next few years underline the
2,100 tons of carbon dioxide emissions can be
­importance of biopharmaceutical production for
avoided per year and the consumption of water
Boehringer Ingelheim.
at the site can be reduced by 21,500 m³ per year.
Environmental and employee protection
An important indicator of occupational safety at
The protection of our employees, our facilities
our sites is the accident rate relative to hours
and our environment from harmful influences,
worked. Through continual improvements, we
the conservation of natural resources and the
have managed to reduce the number of accidents
promotion of environmental awareness are of
to an average of 3.4 accidents for every million
central importance to Boehringer Ingelheim.
hours worked.
This is made particularly clear by the anchoring
of this principle in our company’s Leitbild.
The certification of our production sites by
Group-wide standards relating to occupational
part of our environmental and safety manage-
safety and the protection of the environment
ment in 2008. After our chemical plants in
­external organisations was also an important
16
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
France and Italy, our site in Malgrat, Spain, also
aim to continue recruit the best ­ employees in
received ISO 14001 certification, thereby con-
­future and tie them to us in the long term.
firming the quality of our internal standards.
For this purpose, wide-ranging ­ opportunities
The site in Fornovo, Italy, achieved the objective
for further development are available to our
of total quality management with the OSHA
­employees. We offer particularly talented
18001 certification of its safety management.
­employees challenging measures for the advancement of their social and managerial skills.
Employee reporting
Programmes with an international focus, such
As in the preceding years, the average number of
as the “International Management Development
employees rose in 2008. On average, 41,300 per-
Program” (IMDP), are also available as part of
sons were employed at Boehringer Ingelheim
the “BI Academy”.
during the year, which represents growth of
3.8 % compared with the previous year. The
We believe that we are in a good competitive
group’s personnel costs rose by 4 % in 2008.
­position with our remuneration system. In addition to the basic salary that is usual for the
Allowing young people to make a successful start
­market, we have established a performance-
to their professional lives has traditionally been
­related salary component, which represents a
a matter of particular importance to Boehringer
significant part of remuneration. The size of the
Ingelheim. In the period under review, we
performance-related pay depends essentially on
­offer­ed 673 young people an apprenticeship pro-
the success of the company and the attainment
gramme at our three German sites (2007: 660).
of individual targets. Extensive benefits, such as
Thereby we pay special attention to the goal of
company pension schemes and preventive health
also enabling young people with handicaps to
checks, also make our overall remuneration
participate in these apprenticeship programmes.
­system more attractive.
Boehringer Ingelheim’s employees are the most
The creation of an excellent framework for the
­important factor in the future success of the
compatibility of career and family is of major
company. We therefore believe we have a special
concern to Boehringer Ingelheim. An important
commitment to the active further development
instrument for the systematic and future-
and promotion of their abilities, in order to be
­oriented creation of a family-friendly corporate
equipped as well as possible for the challenges
culture is the “audit berufundfamilie” of the
that lie ahead. As part of the annual “Value
Hertie Foundation. Following basic certification
through Innovation Day” (VTI Day), proposals
in 2005, we received recertification/re-auditing
for improvements on the subject of coaching and
in the last financial year. We will continue to
development were drawn up at our head office
promote a family-friendly management culture
in Ingelheim and have already begun to be im-
in future and will support our employees with
plemented.
balancing work and family life.
Following the first worldwide employee survey
In 2008, Boehringer Ingelheim was once again
in 2007, we also used the insights gained to
among the top companies in several surveys
­implement improvements. A second survey will
identifying the best employers. The awards that
be carried out in 2009. All personnel measures
have been received in many countries confirm
17
Group Management Report
the attractiveness of our company and are also a
medication essential for survival. Another im-
continual incentive to offer our employees an
portant issue that we are involved in as a com-
excellent working environment in future.
pany is dealing with demographic change. In
Germany, Boehringer Ingelheim has since 2006
Corporate responsibility
supported the construction of premises that
Commitment to society and awareness of social
bring the generations together in the city of
responsibility have been firm components of
­Ingelheim and has provided assistance as a co-
Boehringer Ingelheim’s corporate culture for
operation partner with planning and implemen-
over a century. We regard ourselves, both in
tation.
­economic and in social matters, as an active
­promoter of welfare in the countries and regions
In addition to our company’s commitments,
in which we operate. As a “good corporate citi-
many of our employees are involved in numer-
zen”, we actively fulfil our responsibility towards
ous social projects on a voluntary basis in their
society as a whole, our patients, our employees
free time. We believe their personal commitment
and their families and with a high level of com-
is the expression of a basic attitude that matches
mitment.
Boehringer Ingelheim’s understanding of itself
and that we will promote and support where
One focus of Boehringer Ingelheim’s charitable
possible. During a special promotion day
work is combating the HIV/AIDS pandemic in
­employees from Ingelheim, for example, were
the most severely affected countries. With our
able to obtain information on important sub-
Donation Programme, we have provided our
jects concerning voluntary work and care.
AIDS medication viramune® free of charge
since 2000, which significantly reduces the risk
of transmission of HIV between mother and
child during birth. In this way, 169 individual
support programmes have been set up in 59
countries since the beginning of the initiative.
We observe our social responsibility in other
Results from operations,
financial position and net
assets
international initiatives geared towards the
par­ticular needs of people in various countries
Results from operations
and regions. In the USA, the Boehringer Ingel-
Last year, Boehringer Ingelheim was once again
heim Cares Foundation provides free medical
one of the fastest-growing companies worldwide
care together with AmeriCares. Employed peo-
in its reference group. This is shown by the
ple living below the poverty line, who would
­market data currently available, according to
otherwise not receive any medical care, are
which our growth was once again well above
looked after here. In the province of Sichuan in
that of the worldwide pharmaceutical market.
south-western China, which was devastated by
We were again in a position to achieve growth
earthquakes, we supported affected people
organically and with products from our own re-
in cooperation with a local partner, the R&D-
search and development. According to the latest
based Pharmaceutical Association Committee
market data, Boehringer Ingelheim has a world-
­(RDPAC), with both donations of money and
wide market share of approximately 2 %.
18
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Boehringer Ingelheim increased its net sales by
Prescription Medicines
5.9 % in the last financial year to EUR 11,595
Within our Human Pharmaceuticals business,
million. Growth in local currency terms was
the Prescription Medicines segment represents
even as high as 9.5 % (2007: 8.8 %). This means
the focus of our activities. In relation to the
that the development of our sales in 2008 in
­Human Pharmaceuticals business as a whole,
euro terms was again impaired by unfavourable
the segment represents around 82 % of sales.
developments in exchange rates. After the US
Sales of Prescription Medicines totalled EUR
dollar showed considerable weakness in the
9,111 million in 2008, following sales of EUR
­previous year, this trend continued in 2008.
8,660 million in the previous year. With growth
Compared with its average value in 2007, the US
in sales of 5.2 % (growth in local currencies:
currency declined in value by around 7 %.
9.3 %), the previous year’s growth (2007: 4.2 %)
­Because of the high proportion of our sales in
was exceeded.
this currency region (over 35 %), a burden of
around EUR 365 million was placed on group
Our strategic products, all of which recorded
sales. Without these negative effects, the group’s
positive growth, made a significant contribution
sales in 2008 would have totalled almost EUR
to this development (sequence in order of sales):
12 ­ billion. As in previous years, there were no
significant changes in 2008 in the companies to
Net sales
be consolidated, which means that any effects
(in millions of EUR)
2008
spiriva®
2,070
1,792
+16 %
micardis® (*)
1,219
1,059
+15 %
flomax®
from this on the analysis of sales are negligible.
Boehringer Ingelheim is focused on two businesses: Human Pharmaceuticals and Animal
Health. Human Pharmaceuticals encompasses
the segments Prescription Medicines (PM),
­Consumer Health Care (CHC) as well as Indus-
2007 Growth
1,075
1,020
+5 %
mirapex®/­sifrol®
752
644
+17 %
aggrenox®
313
278
+12 %
*As of 2008, without sales from business with partners.
The previous year’s figure was adjusted accordingly.
trial Customer. In 2008, Boehringer Ingel­heim’s
Human Pharmaceuticals business generated
Boehringer Ingelheim thus has four products
­total sales of EUR 11,128 million. This re­presents
with sales of over USD 1 billion, all of which
growth of 5.5 % compared with 2007. The pro-
­underlined their potential through further
portion of group sales that comes from Human
growth in the last financial year. mirapex®/­
Pharmaceuticals is 96 %.
sifrol® achieved the highest growth rate in
2008
2007
2006
2005
2004
Price/quantity/new introductions
9.7
7.9
12.1
17.4
16.1
Acquisitions and sale of business
-0.2
0.9
-0.3
-0.5
-0.5
Currency effect
-3.6
-5.2
-0.9
0.0
-5.1
Components of growth in net sales (as %)
19
Group Management Report
2008. With regard to sales and in terms of abso-
Net sales
lute growth, spiriva® is our most important
(in millions of EUR)
product, as in the previous year. The market
­position of our COPD blockbuster was further
strengthened by the results of the milestone
study uplift®, which were published in 2008.
We expect spiriva® to remain our main growth
engine in the next few years. Our products
2008*
2007* Growth
dulcolax®
134
125
mucosolvan®
125
117
+7 %
pharmaton®
115
95
+21 %
99
80
+24 %
buscopan®
+7 %
*As of 2008, switch to presentation of brands.
The previous year’s figures were adjusted accordingly.
­m icardis® and aggrenox®, for which important studies were also concluded in 2008
The Europe region represented the highest share
­(profess®, ontarget™ and transcend®), also
of sales in the CHC segment at Boehringer Ingel-
showed pleasing development and each recorded
heim, with sales of EUR 480 million (+2.1 %).
double-digit growth.
With regard to growth in sales, the AAA region
In the Prescription Medicines segment, regional
with sales of EUR 364 million in 2008. The
achieved the strongest growth rate of 10.5 %,
development varied considerably. While the
Americas region increased its sales to EUR 347
­Europe (+EUR 265 million) and Asia, Austral­
million, which represents growth of 7 % in local
asia, Africa (AAA) regions (+EUR 135 million)
currencies.
grew, sales in euro terms in the Americas region
remained at the same level as the previous year,
Industrial Customer
owing to the ­exchange rate development. Based
The third party business of Pharmaceuticals
on local currencies, however, our business grew
Production, Pharma Chemicals and contract
by 6.8 % in the Americas region. The countries
manufacturing by Biopharmaceuticals are com-
with the highest sales in this segment are the
bined under Industrial Customer business. In
USA, followed by Japan and Germany.
Net sales
total, sales in this business segment amount to
% share
EUR 819 million, around 11 % higher than in the
previous year. However, this increase is mainly
2008
2007
in 2008
Americas
4,495
4,502
49 %
site in Biberach, Germany, for technical altera-
Europe
2,640
2,374
29 %
tions and extensions, which had a negative
AAA
1,581
1,446
17 %
­impact on sales in the previous year. With sales
9,111
8,660
(in millions of EUR)
due to the temporary closure of our production
of EUR 569 million, contract manufacturing of
bio­technologically produced medication forms
Consumer Health Care (CHC)
In our business segment Consumer Health Care,
we increased net sales by 5.4 % compared with
the previous year, discounting currency effects.
Sales for 2008 totalled EUR 1,190 million (2007:
EUR 1,141 million). Sales of our core international brands showed positive development (in
order of sales):
20
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
the focus of our Industrial Customer business.
Animal Health
In our business Animal Health, we increased our
sales to EUR 467 million. This represents growth
of 14.4 % compared with the previous year –
without taking into account negative currency
effects. With adjustments for currency effects,
the Animal Health business recorded growth in
sales of 19.5 %. This makes us one of the fastest-
Depreciation increased by 4 % compared with
growing companies in the field of animal health
2007 and amounted to EUR 524 million (2007:
and puts us well above market growth of
EUR 504 million). Other operating expenses in-
­approximately 4.7 % (according to provisional
creased to EUR 5,198 million, which represented
market data). This remarkable success is largely
a rise of EUR 731 million (+16 %) compared with
due to our product ingelvac circoflex®,
the previous year. This included payments of
which achieved sales of around EUR 90 million
commission to our sales partner Pfizer, which
in 2008. Sales of the PCV2 vaccine (porcine
grew in line with the increase in sales of spiriva®.
circovirus type 2) for pigs thus more than
Operating income fell compared with the previ-
­doubled compared with the previous year.
ous year and amounted to EUR 1,980 ­ million.
The return on net sales was also below the previ-
In particular, the following product groups
ous year’s level at 17.1 %, owing to ­ additional
­contributed to worldwide growth:
­efforts in Research & Development (+EUR 209
million) and the negative currency effects
­already mentioned.
Net sales
(in millions of EUR)
2008
2007 Growth
ingelvac circoflex®
90
37
> 100 %
vetmedin®
29
24
+24 %
ingelvac® m. hyo
27
23
+14 %
metacam®
78
77
+1 %
The financial result amounted to EUR -40 million in 2008, which corresponds to a drop of
about EUR 300 million compared with the previous year. This was largely due to the share of
interest in additions to pension provisions and
the sale of some financial assets in the previous
Impressive growth of 44.4 % was achieved in the
year. As a result, income before taxes amounted
AAA region. In particular, developments on the
to EUR 1,933 million.
Japanese and Chinese markets contributed to
this success. Our sales also showed positive
Tax expenses amounted to EUR 505 million.
­development in the other regions. We have a
Here, it must be taken into consideration that,
share of 3.5 % in the global market for animal
due to regulations of the German commercial
health products (based on provisional market
code, personal taxes on group activities levied
data).
on the shareholders must not be shown as tax
Expenditure and income
drawals from accumulated group equity. Taking
Operating expenses were up by 9.3 % on the
this extraordinary effect into consideration, the
­previous year, at EUR 10,368 million (2007:
actual tax burden is markedly higher than the
EUR 9,484 million). Material costs amounted
figure shown in the profit and loss statement.
expenses. These are presented as part of with-
to EUR 1,642 million, which represents a slightly
lower proportion of total sales of 14.2 %.
Overall, the increase in sales did not compensate
­Personnel costs rose by EUR 118 million in 2008
for the effects of other operating expenses and
and totalled EUR 3,004 million (+4 %). This
the financial result. In summary, net income
­increase was mainly due to a higher average
­totalled EUR 1,424 million and was therefore
number of ­ employees, with around 1,500 addi-
lower than in the previous year (EUR 1,809
tional staff.
­million).
21
Group Management Report
Financial position
high cash flow from operating activities, all the
Boehringer Ingelheim’s financial management
prerequisites for the successful implementation
instruments and methods are aligned with in-
of our strategy are still fulfilled.
ternational standards for a modern industrial
company. The aim is to support the business
In 2008, several investment projects were com-
strategy of our company by providing or invest-
pleted at our sites in Germany and new projects
ing financial assets and taking account of the
were initiated. At our launch site in Ingelheim,
foreign exchange risk.
the first module for the production of pradaxa®
As a result of Boehringer Ingelheim’s interna-
centre (LogiPack-Center) was also officially
should be mentioned here. A new packaging
tional orientation, exchange rate fluctuations
opened. In Biberach, a logistics centre and a kilo
have a considerable impact on the measure of
laboratory for chemical development were
the company’s success. The exchange rate devel-
opened. A cold water storage facility to supply
opment of the US dollar represents the highest
the Biberach plant was also put into service. At
single risk. Within the framework of group-wide
our sites abroad, we continued with necessary
financial reporting, foreign exchange risk is reg-
extensions to capacity.
ularly investigated and systematically analysed.
To secure against risks from goods and services
Net assets
and other risks, derivative financial instruments
Total assets increased by EUR 1,352 million to
are employed. The manner and extent of these
EUR 11,824 million in the last financial year.
measures are regulated by the relevant group
­Intangible and tangible assets totalled EUR
guideline.
3,716 million and are completely covered by
­Boehringer Ingelheim’s group equity.
Cash flow for the period under review amounted
to EUR 1,997 million. Cash flow from operating
Financial assets amounted to EUR 1,739 million
activities dropped to EUR 1,901 million, which
at the end of the year, a slight increase on the
was mainly due to the lower income for the
previous year. The increase in inventories was
­period under review. It is, however, still consid-
slightly larger than the increase in group sales,
erably higher than the funds used for investment.
with adjustments for currency effects. Among
A total of EUR 665 million, which is similar to
other factors, this is due to the creation of initial
the previous year’s level, was spent on invest-
stocks for new product launches, such as
ments in tangible assets in 2008. Investments in
pradaxa®. Trade accounts receivable developed
intangible assets declined. Financing ­ activities
in proportion to growth in our business, with
resulted in an outflow of funds of EUR 935 mil-
adjustments for currency effects. This was
lion, which was largely due to the repayment of
achieved through ­ active management of the
loans. In total, financial assets ­increased by EUR
­duration of our ­ receivables. Liquid funds
351 million to EUR 2,932 million (+13.6 %). There
­(including current ­securities) totalled EUR 1,312
were no changes to cash flows as a result of the
million, which represented a significant increase
crisis on the international financial ­markets.
(2007: EUR 1,015 million).
In summary, it can be emphasised that with the
Group equity rose by 38 % to EUR 4,893 million.
existing liquidity, the financial structure and
The increase in this item is almost entirely due to
22
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
the retained profit for the year. Long-term disposable capital (equity, pension provisions and
Risk report
long-term liabilities) increased to EUR 7,289
million. This corresponds to around 62 % of the
The Boehringer Ingelheim group’s risk manage-
group’s total assets. This means that all intangi-
ment system has proved effective over recent
ble assets, tangible assets, inventories and some
years and the concept was unchanged in the
trade accounts receivable are once again covered
­reporting period. We have an established risk
by this item.
management system that aims to recognise risks
Other provisions increased to EUR 2,290 mil-
level. When looking at the risks identified, we
lion (+16 %). This is partly due to the increase in
endeavour to take into account the business
provisions for anticipated losses on derivative
­opportunities that arise on the other hand and to
financial transactions, owing to the rate prevail-
include them in the analysis.
and reduce them where possible to a reasonable
ing on the reporting date. Translation effects
when converting annual accounts, for example
The task of the group-wide risk reporting and
in Japanese yen, also contributed to the rise.
messaging system at Boehringer Ingelheim is to
­Liabilities also fell to EUR 1,761 million (2007:
systematically identify risks specific to the busi-
EUR 2,151 million), which was essentially due to
ness, particularly risks that threaten the survival
the repayment of loans.
of the company. Hereby, we ensure that all risks
known to us are reported, thoroughly analysed
The combined evaluation of the net assets,
and evaluated at all times. Following appropri-
­financial position and results of operations
ate classification, adequate counter-measures
shows that Boehringer Ingelheim is a soundly
are commenced and their implementation con-
financed and profitable company. In 2008, we
sistently monitored.
created a solid basis for our further business
­development.
Internal auditing conducted routine and
­extraordinary audits worldwide in 2008. The
major focus is on the efficiency of structures and
processes, securing assets, adherence to legal
and internal requirements and guidelines, the
Report on post-balance
sheet date events
functionality of systems and the effectiveness of
internal controls. The audit plan approved by
the Board of Managing Directors was consistently followed.
Since the end of the financial year 2008, we
have not become aware of any events that are of
Against the background of the financial crisis,
material significance to the group of companies,
potential risks for Boehringer Ingelheim were
or could lead to a reappraisal of its asset, finan-
analysed and evaluated in detail. No extraordi-
cial or earnings position.
nary risks to the company were identified, either
with regard to receivables or in terms of liabilities. We will continue to follow overall economic
developments and the effects of the financial
23
Group Management Report
crisis very closely, in order to identify possible
from this largely confirm our strategic guide-
risks at an early stage. Currency and interest rate
lines and objectives. The extend of the effects of
risks that arise because of our group’s interna-
the current developments in the worldwide
tional business relationships are examined at
economy, which, triggered by the crisis on the
regular intervals and limited by appropriate
financial markets, have led to a lasting decline
hedging strategies, such as foreign exchange for-
across all branches of industry cannot yet be
ward contracts and foreign exchange options.
­calculated for the pharmaceutical industry. We
We are not aware of any default risks going
expect the slowdown in the growth rate, which
­beyond the usual level for the market. Our hedg-
has been apparent for years, to intensify as a
ing strategies are used essentially for economic
­result of the difficult overall economic condi-
and political risks.
tions.
Risks in the area of environmental health and
Our core brands spiriva®, micardis®, flomax®
safety (EHS) are minimised preventively by
and mirapex®/sifrol® will continue to achieve
­adherence to our own very high safety standards.
stable growth in 2009. The results of the clinical
Appropriate emergency plans have been drawn
trials of spiriva® and micardis® that were pub-
up for possible incidents and are regularly
lished in 2008 confirmed the potential of these
practised and tested in terms of their quality. In
two products and will provide the basis for
addition, Boehringer Ingelheim has insurance
­further sales growth in 2009. Our stable product
coverage adjusted to the company’s risk profile.
portfolio therefore allows us to view the challenges of 2009 with confidence.
Apart from general business risks associated
with the industry as, already outlined in detail,
In the field of clinical development, we are an-
such as patent expiry, governmental price regu-
ticipating further important milestones in 2009,
lations and launches, we are currently not aware
such as the completion of the re-ly® study, the
of any risks that substantially threaten the fur-
largest in the re-volution® trial programme
ther development of Boehringer Ingel­heim’s
for our innovative oral coagulation inhibitor
business.
pradaxa®. We expect the study to be completed
in the first half of 2009, earlier than originally
planned. Other important development programmes in the indications of oncology, for the
active ingredients bibw 2992 and bibf 1120
Report on expected
developments
(designated brands tovok® and vargatef®),
and metabolic diseases, for the active ingredient
bi 1356 (ondero®), will be continued in 2009.
We also expect the results of the bouquet®
The good results for the last financial year con-
phase III trial programme to provide an impor-
firmed our internal planning guidelines. Our
tant stimulus for the approval of our research
operations and functions revised and validated
compound flibanserin in 2009. ­ Flibanserin is
the existing strategic guidelines during the
being investigated in the treatment of decreased
­period under review, within the framework of
sexual desire in women (HSDD: hypoactive
our planning processes. The insights gained
­sexual desire disorder).
24
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
For the 2009 financial year, we are anticipating
continuing to achieve our ambitious goals. We
further single-digit sales growth, despite the
consider it an obligation to our customers to
overall economic uncertainty mentioned above.
make effective and safe medicines available in
the future.
The challenges inherent in the pharmaceuti­cal
research industry also apply to Boehringer
Ingelheim. In addition to increasing cost pressure in health systems, which are less and less
willing to provide adequate remuneration for
the high cost of innovation, other challenges
include those caused by the expiry of ­patents (or
attacks on patents by generic drug manufac­
turers) and the need to develop new ­innovative
products successfully to market launch. With
the development projects mentioned and further
­approval stages expected in 2009, we believe
that we are well-equipped to deal with the
­anticipated arrival of rival generic versions of
the products flomax® and mirapex®/sifrol®
in 2010.
We have planned investments of over EUR 900
million for the 2009 financial year, which means
that the level of investment will be well above
that of the previous year. Our investment focuses
mainly on production and research. The main
emphasis of our activities is on worldwide
projects to expand capacity in order to ensure a
market supply for our new product launches.
For Boehringer Ingelheim, the declared goal is
to continue running the company as an independent, family-owned company in the long
term. We believe that our high level of innovation, which is based on a well-filled pipeline that
will lead to a series of new product launches in
the next few years, provides the basis for above­average long-term growth. Against this background, we will not only focus on successful
market launches but we will also continue to
pay particular attention to our company’s profitability. Our strategic ­ orientation is focused on
25
Group Management Report
Contents
} Saying it with flowers
} Corporate Responsibility
} Caring for patients – The viramune® Donation Programme
} Caring for our neighbours – “We Care”
} Environmental protection and occupational safety
} Our people
26
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Corporate Responsibility
lena gresser Her handicap is no obstacle to receiving a proper vocational qualification.
28
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
corporate responsibility
Saying it with flowers
Lena Gresser, a cheerful 22-year-old woman, travels to
work by train by herself from her hometown Mainz to
Boehringer Ingelheim’s main German site at Ingelheim, just
a short distance along the River Rhine. She is training to be
a florist in the company’s property and garden maintenance
department, which looks after a sprawling mix of production facilities, offices and laboratories in a park-like setting.
And the fact that she has Down’s syndrome is not preventing her from blossoming in her vocation. The pilot project
Lena is involved in aims to show that her handicap is no
obstacle to receiving a proper vocational qualification.
And the ­company, with important support from a number
of outside agencies, has integrated Lena fully into a working
team of 30 people. Her strong motivation, enthusiasm for
work and reliability have greatly impressed her colleagues.
“I really love coming to work,” says Lena. “Every day I learn
something new, and working with flowers is what I’ve
always wanted to do.”
Making Lena’s ambition to be a florist come true
tives respectively from the company and the staff
calls for long-term commitment by Boehringer
responsible for matters involving handicapped
Ingelheim and, more specifically, the team in
people.
which Lena has been embedded. Master gardener
Pia Winter, a lady well-known at Boehringer
The project for Lena, which started in 2008, is
Ingelheim for her green fingers, plays a lead role
just one example of the active corporate respon-
in providing support for Lena. Her close mentor-
sibility of Boehringer Ingelheim. It is the first of
ing of the trainee and fostering of her strengths
its kind in Rhineland Palatinate, the federal state
and talents is having a decisive impact on Lena’s
in which Boehringer Ingelheim is located. This
progress. Key support is also provided by Olaf
makes it only the second time in Germany that
Guttzeit and Doris Müller, special representa-
such a project has been initiated. The outside
29
Saying it with flowers
agencies supporting the project include the ZSL
Caring for patients – The viramune® Donation
Zentrum für selbstbestimmtes Leben (Centre for
Programme
Independent Living) in Mainz and the PEp Praxis
für Entwicklungspädagogik (The Development
Pedagogy Practice). Lena’s parents have also
helped in drawing up the project concept that is
also supported by the Labour Agency. Pia Winter,
whose personal commitment and understanding
is highly appreciated by everyone involved in the
We have an overarching
commitment to combating
the devastating AIDS
pandemic.
project, is very pleased with the way in which
Lena’s self-esteem has increased with recogni-
Our viramune® Donation Programme has for
tion of her work and the appreciation of her as a
eight years provided our non-nucleoside reverse
valuable member of the team. “She’s a highly
transcriptase inhibitor viramune® (nevirapine)
motivated young woman when it comes to learn-
to target the prevention of mother-to-child trans-
ing. And what’s wonderful to see is how much
mission of the HIV-1 virus in the countries most
more independent she is becoming.” l
in need. By 2008, this programme extended to
169 schemes in 59 countries.
Corporate Responsibility
For more information, please see
www.boehringer-ingelheim.com/
The ethical principles that
have guided our company
for well over a century
have created a culture of
corpor­ate responsibility
and commitment.
Corporate responsibility, as practised by our company, takes many forms. Of paramount import­
ance for us are the needs of patients. It is the
quest for innovation and medical breakthrough
which drives all our activities. We understand
corporate/news/information_material/
hiv_policy_paper.pdf l
Caring for our neighbours – “We Care”
Our activities cover many
areas, including child protection, healthcare projects,
educational programmes,
environmental protection
and emergency aid.
that the importance of our company directly
depends on the value of the therapies which we
The following are examples of some of our
can present to those in need of medical help. And
regional activities.
we fully grasp the central role of our employees
in all our endeavours.
The Americas
The US Boehringer Ingelheim Cares Foundation
Our social activities encompass patients, neigh-
partners with AmeriCares in a programme to
bouring communities and society at large. l
provide free medical care to the uninsured working poor in the Greater Danbury area, Connecticut, using a mobile clinic. This allows physicians
and nurses to voluntarily treat patients who
might otherwise go without care. The mobile
30
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
corporate responsibility
unit also responds to emergencies, such as when
Tanzanian lab technician upskills in Germany
it was sent to Texas in September 2008 to treat
victims of Hurricane Ike.
In Mexico, one of our projects in 2008 was an
ecological education programme for employees’
children – “Sembra uno arbol” – for reforesting
areas around the company site. The aim was to
generate environmental awareness and the need
for protecting green spaces among the coming
generation. Our highly successful project to provide healthier and more ecologically friendly
Ruth Ng’wananogu, a 30-year-old pharma­
wood stoves to poor Indian communities also
ceutical technician from Muhimbili University
continued into its second phase.
of Health and Allied Sciences, Dar es Salaam,
­Tanzania, was in Germany in 2008 to study
Our Brazilian organisation’s charitable activities
­basic technologies, procedures and equipment
included “Conectar”, a programme directed at
used in pharmaceutical development and pro-
disabled people with a view to helping them
duction at Boehringer Ingelheim. A diploma-
prepare to enter the jobs market, many for the
holder in pharma­ceutical sciences, Ruth was
first time.
the first of a team of laboratory technicians to
be trained at our German facilities to staff a
Asia, Australasia, Africa
new teaching and development laboratory at
Opened in 2005, the Boehringer Ingelheim
Muhimbili University in a project jointly imple-
Training and Facilitation Unit in Gaborone, Bot-
mented by the university, the German medical
swana, trains general practitioners, physicians,
aid organisation action medeor and the ­German
occupational health specialists, nurses, pharma-
(GTZ) Agency for Technical Cooperation. “When
cists, pharmacy technicians, medical store man-
I came to Germany, I had only little operational
agers and healthcare managers. In 2006, the first
experience. We in Tanzania are very skilled and
pharmacy student from Botswana commenced
eager to apply what we have learned. But our
studies at Rhodes University, Grahamstown,
opportunities are limited. My stay in Germany
South Africa, under a Botswana government
was very useful and I would clearly recommend
programme funded by Boehringer Ingelheim.
increasing such exchanges and activities.”
­Beneficiaries are required to work in the public
sector after completing their studies. Boehringer
Ingelheim also helped the Government of Bot-
sity of Cape Town, South Africa, Boehringer
swana to build an Infectious Disease Care Clinic
Ingelheim provides full financial support for
(IDCC) at Gumare which opened in 2007.
medical students from disadvantaged backgrounds.
In South Africa, the company supports the
“Turning the Tide” training and education pro-
Some 16,000 of Papua New Guinea’s 5.3 million
gramme for health professionals in HIV, which
inhabitants are infected with HIV, but few
has reached over 1,000 healthcare workers. The
infected people go to healthcare centres, so the
Boehringer Ingelheim Lung Institute at the Uni-
figures are likely to be vastly underestimated.
versity of Cape Town has been set up as a centre
With other pharmaceutical companies, the
of excellence to support clinical trials in infec-
Catholic AIDS Office, the Australasian Society
tious and respiratory diseases. Through its
for HIV Medicine (ASHM) and the government
­Student Education Programme with the Univer-
of Papua New Guinea, Boehringer Ingelheim has
31
Caring for our neighbours – “We Care”
Help after the earthquake disaster in China
responsibility regarding the dangers of smoking.
Our employees also volunteered in 2008 to give
a day to making toys for children from marginalised communities and broken families under
the programme of the “Soñar Despierto” foun­
dation.
In 2008, our Portuguese arm continued its longstanding support for the humanitarian organisation Habitat for Humanity with our employees
helping to build homes for those most in need.
Together with our local distribution partner,
China National Pharmaceutical Group, the
In Turkey, Boehringer Ingelheim launched a
timely supply of Boehringer Ingelheim medi-
“Creative Libraries” project in 2008, which helps
cines to the people of the disaster-hit Sichuan
pupils at disadvantaged elementary schools to
region was ensured.
become socially responsible, and encourages
their creativity by fostering reading and writing.
Our employee volunteers oversee the work of
implemented a project to train healthcare ­workers
the libraries and the pupils involved go on to be
under the auspices of the Collaboration for
ambassadors to their peers. The initial three
Health in Papua New Guinea.
schemes in 2008 were in the Bursa region. l
The earthquake disaster that struck Sichuan
Province in southwestern China in 2008 met
with an immediate response from our Chinese
country organisation and its employees. Cash
donations were made through the collective
­initiatives of the R&D-based Pharmaceutical
Association Committee (RDPAC), a non-profit
and non-governmental organisation. In addition,
a substantial amount of medicines for first aid
treatment were provided.
Environmental protection and
occupational safety
It is our conviction that
commercial success is only
possible if social and ecological factors are also taken
into consideration.
Besides its well-established programmes, including the annual free healthcare day for local
This principle is highlighted in our Leitbild
people near the company’s Bogor site, Boehringer
­(guiding corporate principles), in our worldwide
Ingelheim Indonesia in 2008 addressed the
“Principles for Safety, Quality and Environmental
issue of river health. In cooperation with the
Protection” and through our commitment to the
local authorities, company management and
principles of the “Responsible Care” initiative
­employees devoted a day to cleaning up the
of the chemical industry. For many years now,
nearby Cibalok River.
we have been setting global standards for
­envir­onmental protection and safe working con-
Europe
ditions, which have again been extended and
In Spain, Boehringer Ingelheim has joined forces
adapted in 2008. All our sites have set up appro-
with the town council of Sant Cugat, where the
priate management systems in an effort to
Spanish company is based, to provide education
­guarantee continual improvement, beyond the
and health promotion and encourage collective
legal requirements, on the basis of identification
32
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
corporate responsibility
of goals and appropriate action programmes.
Saving the vultures in India
­Regular audits conducted by Headquarters – ­
11 in 2008 – guarantee that standards are met
and systems continue to function properly.
Several current examples are provided below,
showing how we put our policies into practice.
Green chemistry
The production of drug substances is inevitably
associated with environmental impact in the
form of waste and emissions. Reducing these to
a minimum is generally in our own interest, as
this usually brings considerable savings in costs
at some later stage. The basis is laid during the
development of a new drug substance. While we
have taken this principle into account for many
years, our mission was highlighted in 2008 when
our US R&D site joined the “Green Chemistry
Initiative” of the American Chemical Society. The
aim of this initiative is to embed the sustainability factor in development even more firmly
through detailed information, formal procedures
and objectives.
Handling highly potent compounds
The handling of highly potent compounds is a
crucial issue in the pharmaceutical industry. In
a move to protect the health of our employees in
the production plants, we stipulate and monitor
compliance with the exposure limits for drug
substances. Many sites have already installed
technology that allows high-potency compounds
to be handled without respiratory protection. At
Ingelheim, Germany, alone EUR 5 million was
invested in such systems in 2008.
Implementation of new legal requirements
The focus of our activities in 2008 was on implementing the recent legal requirements according
to REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals). Following
close examination of our supply chain, we have
identified all the substances of significance to
REACH registration at our European sites and
have pre-registered these with the European
Chemicals Agency within the specified timeline.
33
Environmental protection and occupational safety
For many years, diclofenac, a pain-killing drug,
has been used for disease treatment in cattle in
India. As carcasses of dead animals are left to
vultures for traditional reasons, residues of the
drug lead to intoxication and death of the birds.
As a result, more than 99% of the indigenous
species have already vanished from India. Feral
dogs, rats and other vermin have taken over the
role of the vultures and are reproducing without
control, disseminating infectious diseases, like
rabies, threatening animal and man. Two renowned non-governmental organisations* have
convinced the Indian Government to ban the
veterinary use of diclofenac and to promote the
use of alternative drugs, non-toxic to vultures.
Based on our expertise in pain management,
Boehringer Ingelheim is supporting these initiatives with scientific advice and by providing
data for the use of meloxicam in cattle. With
this important help it will be possible to substitute diclofenac, considerably reducing the risk
for vultures, thus reversing an ecological disaster and social harm in one of the most populous
countries of the world.
* The Bombay Natural History Society and
The Royal Society for the Protection of Birds
We are also preparing for implementation of the
in the environment. We help allow the potential
UN’s Globally Harmonised System for the Clas-
risks to be assessed according to substantiated
sification and Labelling of Chemicals (GHS) that
scientific procedures. To this end, we prepare
is to be enacted in 2009 by the European Union.
environmental risk assessments for the registration of our medicines. Within the framework of
Medicinal products and the environment
a Swedish industrial initiative (see www.fass.se),
Our responsibility is not limited, however, to
Boehringer Ingelheim provides data on drug
­production conditions or the obvious, rigorous
­substances as well as on data of environmental
safety tests on our products for use in man.
significance. So far, no significant critical environmental effects have been identified for any of
The consumption of drugs, which are expelled
our drug substances.
from the patients’ bodies, ultimately leaves traces
Reinforcing the safety culture
A mere glance at our accident statistics shows that
we have been improving continually. In the past
Work accidents
few years, however, we have begun to plateau.
In order to implement improvements, it is now
necessary to focus our activities on the reinforcement of our prevailing safety culture.
The safety of our employees is our top priority;
accordingly, large-scale initiatives to further
improve the safety culture have been launched at
our sites in Germany, the USA and Brazil. In
2008, the Board of Managing Directors also
passed our Field Force Safety Policy, thus setting
a clear signal that we will increase our efforts to
The key parameter for our performance in occupational safety is the accident rate in relation
to hours worked. As the diagram shows, they
Work accidents
have decreased slightly, but ultimately on a par
Total work accidents: 242 (Fatality: 0)
with
previous
Absence
days:years.
3,323
improve safety for our field force which, at our
company, along with production, reports the
most frequent and most serious accidents.
Expectations of our business partners
We also expect our business partners – both suppliers and contract manufacturers – to meet
■ Frequency rate (= accidents
x 1 million hours / total labour hours)
■ Severity rate (= lost labour days
x 1 million hours / total labour hours)
­certain requirements in terms of environmental
protection and safety as well as in terms of social
issues. A guideline stipulates that the suppliers
80
must complete a questionnaire and submit to a
70
Boehringer Ingelheim audit, where appropriate.
60
In 2008, internal training measures helped
5
50
advance implementation of this guideline.
4
40
3
Awards and certifications
2
In 2008, the environmental management system
1
at our site in Malgrat, Spain, received ISO 14001
2000
01
02
03
04
05
06
07
08
certification, following the path of our other two
chemical sites in France and Italy. With the
34
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
corporate responsibility
­certification of our industrial safety management
Less can be more – Focus on energy efficiency
system according to OSHA 18001, in addition to
the previous certification of its quality and
­environmental management system, our site in
Fornovo, Italy, achieved its goal of Total Quality
Management. The site in Bogota, Colombia, was
actually recognised several times for excellent
environmental protection and safety performance and “Responsible Care” activities. For 2008,
Boehringer Ingelheim Chemicals in Petersburg,
Virginia, received a Governor’s Environmental
Excellence award.
No hazardous incidents
Boehringer Ingelheim has implemented a policy
Our various projects focus on efficient use of
for crisis management with the aim to protect our
employees, neighbours, customers, products,
energy and thus reduced CO emissions. The
²
latest milestone is the chilled water accumula-
company assets and the environment from harm
tor inaugurated in October 2008 at our
or damage. Our proactive approach is designed
R&D and Biopharmaceuticals site in Biberach,
to primarily prevent incidents or keep them from
­Germany. Here we took a completely new
escalating to critical levels. We have established
­approach with a concept of chilled water accu-
global and local crisis plans and we are ­effectively
mulation, unique in the pharmaceutical indus-
prepared to respond promptly to any ­emergencies.
try. The chilled water accumulator is charged
There were no notifiable incidents within the
from the existing chillers at night or in low-load
Corporation in 2008.
periods. The more constant production of cold
Our goals
energy avoids 2,100 t of CO emissions a year.
²
The EUR 3 million investment is offset by
Attention will continue to be focused on energy
­savings in energy and water consumption as
efficiency, safety culture and social aspects of
well as less maintenance. Generating cold
supplier qualification in the years ahead. We
­energy for controlled room conditions is one of
shall continue to invest in technologies in an
our most energy-demanding processes.
effort to protect employees handling highpotency compounds.
In 2008, construction began which will expand
the wastewater pre-treatment plant expansion at
Boehringer Ingelheim Chemicals in Petersburg,
Virginia, USA. This expansion will effectively
double the organic treatment capacity of the
plant while at the same time significantly improving the quality of the pre-treatment plant’s
effluent to a level where water re-use may become
a possibility.
Facts and figures
The graphs on the following pages show the
­figures for the last five years.
35
Environmental protection and occupational safety
Although we had already reached a high stand-
In this report we are only able to highlight part
ard in the past through technical or organisa­
of the range of our environmental protection
tional measures, we have still been able to
and occupational safety activities in 2008. We
im­prove certain figures.
­constantly deal with a number of further topics,
which are described on our website at
We achieved significant reductions in:
www.boehringer-ingelheim.com/ehs.
• the CO² balance
• with respect to volatile organic
carbon (VOC) emissions
• water consumption
• the chemical oxygen demand (COD) load
The CO² balance improved, thanks essentially
to the wood-fired power station in Ingelheim.
VOC emissions were further reduced following
commissioning of the thermal oxidiser for air
pollution control in Malgrat de Mar, Spain, in
2007, in particular, while we recorded a reduction in water consumption following completion
of the cooling circuits in Fornovo. Changes in the
product portfolio and the production process,
e. g. for dabigatran etexilate, resulted in a remarkable decrease of the chemical oxygen demand
(COD) in the inflow to wastewater treatment. By
inaugurating the expansion of the wastewater
Facts and figures
treatment plant in Ingelheim, we were addition-
The impact of our operations on the environ-
ally able to improve the efficiency and flexibility,
ment is described both in absolute figures and
to maintain the good COD degradation rates even
in relation to the production volume in the
for higher production volumes.
areas Pharma Chemicals, Pharmaceuticals
Production, Bio­pharmaceuticals and Animal
We also improved with respect to:
• energy consumption in relation
respective operations differs depending on the
to production
environmental impact. The reference year is
This is an effect mainly attributable to better
capacity utilisation. With respect to special waste
there has been a steep increase since 2006, while
the recycling rate has dropped. This can be
explained primarily by the change to disposal
of slag from the wood-fired power station in
Ingelheim. In the past, the slag was used for ­
rock-filling in underground salt domes which
is, according to official definition, regarded as
recycling. Since 2006, the slag has been sent to
landfill and therefore counts as special waste.
The slag accounts for almost a quarter of the
­special waste disposed of, and around half of the
special waste going to landfill.
36
Health, whereby the weight attached to the
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
2000.
In 2008, our pharmaceuticals production site
in France was divested and this site was not
­considered any more in the 2008 environmental performance figures.
¹2008 figure for COD inflow to WWTP at Ingelheim site based on calculation (assumption
98% degradation rate).
²Calculated CO² emissions attributable to our
company car fleet (sales force): approximately
76,000 tonnes.
corporate responsibility
Water
■ Water consumption (in millions of m³)
■ Water consumption index (in %)
Energy
■ Energy consumption (in millions of gigajoules)
■ Energy consumption index (in %)
120
120
100
100
80
80
10
60
5
8
40
4
6
3
4
2
2
1
2000
01
02
03
04
05
06
07
08
2000
Wastewater — chemical oxygen demand (COD)¹
■ COD load before treatment (in tonnes)
■ COD load after treatment (in tonnes)
■ COD load (after treatment) index (in %)
01
02
03
04
05
06
07
08
Disposed waste
■ Domestic waste (in tonnes)
■ Hazardous waste (in tonnes), incl. pharmaceutical waste
■ Disposed waste index (in %) ■ Recycling rate (in %)
100
120
80
100
60
80
10,000
40
60
8,000
20
30,000
6,000
22,500
4,000
15,000
2,000
7,500
2000
01
02
03
04
05
06
07
2000
08
Carbon dioxide (CO²)²
■ CO² indirect emissions (in 1,000 tonnes)
■ CO² direct emissions (in 1,000 tonnes)
■ CO² emissions index, direct emissions (in %)
(excluding company car fleet)
01
02
03
04
05
06
07
08
Volatile organic carbon (VOC)
■ VOC emissions, non-halogenated (in tonnes)
■ VOC emissions, halogenated (in tonnes)
■ VOC emissions index (in %)
120
100
100
80
80
60
500
60
1,000
40
400
40
800
20
300
600
200
400
100
200
2000
01
02
03
37
04
05
06
07
08
Environmental protection and occupational safety
2000
01
02
03
04
05
06
07
08
sabrina löffel VTI Day is an excellent platform to present proposals and ideas.
38
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
corporate responsibility
Our people
stellter Akademiker und leitender Angestellter
in der Chemischen Industrie) most preferred
Our guiding principles
– Leitbild – and our vision
“Value through Innovation”
are the fundamental drivers
of all our aspirations and
actions.
em­ployer survey of executives in the German
chemical and pharmaceutical industries. In the
poll, which covers questions on company strategy,
corporate culture, employment conditions and
personal satisfaction, we recorded the highest
scores in all categories. In recognition of this sustained achievement, the VAA awarded ­Boehringer
Ingelheim the first-ever “Cologne Chemicals
Prize” (see also table “Awards 2008”).
Both challenge us to realise the potential and
Responding to external developments
enhance the strengths of our 41,300 dedicated
In the face of unprecedented challenges to the
people around the world who share an aspiration
global economy and intensified competition, we
for innovation. These basic principles also inspire
are paying close attention to enhancing our com-
us to create working environments, which ener-
pany’s and our people’s capabilities to effectively
gise our employees in their pursuit of innovation,
and successfully operate in an ever more inter­
excellence, efficiency and fairness in everything
dependent and diverse business environment.
we do. The ambitious expectations we set ourselves in terms of standards and performance
can only be attained by joining forces.
Boehringer Ingelheim
Our annual “Value through Innovation Day” is
“Value through Innovation Day”
but one example of the way in which we go about
using our insights and creativity to find ways to
build stimulating working environments. Every
year in the spring, employees and management
in our organisations come together to discuss
and propose ways to realise related ideas and
­measures.
Preferred employer
The attractiveness of Boehringer Ingelheim as an
employer of choice is widely acknowledged in
highly regarded and independent surveys. This
recognition reinforces our confidence in our
­distinctive corporate culture and working environment. The outcomes of these surveys underline our prime positives: our innovative and
ambitious culture, our unique working environment, and our working relationships built on
mutual respect and fairness.
Special achievements were registered in 2008,
when we succeeded for the seventh consecutive
year in coming first in the VAA (Verband an­ge­
39
Our people
At our headquarters in Ingelheim, Germany,
the 2008 “Value through Innovation Day”
­focused on how to enhance coaching and development for our long-term individual and corporate success. In the spirit of the “Lead & Learn”
initiative, our understanding of the way we
work together, all employees and management
engaged in interactive group discussions that
generated a number of practical and beneficial
recommendations. Many of them are already on
the way to being implemented. Others are to
­follow soon.
As a corporation with employees in 138 affiliated
companies worldwide, we have access to a highly
effective means of identifying emerging customer
needs, staying on top of the latest technology and
­scientific developments, as well as gaining from
the viewpoints of our employees who represent
a wealth of societies and backgrounds. Strengthening this network enables us to access manifold
sources of know­ledge sharing and knowledge
Top equality performance
In the USA, Boehringer Ingelheim secured the
top rating of 100 % in the Corporate Equality
Index, an annual survey administered by the
Human Rights Campaign Foundation. We
thereby join 259 other major US businesses that
have been given top marks for their equality
performance.
generation for the benefit of all.
In this context, developing language and
­technology skills, encouraging the acquisition of
international project work, global task-forcing,
intercultural knowledge and abilities, and
cross-border knowledge transfers as well as short
­providing experience that gives a global outlook,
and long-term assignments abroad represent
are essential. Multidimensional, long-term
substantial constituents.
approaches are developed and introduced to foster lifelong learning, employability, diversity
Furthermore, in 2008, another cohort of 120 par-
management, enhancement of work-life balance,
ticipants completed our 14-month International
and the maintenance and enhancement of phys-
Management Development Program (IMDP), one
ical, mental and social well-being.
of the developmental approaches that provide a
unique learning environment for management
Developing talent
potentials.
In our focus on developing talent, our philosophy underlines the active learning and develop-
Another forward-looking example for ensuring
ment of every employee as central to the success
and developing bench strength for the future
of our company. We are convinced that discover-
has again been set by our German operating unit.
ies and results are generated by people and we
In 2008, a noteworthy 673 individuals in 35
therefore continue to ensure that our ­employees
­professions commenced vocational training
maintain and enhance their professional and
within the highly regarded and well-established
vocational capabilities. In our annual employee-
­B oehringer Ingelheim apprenticeship pro-
supervisor dialogue, respective individual meas-
gramme.
ures that are mapped and jointly agreed form a
central element of discussions.
Family-friendliness reconfirmed
At all times, Boehringer Ingelheim has set great
The Boehringer Ingelheim Academy plays a sig-
importance on being a family-friendly company.
nificant role in realising our goals of lifelong
To continue to ensure that we are enabling our
learning and internationalisation. In 2008, a
employees a good work-life balance, we have
number of new or revised programmes were
subjected our personnel policy to a recurring
introduced to meet the changing needs of our
external audit.
business. The Academy offers are designed to
give employees local and international options
The highly respected “berufundfamilie GmbH”
to address targeted developmental aspects in a
foundation conducted its initial audit and certi-
wide range of areas.
fication in 2005. Boehringer Ingelheim subjected
its efforts to a re-auditing, and was awarded a
In our approach to developing leadership and
new certificate in 2008. Audits are monitored
specialist talent throughout our organisations,
yearly, with re-audits every three years.
40
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
corporate responsibility
The audits are a strategic management tool for
systematically identifying and evaluating ­positive
ways of combining working life with family life,
with participating organisations agreeing to
address targets for improvements by the next ­­
re-audit.
The auditing scope includes working time,
work organisation, work location, information
and communication policies, management
­competence, personnel development, remuner­
ation structure and the value of services for
­families. l
Awards 2008
Country
Ranking
Brazil
Germany
Survey
20
100 Best Companies to Work For in Brazil (Great Place to Work Institute)
9
25 Best Companies for Executives to Work for in Brazil
(Great Place to Work Institute)
1
“Bester Arbeitgeber” (Survey VAA)
“Cologne Chemicals Prize” (VAA)
Audit as family-friendly company
Italy
Special Award
Gender-equal opportunity employer (Assolombarda – Industrial Association)
Japan
Next-generation accreditation “KURUMIN” in recognition of NBI
as a very family-friendly company in Japan
Mexico
Leader Companies in Mexico (HayGroup and HSM Editorial Group)
The Netherlands
Best werkgever Nederland (Best Employer Netherlands)
(Corporate Research Foundation)
Spain
Family Award for Reconciliation Between Work and Family Life
UK
Best Places to Work (Sunday Times)
2
�
Best Places to Work in IT 2008 – Manufacturing & Engineering
(Computer Weekly)
NorthCoast 99 Award
USA
Best Places to Work for LGBT Equality – 100 % Corporate Equality Index
Human Rights Campaign
Top 50
41
Our people
Careers & the disABLED Magazine
Contents
} Personal passions – A beneficial balance to research
} Our R&D strategy
} Our R&D sites
} Non-clinical research and development
} From test tube to bioreactor –
A seamless path for biopharmaceuticals
} Clinical development
} 2008 – The year of landmark trials
} Bridge to academia
42
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Research & Development
dr heike neubauer “Painting is in many ways like research.”
44
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
research
&
development
Personal passions – A beneficial balance to research
Research and development in the pharmaceutical industry
calls for imagination, determination, persistence and
the crucial ability to work as an integral part of a team.
New drugs take years, often a decade, from discovery of
the initial molecule to a marketable medication. And
throughout this long and sometimes challenging process
researchers must stay alert, focused and flexible. So keeping
fit, both mentally and physically, can make an important
­contribution to the final outcome of a research or development programme. At Boehringer Ingelheim, our company
schemes provide support, but ultimately it is the employees
themselves who find their own ways of staying fit and
achieving a good work-life balance.
Dr Heike Neubauer, principal scientist at
For mental fitness, Dr Neubauer paints, some-
Boehringer Ingelheim’s Biberach research
thing she has loved doing since childhood. Today,
­campus since spring 2003, is highly aware of the
her work is mainly in oil paint and she does much
need to stay in good physical and mental shape.
of her painting together with friends or in more
­Indeed, she has a personal passion, painting,
formal painting groups. She has already had
which provides a very effective balance to her
work displayed in several exhibitions.
demanding daily research work. Her working day
at ­Boehringer Ingelheim concentrates on identi-
“Painting, for me, is in many ways like research.
fying new ­molecules that potentially may become
You need technical knowledge how to do it, prac-
drugs for the treatment of metabolic diseases,
tice, persistence and creativity – some thinking
such as the current and fast-growing scourges of
outside the box. It helps you look again at things
obesity and diabetes.
with fresh eyes,” she notes. And some of her
45
Personal passions – A beneficial balance to research
paintings have taken years to finish. “As a
Increased research productivity has led to a well-
researcher, I’m familiar with working with
balanced pipeline with a substantial number of
persistence to achieve results.”
innovative first-in-class and best-in-class new
molecular entities (NMEs) and a high share of
In her passion for painting, Dr Neubauer sees a
substances in late-phase development, strength-
similar challenge to that in her profession. Both
ening our competitive position.
make her want to learn, to improve, and to find
new ways forward. Both pursuits also bring her
A continuous flow of innovative new chemical
into regular contact with very different groups of
entities (NCEs) has contributed substantially to
people who think very differently, too. She finds
our pipeline. Additionally, the discovery and
that this provokes new thoughts and ideas
­development of new biological entities (NBEs)
beyond the world of pharmaceutical research
from our internal research and in-licensing con-
that may also help her in her work. ●
stitute another part of our strategy. The NBEs are
co-developed and produced by our Biopharmaceuticals division in our facilities in Vienna,
Our R&D strategy
­Austria, and Biberach, Germany.
Boehringer Ingelheim’s
success is based on its own
research and development,
which continues to be the
pre-eminent driver for innovative, new medicines to
address unmet therapeutic
need. Our constant quest for
pharmaceutical innovation
has resulted in successful
ongoing collaborations as
well as external partnerships
with academic institutions,
biopharmaceutical and
start-up companies.
In order to improve efficiency and secure equal
access to state-of-the-art technologies and informatics platforms across our R&D sites we have
implemented global skill centers. To ensure the
most efficient drug development our non-clinical
development operates as a single internationally
integrated organisation based on two major
­regional centers, one in the USA and one in
Germany.
Worldwide, we employ 3,700 scientists, technicians and support personnel in preclinical R&D.
They are complemented by about 2,800 clinical
monitors, statisticians and data managers in
clinical development and medical departments.
In-licensing and partnering
In-licensing and partnering activities constitute
essential elements of Boehringer Ingelheim’s
R&D strategy. Together with our partners we in
2008 accomplished a series of important success
milestones in our ongoing collaborations. In
order to forge new partnerships, we are prepared
to adopt creative deal structures. An example is
Our R&D direction
the acquisition of San Diego-based Actimis Phar-
Our R&D strategy focuses on seven major thera-
maceuticals Inc. This transaction will occur
peutic areas: central nervous system (CNS)
through a structured buyout in which Boehringer
diseases, cardiovascular diseases, immunology/
Ingelheim will acquire shares of Actimis depend-
inflammation, metabolic diseases, oncology,
ing on the achievement of several successive
respiratory diseases and viral diseases.
milestones with Actimis’ leading asthma com-
46
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
research
&
development
pound AP768. If AP768, currently in phase I
Basic research partnerships
clinical development, is successfully advanced
The bridge between our R&D researchers and
into a phase III, Boehringer Ingelheim will own
academia is reinforced by the strong link to the
100 % of Actimis shares. The compound AP768
renowned Research Institute of Molecular
interacts with CRTH2, a novel target for asthma
Pathology (IMP) in Vienna. IMP scientists from
and allergic rhinitis, which has the potential
30 different countries are at the forefront of
to be more effective than currently marketed
discovery, defining fundamental mechanisms in
­leukotriene receptor antagonists.
areas ranging from cellular proliferation to
cancer and neurobiology. The collaboration
We also continue to expand our R&D pro-
between the IMP and the Institute of Molecular
grammes in biopharmaceuticals through col-
Biotechnology of the Austrian Academy of
laborative research and license agreements. Thus,
Science (IMBA) has given an additional dimen-
we have entered into a partnership with Evec Inc.,
sion to our academic network. ●
a Japanese biotechnology company, for one of its
fully human therapeutic antibody programmes.
Based on the agreement, Boehringer Ingelheim
will obtain worldwide exclusive development
and commercialisation rights for the complete
programme. This collaboration is considered to
be one of the first compound-related license
agreements between a Japanese biotech venture
and a multinational pharmaceutical company
outside Asia.
Oncology
Human tumour cells after 24 hours of treatment
with an anti-mitotic substance (immunofluorescence stain). The picture shows faulty cell
spindles (green) and fragmented DNA (red).
Link to research in oncology:
http://www.boehringer-ingelheim.com/
corporate/research/index.asp.
47
Our R&D strategy
Our R&D sites
In accordance with our
R&D strategy we carry out
drug discovery and development in seven therapeutic
areas at four major R&D
sites and three smaller
­specialised sites. These R&D
sites maintain responsibility
and accountability for their
therapeutic areas with
regard to output and quality
of novel drug candidates.
Major R&D sites and main R&D areas
Ridgefield, USA
Laval, Canada
• Cardiovascular (chronic heart
• Virology (acute and chronic
failure, atherosclerosis, hypertension) viral diseases, HIV, hepatitis C
• Immunology and inflammation
virus)
(rheumatoid arthritis, psoriasis,
multiple sclerosis)
• Non-clinical drug development
48
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Biberach and Ingelheim,
Germany
• Central nervous system – CNS
(Alzheimer’s disease, Parkinson’s
disease, chronic pain, migraine)
• Metabolism (type 2 diabetes,
obesity, dyslipidaemia)
• Respiratory (COPD, asthma,
chronic bronchitis, idiopathic
­pulmonary fibrosis)
• Non-clinical drug development
research
&
development
• Ingelheim
Biberach •
• Vienna
• Milan
• Laval
• Ridgefield
• Kobe
• Buenos Aires
Smaller, specialised R&D sites
Vienna, Austria
Buenos Aires, Argentina
Milan, Italy
Kobe, Japan
• Oncology (signal transduction,
cell cycle therapeutic proteins)
Center for non-clinical
development:
• Drug formulation,
manufacturing of medication
for clinical trials
Center for chemical synthesis:
• Synthesis in exploratory and
lead optimisation projects
Center for molecular biology
and non-clinical drug
development:
• International drug
discovery activities
• Early drug formulation
• Specific pharmacokinetic
investigations
49
Our R&D sites
dr reiner meyer “For me, research means scope to try out new ideas.”
50
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
research&& development
development
research
Non-clinical research and development
The unravelling of the human genome has
accelerated the identification of the faulty
biochemical circuitry that underlies the prolifera-
Boehringer Ingelheim
successfully rises to the
challenges of discovery
and development to
bring innovative and safe
drugs to patients.
The focus of our drug discovery is on several
Metabolic diseases
­targets, which we try to attack with small mole-
tion, invasion and metastasis of cancerous cells
in the body. These insights provide important
clues to new drug targets and the early identification of patients whose cancers are most likely to
respond to novel drugs, a process known as
biomarker-guided therapy.
novel mechanisms to interfere with cancer
Our broad engagement in preclinical research in
cules and biopharmaceuticals. The newest
metabolic diseases is focused on type 2 diabetes,
­biological entity (NBE) molecules (human mono-
obesity and dyslipidemia. The research activities
clonal antibodies) from Boehringer Ingelheim
in the field of type 2 diabetes concentrate on sev-
trigger the death of tumour cells, or inhibit
eral new approaches to delay disease progression.
­uncontrolled cell growth, whereas our current
Furthermore, new projects have been initiated
small molecules prevent the unimpeded prolif-
with the potential to target other cardiovascular
eration of cancer cells.
risk factors in addition to their glucose-lowering
effect, thus allowing simultaneous intervention
Central nervous system (CNS) diseases
in various risk factors of the metabolic syndrome,
Our research in CNS diseases addresses four
such as hyperglycaemia, dyslipidaemia, obesity
­major indication areas characterised by a high
and hypertension. In the future, our major
unmet medical need and a heavy burden for
­emphasis will be on dyslipidemia and athero­
­patients and caregivers, especially in an ageing
sclerosis targets.
population. These include the most prevalent
neurodegenerative disorders, such as Alz­heimer’s
In 2008, we started pre-development activities
disease and Parkinson’s disease, as well as
with another compound based on a novel
­chronic pain and migraine. Our major goal in
principle to target the metabolic syndrome. With
Alzheimer’s disease and Parkinson‘s disease is to
the University of Dresden and the Max-Planck-
interfere with the processes underlying the
Institute, Dresden, Germany, we continued our
­continuous degeneration of nerve cells in these
collaboration to identify and validate novel
devastating disorders, concentrating on targets
­targets in metabolic diseases. Promising initial
established by histopathological and genetic
data have been obtained.
evidence.
Oncology
In chronic pain we focus on new molecular tar-
Boehringer Ingelheim is actively developing
gets involved in pain transduction pathways and
small molecules and biopharmaceuticals as ­novel
validated in neuropathic and inflammatory pain
drugs for combating cancer. With front-line re-
models. Our endeavours have resulted in two
search and development projects the company
development compounds for the treatment of
aims to fill therapeutic gaps by offering treat-
chronic pain, both compounds having a different
ments that improve survival and enhance the
but complementary efficacy profile in preclinical
quality of life of cancer patients.
models.
51
Non-clinical research and development
To complement our activities in the indication
and to improve treatment of atherosclerosis.
areas pain and neurodegeneration, we have
These efforts have resulted in the identification
joined an academia/university consortium
of several novel approaches for cardiac and renal
­Innovative Medicines Initiative (IMI), created by
protection and treatment of atherosclerosis. In
the European Federation of Pharmaceutical
2008, dabigatran etexilate (pradaxa®) from
­Industries and Associations (EFPIA) and the EU.
Boehringer Ingelheim was the first oral anti­
coagulant to achieve approval for more than 50
Respiratory diseases
years. It is a first-in-class direct oral thrombin
The key goal in our research is to extend our
inhibitor. Following dabigatran etexilate, we suc-
portfolio in chronic obstructive pulmonary
ceeded in nominating another two compounds
disease (COPD) to directly treat the underlying
for development, targeting alternative mecha-
inflammation and the related tissue remodelling
nisms for the treatment of thrombo-embolic
processes.
diseases.
To prevent or delay tissue remodelling processes
Viral diseases
we target lung growth factors. Two first-in-class
Drug discovery and development efforts in virol-
mechanisms focused on mucous hyperplasia and
ogy are focused on the treatment of HIV and
fibrosis are being tested clinically. Beyond COPD,
hepatitis C virus infection in order to improve
such new mechanisms have a therapeutic poten-
existing therapy by providing patients with safe
tial in idiopathic pulmonary fibrosis (IPF) and in
and more effective antiviral drugs.
severe asthma, where mucous plugging is considered the main cause of death.
Thus, we are pursuing a number of promising
targets for direct-acting antivirals that will ­inhibit
For severely asthmatic patients, our research
the replication of the virus within the infected
goals focus on new targets to overcome steroid
cell by interfering with the virally encoded
resistance and to replace or reduce the doses of
­enzymes involved. Several compounds from
inhaled steroids by providing better tolerated
these projects are being pursued in pre-clinical
anti-inflammatory therapy superior to leuko­
research and offer promise as future development
triene receptor antagonists.
candidates and ultimate treatments for patients.
In this context, a new mechanism effective in
Immunology & inflammation
asthma and allergic rhinitis was taken up in early
Our drug discovery focuses on mechanistic
discovery phase; moreover, several additional
understanding of rheumatoid arthritis, multiple
screening programmes were successfully
sclerosis and psoriasis disease processes in order
completed.
to identify novel targets for developing drug can-
An additional step to extend our development
we in-licensed two potential targets from the
didates. For the treatment of rheumatoid arthritis
portfolio was achieved when in-licensing the
­collaboration with Galapagos NV / ­BioFocus DPI.
compound AP768 from Actimis Pharmaceuticals
Based on these new ­ approaches, we advanced
for treatment of rhinitis and asthma.
two compounds into preclinical/clinical development, one inhibiting the invasion of inflam-
Cardiovascular diseases
In our research activities we strive to identify
novel approaches for the treatment of risk factors,
such as hypertension, to follow disease modifying therapeutic strategies, for instance in heart
failure, providing cardiac and renal protection,
52
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
matory cells into inflamed tissue and joints. l
research&& development
development
research
From test tube to bioreactor –
manufacturing cell lines and establishes fermen-
A seamless path for biopharmaceuticals
tation and downstream processes. Once a project
passes the gate to pre-clinical development, bio­
Capitalising on our scientific
and technical capabilities in
drug discovery and in the
development and manufacturing of bio­pharma­
ceuticals, Boehringer Ingelheim is well positioned to
develop next-generation
therapeutic proteins.
Across therapeutic areas, we have built a broad
new biological entity (NBE) project portfolio
that largely, though not exclusively, comprises
monoclonal antibody (MAb) drug candidates.
A special challenge in MAb drug discovery
pharmaceutical manufacturing scales up and
optimises the production process to ensure a
seamless transition to clinical trial and market
supply. ●
Clinical development
Continuous initiatives to
increase R&D productivity
have resulted in a wellbalanced pipeline showing a
substantial number of new
molecule entities and a high
share of compounds in late
phase development.
is the need to integrate expertise in diseasespecific pharmacology and in NBE-specific
Metabolic diseases
biotechnologies.
In our therapeutic area metabolic diseases
the research teams have been focused on the
At Boehringer Ingelheim, screening to identify
discovery and development of oral anti-diabetic
high-affinity human MAbs for all therapeutic
treatments targeting new principles, such as
areas is the task of a single, specialised team
inhibition of dipeptidylpeptidase-4 (DPP-4) and
applying multiple technologies in parallel,
of sodium-dependent glucosetransporter-2
­including antibody phage display and transgenic
(SGLT-2). These compounds reflect the dedica-
mice carrying human antibody genes. In addi-
tion of Boehringer Ingelheim to harnessing the
tion, access to camelide nanobodies, the smallest
most advanced science to efficiently control type
antibody-like protein domains created by nature,
2 diabetes and its often serious consequences.
is available through collaborative research.
At each research site, dedicated NBE technology
Our compound bi 1356 (intended brand name
groups take over the screening hits, engineer
ondero®), a DPP-4 inhibitor, has entered a
protein formats and expression systems, and
broad phase III study programme. By the end
produce and purify pilot quantities of MAbs.
of 2008, the recruitment of more than 4,000
Finally, pharmacologists in the respective thera-
randomised patients was successfully achieved
peutic area profile the drug candidates in models
ahead of plan. bi 1356 is studied in monotherapy,
of human disease. Early on, NBE experts from
as well as in combination with established
the development disciplines, such as non-clinical
­therapies, such as metformin, a sulfonylurea, or
drug safety and pharmacokinetics, are integrated
a thiazolidindione. In addition, bi 1356 is under-
into the project teams, and biopharmaceutical
going a large two-year study comparing bi 1356
process development initiates generation of
to glimepiride.
53
Clinical development
Our second principle under development in
Boehringer Ingelheim is broadening its cell-cycle
type 2 diabetes is targeting therapeutic glucose
kinase inhibitor portfolio by investigating poten-
elimination. With proof-of-principle and good
tially first-in-class compounds, so-called PLK-1
tolerability established for our SGLT-2 inhibitors
inhibitors. bi 6727, a PLK-1 (Polo-like-kinase-1)
in short term phase II clinical studies during the
inhibitor, is blocking the cell cycle, and thereby
year, several studies of 12 weeks duration with
cell division and has shown encouraging results
mono and combination therapy have been
in a phase I clinical trial in patients with ad-
initiated.
vanced tumours who have failed to respond to
other treatments. The compound is now in phase
Oncology
II clinical development in solid tumours and
In the therapeutic area oncology, our portfolio of
­haematological cancers.
compounds matured significantly in 2008. One
of our most advanced compounds, bibw 2992
As planned, another cell-cycle kinase inhibitor
(intended brand name tovok®), is a novel repre-
with, however, different mode of action (mitotic
sentative of the new generation of tyrosine ki-
kinase inhibitor) has already entered clinical
nase inhibitors. It is an irreversible inhibitor of
phase I.
both EGFR and HER2. Promising phase II data
showed that advanced non-small-cell lung can-
Central nervous system diseases
cer (NSCLC) patients treated with bibw 2992
With the importance of non-motor symptoms
experienced a high rate of disease control (87 %)
in Parkinson’s disease widely recognised, the
and promising overall response rate (50 %). The
results of a dedicated randomised placebo-con-
compound has now entered phase III clinical
trolled clinical trial of sifrol® (pramipexole) in
trial in the most frequent form of non-small-cell
alleviating depressive symptoms associated with
lung cancer (NSCLC). As bibw 2992 also inter-
Parkinson’s disease have become available: the
feres with HER2, a phase II programme in
six-month placebo-controlled study established
­patients with breast cancer failing trastuzumab
for the first time significant beneficial effects of
treatment is ongoing.
pramipexole on depressive symptoms in patients
with Parkinson’s disease.
The second principle, which has concluded
phase II and is entering phase III, is bibf 1120
The worldwide phase III programme for
(intended brand name vargatef®), a novel ­triple
pramipexole extended release has been success-
angiokinase inhibitor. The substance simultan­
fully brought forward both in patients with early
eously inhibits three growth factors and recep-
and with advanced Parkinson’s disease. The
tors (VEGFR, PDGFR and FGFR) that play an
pivotal phase III studies established clinical
important role in angiogenesis. Promising effi-
efficacy and confirmed the expected good toler-
cacy and tolerability data have been reported
ability. It was also demonstrated that almost all
from a phase II study in patients with advanced
patients can be switched smoothly and without
non-small cell lung cancer (NSCLC), when
dose adjustment from sifrol® to its extended
bibf 1120 was ­ administered as monotherapy.
release formulation. Market authorisation is
Two clinical phase III pivotal trials with 1,300
expected for 2009.
­patients were initiated around the world by the
end of 2008.
In one study, it was shown that duloxetine
(cymbalta®/xeristar®) is not only effective
bibf 1120 (vargatef®) is also being investigated
for the treatment of depression, but also in the
in first-line treatment of ovarian cancer with a
prevention of recurrence of depression in
1,200 patient phase III study in pre-initiation, as
patients who have shown initial treatment
well as in prostate cancer and colorectal cancer.
response.
54
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
research&& development
development
research
Flibanserin is an investigational compound
inhaler respimat® has been successfully com-
in clinical development for the treatment of pre-
pleted and has led to a submission for registra-
menopausal women suffering from hypoactive
tion shortly after close-out of the pivotal study.
sexual desire disorder (HSDD). This is a common
condition affecting up to one in ten women and
Cardiovascular diseases
can frequently cause substantial distress and
pradaxa® (dabigatran etexilate), our orally
inter­personal difficulties.
available anticoagulant which acts through
bouquet®, an extensive phase III trial pro-
registration in Europe and in an increasing
gramme involving approximately 5,000 women,
number of countries outside of Europe. Accord-
has been completed in North America and a cor-
ing to the front-runner programme in clinical
direct thrombin inhibition, has obtained first
responding study in Europe has fully recruited.
development, pradaxa® is approved to prevent
We are confident that with the integration of the
venous thrombo-embolic events after elective
European study results we will have a promising
total hip or knee replacement and needs no
submission dossier for Europe and the USA.
regular monitoring of thrombocytes or coagulation parameters.
Respiratory diseases
From our earlier pipeline the long-acting inhaled
In addition to the ongoing phase III programmes
beta-agonist bi 1744 has shown conclusive posi-
in surgical and non-surgical conditions, includ-
tive clinical phase II results which are the robust
ing long-term prevention of venous thrombo-
basis for a large phase III programme for bi 1744
embolism and stroke prevention in atrial fibril-
as a maintenance treatment of chronic obstruc-
lation, we initiated a large phase II study for the
tive pulmonary diseases (COPD). This pro-
secondary prevention of acute coronary
gramme has been initiated internationally. The
syndrome (re-deem™), which has already in-
bi 1744 mono compound development is com-
cluded some 1,000 patients.
plemented by a phase II programme for its
­combination with spiriva® (tiotropium), our
In total our re-volution® trial programme has
leading long-acting anticholinergic medication
recruited more than 30,000 patients. The largest
for COPD. With the good ongoing progress we
trial re-ly® for stroke prevention in patients
expect the combination programme to enter
with atrial fibrillation has rapidly included more
phase III in 2009.
than 18,000 patients and will have last patient
The worldwide proof-of-concept study of our
quarter of 2009, with results published in the
new anti-angiogenesis molecule in development
autumn.
out several months ahead of plan in the first
for the treatment of idiopathic pulmonary fibrosis was initiated and is recruiting well ahead of
The studies for the treatment of acute venous
schedule.
thrombo-embolism (VTE) – re-cover™ – and
for secondary long-term prevention of VTE in
In the USA, the spiriva® respimat® new drug
­patients at risk – re-medy™ – are running in
application (NDA) has gone through the first
­parallel to ­ re-ly® and will after the review of
Food and Drug Administration (FDA) review
stroke prevention in atrial fibrillation, provide
cycle.
additional submission opportunities.
Other respiratory programmes have also seen
Due to the need of results from still ongoing
relevant progress. In the USA, the clinical
studies in the USA, the submission of pradaxa®
development of combivent® (ipratropium and
for the primary prevention of VTE has been
salbutamol) in our innovative propellant-free
postponed.
55
Clinical development
For micardis® (telmisartan) the studies to inves-
2008 – The year of landmark trials
tigate the combination product with the calciumantagonist amlodipine in severely hypertensive
patients who are not sufficiently treated with
the mono-compounds have been successfully
concluded, with submission planned in the USA
in the first quarter of 2009. The European longerterm follow-up studies will be completed in time
to support a European submission later in 2009.
Viral diseases
The large pivotal clinical phase III trial for
the new once-daily extended release form of
vir amune®, our non-nucleoside reverse
transcriptase inhibitor (NNRTI), has completed
patient recruitment, and is progressing smoothly
towards one-year follow-up at the end of 2009.
We aim to establish advanced convenience and
good safety combined with reliable efficacy for
worldwide registration.
For two new hepatitis C compounds with different but potentially complementary mechanisms,
we established proof of potent antiviral efficacy
when given to infected patients for up to two
weeks. Both compounds will move forward into
Boehringer Ingelheim is
proud to have provided the
medical community with the
results from five landmark
trials – all in 2008. These
results enhance medical
knowledge and management
of three diseases, which are
common causes of death:
stroke, chronic obstructive
pulmonary disease (COPD)
and heart disease.
Stroke
Stroke is a debilitating disease that puts a great
burden on the lives of patients and their
families.
phase II and phase IIb.
Urological diseases
For flomax® (tamsulosin), our leading treatment
ecass 3™, which included 821 patients, investi-
for the symptoms of benign prostate hyperplasia,
gated whether the efficacy and safety of alteplase
we have received agreement with the Food and
(actilyse®) were maintained up to 1.5 hours be-
Drug Administration (FDA) to perform a paedi-
yond the standard 3-hour time window. The
atric development programme in children with
study results, published by the New England
neurogenic bladder dysfunction. Since these
Journal of Medicine, showed that patients treated
children are severely ill and normally have the
with alteplase in this extended time window had
congenital malformation spina bifida, recruit-
a 34 % improvement in the odds of having a
ment into such clinical trials is extremely ­difficult
­favourable outcome versus placebo. Internation-
and often unsuccessful. Nevertheless, by the end
al stroke experts agree that this new study in the
of 2008 we had successfully completed recruit-
management of acute stroke has set a landmark,
ment into all required trials and will thus be able
as ecass 3™ has demonstrated that stroke can be
to fulfil the commitments for this paediatric pro-
safely and effectively managed also in the
gramme in time for submission. ●
3–4.5-hour treatment window. While early treatment remains the cornerstone of acute stroke
therapy, many patients who are unable to reach
a stroke centre within three hours may benefit in
the future from these positive findings.
56
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
research&& development
development
research
The prevention of stroke was specifically investi-
from 37 countries. The results were published in
gated in profess® and stroke was also included
the New England Journal of Medicine. The trial
in the primary endpoint of ontarget™ and
compared spiriva® (tiotropium) versus placebo,
transcend®. profess®, the world’s largest trial
allowing all patients throughout the trial to use
in recurrent stroke prevention, included more
all prescribed respiratory medications other than
than 20,000 patients. The study compared
inhaled anticholinergics.
­aggrenox® (extended release dipyridamole +
ASA) with clopidogrel, while also analysing
While in the trial, spiriva® (tiotropium) did not
whether telmisartan, on top of other standard
alter the rate of decline in lung function versus
therapy, would further reduce the risk of recur-
the control groups, it demonstrated that spiriva®
rent stroke when compared with placebo. These
(tiotropium) impacts the clinical course of COPD
study results too were published in the New Eng-
over the long term through sustained improve-
land Journal of Medicine. In the two antiplatelet
ments in lung function and quality of life. In
regimens the patients had a comparable risk for
addition, tiotropium significantly reduced the
stroke, as well as for myocardial ­ infarction or
risk of exacerbations and severe exacerbations
vascular death.
leading to hospitalisation. To date, no medication
has been conclusively shown to reverse the
­decline in lung function. In uplift®, the rate of
decline of lung function was the lowest of any
Hypertension is one of the most important risk
large-scale COPD trial, signifying that patients
factors for recurrent stroke, and reducing blood
today are treated more effectively than in the past.
pressure is a key goal in stroke prevention. In the
Despite this better treatment, tiotropium resulted
telmisartan arm of profess®, the duration of the
in significant and patient-relevant improvements
study was not considered long enough to reliably
of many long-term outcome parameters.
evaluate whether blood pressure lowering is of
Throughout the four-year trial period, patients in
clinical value in post-stroke patients. However, in
the tiotropium group consistently reported a
an analysis conducted after the end of the trial, it
­better health-related quality of life than at study
was demonstrated that telmisartan did have a
initiation.
significant protective effect emerging six months
after the initiation of treatment.
In addition, an increase in survival was observed
under tiotropium, as well as a reduction in
Chronic obstructive pulmonary disease (COPD)
respiratory and cardiac morbidity, which conclu-
COPD is a progressive yet treatable disease that
sively reaffirms the favourable safety profile of
restricts patients’ lives over time and is a major
tiotropium. uplift® demonstrated that tiotro-
cause of death and disability throughout the
pium can impact the clinical course of COPD
world. The latest World Health Organization
over the long term through sustained improve-
(WHO) figures estimate that 210 million people
ments in lung function, quality of life, exacerba-
are currently living with COPD and more than
tions and improved survival.
three million people died from the disease in
2005 – more than breast cancer and diabetes
Cardiovascular protection
combined.
Cardiovascular (CV) diseases remain the primary
cause of death in the industrialised world.
uplift® is one of the largest COPD trials ever
In the ontarget™ trial programme, the efficacy
undertaken, involving nearly 6,000 patients
of telmisartan in the reduction of CV events
57
2008 – The year of landmark trials
was studied in more than 30,000 patients. In
transcend® also demonstrated that patients are
ontarget™, published in the New England
treated better today than ten years ago. For
Journal of Medicine, the angiotensin II receptor
instance, the percentage of patients experiencing
blocker (ARB) telmisartan (micardis®) matched
a myocardial infarction was about three times
the cardiovascular protection of the current gold
lower in transcend® than in the hope trial
standard ramipril, an angiotensin-converting
placebo groups. Despite this much improved
enzyme (ACE) inhibitor, in protecting against the
standard of care, telmisartan treatment resulted
risk of CV death, myocardial infarction, stroke
in a significant risk reduction in CV death,
and hospitalisation for congestive heart failure
myocardial infarction and stroke, a result that is
in high risk patients. The results also provided
clinically meaningful for patients at high cardio-
another important answer to an open question,
vascular risk.
whether the combination of an ARB and an ACE
inhibitor, if added to best standard of care, does
ontarget™, together with its sister trial
not provide further protective benefit. Impor-
transcend®, confirm, on top of best standard of
tantly, ontarget™ showed that patients tolerate
care, telmisartan’s long-term protective benefits
telmisartan significantly better than the ACE
with regard to cardiovascular events and its
­inhibitor ramipril, which supports a better
excellent tolerability profile. ●
­adherence of the patients to their medication and
is crucial for the effective long-term prevention
of serious cardiovascular events.
The transcend® trial involved almost 6,000
patients who did not tolerate an ACE inhibitor
due to side effects and was published in The
Lancet. This ambitious trial had predefined a
four-fold composite primary endpoint consisting
of CV death, myocardial infarction, stroke and
hospitalisation for congestive heart failure. For
this combined primary endpoint, transcend®
showed a risk reduction of 8 % for telmisartan,
although this was not statistically significant.
The main secondary endpoint (CV death, myocardial infarction and stroke) was similar to the
primary endpoint of the hope trial, the first trial
demonstrating a reduction of CV events by inhib-
Bridge to academia
The bridge between our
R&D researchers and
academia is built by the
strong link to the renowned
Research Institute of
Molecular Pathology (IMP)
in Vienna. We are also
engaged in several successful ongoing partnerships
with leading academic
institutions.
iting the angiotensin system. A statistically significant 13 % reduction was demonstrated for
PREVENT-it maps cardiovascular disease
telmisartan in this endpoint. In the control group
on a broad front
there was extensive use of CV drugs; for some CV
In the search for new approaches to preventing
drug classes (diuretics, calcium channel blockers,
and treating cardiovascular disease, the leading
beta-blockers) there was substantially more use
cause of death in the developed world, the Clinic
in the control group than in the telmisartan
and Medical Department of Johannes Gutenberg
group, which probably impacted the outcome
University, Mainz, supported by Boehringer
and potentially blurred some of the benefits of
­Ingelheim, is conducting a broad-scope, long-
telmisartan.
term clinical study.
58
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
research&& development
development
research
The seven-year study – PREVENT-it (PRoteom-
physical condition, lipids and blood glucose, as
ics, genomics and Vascular ENdoThelial dys-
well as DNA and protein patterns. Using ultra-
function) – also known as The Gutenberg Heart
sound technology, the investigators measure
Study, will involve 17,000 people from the
­vasodilatory and endothelial functions to detect
­German city of Mainz and its environs. Recruit-
early damage to blood vessels.
ment is among the age group 35–75. Baseline
examinations take place in the first 2.5 years,
IMP – The life science think-tank
with follow-up examination after 4.5 years. The
The Research Institute of Molecular Pathology
primary objective of PREVENT-it is on achieving
(IMP), the prestigious basic research institute,
an improved risk assessment of cardiovascular
which celebrated its 20th anniversary in 2008, is
disease.
firmly committed to uncovering fundamental
molecular and cellular mechanisms underlying
A score system for cardiovascular risk stratifica-
complex biological phenomena.
tion will be established, taking into account
psychosocial, environmental and lifestyle factors,
A Boehringer Ingelheim research institute, the
the relevance of sub-clinical disease, observable
IMP, based in Vienna, Austria, has made great
characteristics and genetic variability. New target
strides since it started out as an oncology-focused
molecules for an improved medical treatment of
institution. Today, its curiosity-driven research
cardiovascular and metabolic diseases will also
programmes are conducted by 15 independent
be identified and validated. New biomarkers will
groups spanning the molecular processes in the
be identified, which could lead to early diagnosis
development, functioning and disease mecha-
and increased predictability of cardiovascular
nisms of all living beings. Main areas of research
diseases.
include developmental biology, cell cycle control,
cell differentiation, oncogenesis, chromosome
This is to be achieved with the means of a bio-
biology and bioinformatics.
databank: population data is collected on general
Boehringer Ingelheim can benefit both from targets the IMP researchers discover for new drugs
Professor Stefan Blankenberg,
University Clinic Mainz, Germany
and from the bridge the institute is building to
academia worldwide. The IMP’s 200 scientists
are drawn from 30 countries. IMP research has,
for instance, recently led to Boehringer Ingelheim
developing a new cancer drug, now undergoing
phase II clinical trials, that involves a wholly new
mode of action.
The IMP cooperates closely with the Austrian
Academy of Sciences, mainly through its Institute for Molecular Biotechnology – a partner
Study leader, Professor Stefan Blankenberg,
University Clinic, Mainz: “We expect significant
findings about the prevention and treatment of
cardiovascular and metabolic diseases and
hope that they will improve predictability as
well as optimise the clinical development of
new drugs.”
59
Bridge to academia
and neighbour of the IMP. Dr Barry Dickson,
the IMP Director, says: “IMP has developed into
one of the most dynamic innovative life science
centres in Europe. We can attract the best ­people
in the world and help them realise their full
­potential. And it’s also great to see our ­researchers
taking top positions when they move on.” ●
Contents
} Courage and persistency in fighting COPD
} Highlights Branded Prescription Medicines
} Highlights Generic Prescription Medicines
} Highlights Consumer Health Care (CHC)
} actilyse® – A 20-year strike against stroke
} Biopharmaceuticals
} Pharmaceuticals Production
} Pharma Chemicals
} Manufacturing excellence in our centre
for global animal health vaccines
} My lion queen leaps again!
} Highlights Animal Health
} Samples of the product portfolio
Net sales 2008 in millions of EUR
Change in euro terms (change in local currencies)
Boehringer Ingelheim Corporation
11,595
+ 5.9 % (+ 9.5 %)
60
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Our business
Human Pharmaceuticals
11,128
+ 5.5 % (+ 9.1 %)
Prescription Medicines 9,111
+ 5.2 % (+ 9.3 %)
Branded Prescription
8,662
Medicines
+ 6.9 % (+ 10.9 %)
Generic Prescription 449
Medicines
- 19.7 % (- 13.9 %)
Consumer Health Care
1,190
+ 4.3 % (+ 5.4 %)
Industrial Customer
819
Biopharmaceuticals
+ 10.8 % (+ 12.3 %)
569
+ 22.8 % (+ 22.8 %)
Pharmaceuticals Production
121
- 7.4 % (- 2.8 %)
Pharma Chemicals
Animal Health
467
+ 14.4 % (+ 19.5 %)
129
- 11.2 % (- 9.0 %)
sebastião francelino “The start of the COPD treatment was the turning point in my life.”
62
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
human pharmaceuticals
Courage and persistency in fighting COPD
Sebastião Francelino, a 68-year-old retired Brazilian salesman, who loves life and driving, visited most of his vast
country when he was working. “This is what I miss most.
COPD took it from me,” says Tião, as he prefers to be called.
A native of Rio de Janeiro who, from his condo balcony
in the city’s traditional Penha district, can see the famous
Guanabara Bay. Tião tells of how hard it was to quit
­smoking, an ­addiction that caused his chronic obstructive
pulmonary disease (COPD), an illness currently affecting
over 5.5 million Brazilians. A smoker from just 13 years of
age, Tião suffered his first pulmonary crisis at the age of 55.
“I was extremely tired and short of breath and had to be
hospitalised. I already had COPD then, but was only
­diagnosed at the age of 59 years,” he explains. Frequently,
during his business trips, he had had to rush to the closest
point where he could get emergency assistance with
­breathing. The symptoms worsened, and only six years
later, after he was finally diagnosed ­correctly, he started
to receive the ­appropriate treatment.
The start of his COPD treatment at Hospital Uni-
­Maria Helena and walk my little dog Luke Sky-
versitário Clementino Fraga was a turning point
walker. Some day, I will take Maria Helena up to
in Tião’s life. He was the first patient to obtain
the Christ the Redeemer statue in Rio and the
treatment free of charge from the Rio de Janeiro
Sugar Loaf, two of Rio’s most famous sights, and
State public health system. This led him to
take many photos for posterity.”
­successfully manage his life with COPD and
regain some of the freedom to do things that he
Realising the difficulties COPD sufferers face, to
had missed. Very much a family man and a fan of
fight smoking and help other COPD sufferers,
romantic songs, he says: “I want to go back trav-
Tião founded, and is still chairman of, the Asso-
elling, spend more quality time with my wife
ciação Fluminense de Portadores de DPOC (Rio’s
63
Courage and persistency in fighting COPD
COPD patients’ association). With four children,
spiriva®
six grandchildren and one great-grandchild, Tião
wants his descendents to clearly understand
the dangers of cigarettes and never surrender to
smoking.
210 million people are currently living
with COPD
Tião is far from alone in his battle with COPD.
Although still a relatively unknown disease compared to other lung conditions, such as asthma,
and one that frequently goes undiagnosed, the
spiriva® is widely available in the HandiHaler®
latest World Health Organization (WHO) figures
and the respimat® Soft Mist™ Inhaler (SMI),
estimate that 210 million people are currently
a unique and technologically advanced new-
living with COPD and over three million people
­generation inhaler.
died from the disease in 2005 – more than breast
cancer and diabetes combined.
Initially launched in 2002, spiriva® is now
Breathlessness, the main symptom of COPD, is
­available to COPD patients in more than 80
characteristically persistent and progressive, and
countries and is marketed jointly by Boehringer
has a serious impact on patients’ quality of life.
Ingelheim and Pfizer, Inc. It is the most ­prescribed
At its most severe, it even limits a patient from
medication for COPD and more than 10 million
simple tasks, such as washing and dressing. l
patients worldwide have so far benefited from
taking spiriva®. Its efficacy and favourable
­safety profile have been demonstrated by an
Highlights Branded
Prescription Medicines
­extensive clinical development programme,
which included approximately 20,000 patients.
Long-acting bronchodilators, such as spiriva®,
spiriva®
are recommended by international guidelines as
first-line maintenance therapy for COPD.
spiriva® (tiotropium) is an
inhaled, long-acting anticholinergic. It is the only
once-daily COPD medication that maintains 24-hour
bronchodilation, resulting
in significant and sustained
long-term improvements
in lung function and quality
of life.
64
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
spiriva® positively impacts the clinical course of
the disease, helping patients to live a more active
life. COPD is often misdiagnosed as asthma, but
an accurate diagnosis to distinguish between
them is essential to ensure patients receive the
best therapy. Early diagnosis and treatment of
COPD can positively impact the clinical course
of COPD and change the way patients live with
their disease.
Please refer to the chapter Research & Development for more information on the uplift®
­landmark trial reporting results in 2008 for
­tiotropium. l
human pharmaceuticals
mirapex®/sifrol®/mirapexin®/pexola®
treatment of idiopathic restless legs syndrome in
2006 based on its favourable efficacy and safety
Physicians already have
over a decade of real-life
experience in successfully
using pramipexole for the
treatment of patients with
Parkinson’s disease (PD),
and its effect in improving
the motor symptoms of
PD is well documented.
The outstanding efficacy and good tolerability of
pramipexole in PD has led to the drug, developed
by Boehringer Ingelheim, being the most prescribed dopamine agonist brand worldwide. In
addition to PD, mirapex®/sifrol®/­mirapexin®/
pexola® (pramipexole) was ­ approved for the
Battle against Parkinson’s Disease
profile. In 2008, pramipexole passed the benchmark of 1 billion USD in worldwide ­annual net
sales. A once-daily formulation of prami­pexole
has been developed. The approval is expected in
2009, thus increasing the broad range of formulations from which physicians and ­patients can
choose to meet patients’ individual needs. l
pradaxa®
pradaxa® (dabigatran
etexilate) is a once-daily oral
anticoagulant for use in
post-operative prevention
of venous thrombo­embolism (VTE) after
orthopaedic surgery. It will
enable ­clinicians and
patients to make decisions
on choice of treatment
appropriate to their clinical
needs.
2008 was a very important and successful year
for pradaxa®. The European Commission granted marketing authorisation for pradaxa® within all 27 EU member states for its first indication,
“I had been a professional artist since I finished
art school in 1972 and my work was successful,
so it was devastating being diagnosed with a
neurological illness that could in all probability
make me an invalid in the near future. Ten years
have meanwhile passed since my diagnosis.
I have great determination and have decided
to fight against Parkinson’s disease and its ­effect
on my life and that of my family.” Kristina
­Löfdahl, Parkinson’s patient from Gothenburg,
Sweden.
65
Highlights Branded Prescription Medicines
prevention of ­venous thrombo-embolic events in
patients who have ­undergone total hip or knee
replacement surgery. The approval of pradaxa®
provides clinicians and patients a major advance
in anticoagulation therapy for thrombo-embolic
diseases. ­Initial market launch occurred in both
the UK and Germany, with the first patient ­
treated with pradaxa® in April 2008. Further
marketing ­ authorisations have been granted to
­Boehringer Ingelheim since then in key markets,
including Canada, Brazil, New Zealand and
­Argentina.
Soon after this approval, the clinical and cost-
micardis®
­effectiveness of pradaxa® was favourably
­appraised by several health technology assessment bodies. Leading the way was one of the
most widely recognised, the UK’s National
­Institute for Health and Clinical Excellence
(NICE), providing a significant endorsement for
this new product.
pradaxa® is a novel oral once-daily direct
thrombin inhibitor from Boehringer Ingelheim
research and development. It prevents thrombus
(clot) formation by specifically and selectively
inhibiting free and clot-bound thrombin, the
central and essential enzyme in the coagulation
cascade. pradaxa® has a favourable efficacy
and safety profile, both in and out of hospital, for
­patients undergoing total hip or total knee
­replacement surgery.
Boehringer Ingelheim offers
innovative options for the
treatment of essential hypertension with micardis®
­(telmisartan 20/40/80 mg),
our angiotensin II receptor blocker (ARB), and
micardisplus®/micardis®
hct (telmisartan in fixed
dose combination with the
diuretic hydrochlorothiazide
40/12.5; 80/12.5; 80/25 mg).
Please refer to the chapter Research & Devel­
opment for more information on the clinical
Hypertension is one of the most important but
­trials reporting results in 2008 for dabigatran
modifiable risk factors for cardiovascular
etexilate. l
­morbidity and mortality. The organ systems most
affected from end organ damage are the heart,
the main blood vessels, the brain and the kidneys.
Eve Knight,
Therefore, the primary goal of any antihyperten-
Chief Executive AntiCoagulation Europe
sive treatment is to prevent ­cardio­vascular events,
such as heart attacks or stroke, and finally reduce
cardiovascular ­mortality.
micardis® is characterised by high tissue concentrations, the longest duration of action in the
ARB class and a tight binding to the ­angiotensin I
receptor, which in clinical practice leads to blood
pressure reductions over the full 24-hour period
with a once-daily dosage.
“It is appalling that patients are still developing
and dying from venous thrombo-embolism,
which could very often be prevented by risk
­assessing every patient on admission to hospital
and giving preventative treatment where ­needed.
pradaxa®, a once-daily oral therapy for use in
post-orthopaedic surgery, will enable clinicians
and patients to make decisions on choice of
treatment appropriate to their clinical needs.”
66
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Please refer to the chapter Research & Development for more information on the clinical trials
reporting results in 2008 for telmisartan. l
human pharmaceuticals
Highlights Generic
Prescription Medicines
The Generic Prescription Medicines (GPM) business of Boehringer Ingelheim, which operates
exclusively in the USA, consists of Bedford
­Laboratories, a division of Ben Venue Labora­
tories and Roxane Laboratories, Inc.
Injectable Generics – Bedford Laboratories
As one of the top generic
injectable pharmaceutical
companies in the USA,
­Bedford Laboratories offers
a broad range of multisource injectables across
multiple therapeutic
classes, including oncology,
­cardiovascular, anti­infective and anaesthesia.
Oral Generics – Roxane Laboratories
In recent years, Roxane
has further developed
its differentiated strategy
and ­contributed to the
launch of many successful
products.
Allergic and non-allergic rhinitis
Roxane Laboratories launched fluticasone in
February 2006 for the treatment of allergic and
non-allergic rhinitis. Since launch fluticasone
has played an important role in achieving multisource business targets.
Metabolic diseases – type 2 diabetes
Roxane’s acarbose, an adjunct to diet to lower
blood glucose in patients with type 2 diabetes,
launched in May 2008, was an immediate ­success,
achieving an overnight market share of 70 %.
Hyperphosphataemia – kidney failure
Roxane launched calcium acetate capsules in
­October 2008 for the control of hyperphospha-
Cardiovascular diseases
taemia in renal failure. Since launch, this has
Among Bedford’s portfolio is an abundant selec-
become an important addition to Roxane’s port-
tion of cardiovascular products, including anti­
folio, with a market share of over 80 %. l
arrhythmics, e. g. diltiazem, treatment of atrial
fibrillation and flutter, cardio­myopathy and
blood pressure control (norepinephrine).
Oncology
Bedford Laboratories is committed to helping
cancer patients with safe, effective and afford­
able medication. With 26 oncology products,
amongst them being adriamycin and amifostine
­Bedford’s portfolio offers one of the largest lines
of injectable oncology products in the US
­pharmaceutical market. Its portfolio addresses
numerous cancer indications, such as ovarian,
­leukaemia and breast. In a very competitive
­oncology market, many of Bedford’s products
rank No. 1 in unit market share. l
67
Highlights Generic Prescription Medicines
Ben Venue’s newly opened laboratory office
building is a Leadership in Environmental and
Energy Design (LEED) certified green building.
Highlights Consumer
Health Care (CHC)
has a positive spillover to the new brand extension.
With these latest additions to our CHC portfolio,
The buscopan® product family
the company has taken an important step to develop buscopan® into a global OTC franchise
buscopan® – the world’s
leading over-the-counter
(OTC) antispasmodic
brand – is marketed in over
100 countries. Expanding
the brand into a family of
different sub-brands within
abdominal categories was
one of the most important
strategic objectives in 2008.
The buscopan® family in some important countries not only consists of antispasmodic products
but, for example, of remedies against menstrual
pain (buscofem®).
In this respect, Boehringer Ingelheim Brazil successfully launched buscofem® – the first liquid-
and to position Boehringer Ingelheim as the
leading abdominal specialist. l
dulcolax® – Intestinal irregularity and
disruption
dulcolax®, our leading
laxative brand, has been
providing relief to sufferers
of constipation in many
countries for over 50 years.
Through its active ingredient
bisacodyl it has grown to
become one of our flagship
Consumer Health Care
brands, trusted by millions
worldwide.
filled softgel capsule with 400 mg ibuprofen on
the Brazilian market – in August 2008. Part of its
In 2007, we redefined our global target market
success is the extraordinarily high consumer
for dulcolax® from “constipation” to “intes­
awareness and positive image that the brand
tinal irregularity and disruption”, moving purely
buscopan® has acquired over more than 50
from looking at treatments to the future aim of
years in the Brazilian market. In July 2008, the
providing solutions for treatment, maintenance
launch of the first anti-heartburn product under
and prevention.
the buscopan® umbrella brand marked another
major milestone in our global strategy. Interna-
In the USA, dulcolax® has a growing market
tional consumer research shows that a heartburn
share, and the brand continues to outperform
remedy ideally complements the buscopan®
the market. As a result it has now been rolled out
brand.
to France and Germany as well as being adapted
for the South Korean and Spanish markets.
Argentina is the first country with buscasan® ­
24 (omeprazole 20 mg) on the market. This ­offers
The growth of the new product developments
targeted relief from heartburn for a full
dulcolax® m balance and dulcofibre®,
24 hours with just one capsule per day. Here
launched in Germany and Italy respectively in
again, the positive brand image of buscopan®
mid-2007, have continued to ensure that the
68
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
human pharmaceuticals
mucosolvan® – Building consumer excellence
on medical heritage
The roll-out of the new global packaging design
began in Germany with the biggest overhaul of
the brand in over 50 years. The combination
of globally aligned activities and strong local
initiatives helped achieve record net sales and
maintain the position of dulcolax® as the
­global market leader in an increasingly competitive environment.
franchise outperforms the market in both countries. In Germany, dulcolax® continued to
strengthen it’s market leadership position, while
the total market showed a slight decline. In Italy,
the brand franchise has shown strong market
value growth in a declining market.
The further roll-out of dulcofibre® began in
the fourth quarter, 2008. l
The active ingredient of
mucosolvan® – ambroxol
hydrochloride – was ori­
ginated and developed by
Boehringer Ingelheim and
first registered in Germany
in August 1978. Since then,
mucosolvan® formulations
have been registered in
more than 100 countries
worldwide.
mucosolvan® is our leading cough brand and
maintained its No. 1 position in the global cough
category in 2008. It is one of our international
CHC brands, trusted by millions of users worldwide who seek to be freed of the annoyance of
cough.
lasolvan® (local brand name of mucosolvan®
in Russia) growth is the best proof that comprehensive consumer information can be very
­successful.
mucosolvan® – Russia
After the switch from prescription medicines
in 2002, Boehringer Ingelheim Russia implemented a strong and successful consumer­orientated marketing strategy and tactics,
­supported by the medical heritage of lasolvan®.
lasolvan® showed a growth rate that significantly exceeded that of the market. lasolvan®
growth in 2008 was 33 % (according to the RMBC
database) and thereby Russia developed into our
largest market for mucosolvan®. l
After six years of rapid growth, Russia became
the biggest mucosolvan® country market
worldwide.
69
Highlights Consumer Health Care
serhat gürsoy “I produce medications and help to improve the well-being of people.”
70
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product supply and industrial customer
actilyse® – A 20-year strike against stroke
For a long time, researchers had been looking for a therapy
that would lead to the dissolving of fibrin clots – the major
cause for acute myocardial infarction (AMI) and ischaemic
stroke. AMI is still the main cause of death in the industrial
nations, with around three million people suffering from
it every year. During the last decade, the treatment of
patients with AMI has been revolutionised. And the most
marked change was the significant increase in the use of
thrombolytic treatments. With the approval of the tissue
plasminogen activator (tPA) actilyse® (alteplase), a joint
product development between Genentech Inc. and
­Boehringer ­Ingelheim, the first thrombolytic treatment
against heart attack was born in autumn 1987. The success
story ­continued when actilyse® subsequently received
approval for ­additional indications in the management of
acute massive pulmonary embolism and for the treatment of
acute ­ischaemic stroke, where it is still the only thrombo­­lytic
product in the USA.
In order to manufacture commercial amounts
started in August 1983 with the licensing of tPA
of tPA, Boehringer Ingelheim invested EUR 90
(alteplase) from Genentech Inc. covering the
million in the first biotechnology plant in
worldwide marketing rights, except for the USA,
­Biberach, Germany, at the time the company’s
Canada and Japan. Even though both parties
largest single ­investment.
were as different as day and night – on the one
hand a big pharmaceutical company and on the
In 1986, the development of actilyse® as the
other hand a young biotechnology company –
first biopharmaceutical drug in Germany paved
they complemented each other perfectly. In joint
Boehringer Ingelheim’s way to its current leader-
project teams both companies developed tPA and
ship position in biopharmaceutical manufactur-
succeeded in under five years of development
ing. The success story of actilyse® really got
with the approval in 1987 of actilyse® against
71
actilyse® – A 20-year strike against stroke
Columbus • • Bedford
St. Joseph •
• Petersburg
Bracknell •
• Dortmund
Ingelheim ••
• Vienna
•• Lugano • • Biberach
Fornovo
Blanquefort •
• Reggello
Malgrat••
Sant Cugat
• Koropi
Guadalajara • • Mexico City
Bogota •
Itapecerica •
acute myocardial infarction in Germany.
­commercial production plant for mammalian
­Approval for the treatment of ischaemic stroke in
cell culture in Europe, which was inaugurated in
1996 in the USA and in Germany in 2002 was a
­November 1986. This courageous investment in
breakthrough in the treatment concept of this
a future technology demonstrates once more
life-threatening disease caused by a blood clot.
Boehringer Ingelheim’s pioneering engagement
actilyse® immediately ­dissolves the blood clots
in the area of biopharmaceuticals, as actilyse®
that cause many strokes, drastically reducing the
is the first drug worldwide that was produced
amount of tissue damage in the brain. The time
from cell cultures in a large-scale approach.
window for getting the best results from ­actilyse®
is up to three hours from the first signs of stroke.
Industrial Customer
The ecass 3™ trial has recently shown that stroke
Our business segment Industrial Customer has
can also be effectively treated in a time frame
the strategic role of supplying other biotechno­
from 3—4.5 hours.
logy and pharmaceutical companies worldwide
with the same developmental services and
To guarantee the worldwide supply of actilyse®,
­production capabilities that support our own
Boehringer Ingelheim constructed the first
pharmaceuticals. The aim is to offer added value
72
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product supply and industrial customer
C
Bedford, USA
Petersburg, USA
P
B
l
l
St. Joseph, USA
●
Columbus, USA
l
Mexico City, Mexico
l
Guadalajara, Mexico
●
Bogotá, Colombia
l
Itapecerica, Brazil
l
Bracknell, UK
l
Blanquefort, France
Yamagata •• Fukushima
Narita•
l
Sant Cugat, Spain
Shanghai •
Bogor •
l
Malgrat de Mar, Spain
l
Fornovo, Italy
l
Reggello, Italy
l
Lugano, Switzerland
l
Ingelheim, Germany
AH
l
l
Dortmund, Germany
l
Biberach, Germany
l
Vienna, Austria
l
l
Koropi, Greece
l
Yamagata, Japan
l
Fukushima, Japan
l
Narita, Japan
l
Shanghai, China
l
B = Biopharmaceuticals
Bogor, Indonesia
l
AH =Animal Health
C = Pharma Chemicals
P = Pharmaceuticals
Production
Status as of 31 December 2008
to customers ranging from research-led start-ups
Our three highly focused units provide compre-
to the major pharmaceutical groups. Industrial
hensive, world-class expertise, innovation and
­Customer accomplishes this global ­ mission
service for industrial customers as a full service
through three specialised units:
supplier.
• Biopharmaceuticals
• Pharmaceuticals Production
• Pharma Chemicals
Together, they form a pharmaceutical network
whose combined expertise, experience and
­service quality is unparalleled in the industry.
­Total Industrial ­ Customer revenues of around
USD ­ 1 billion make it one of the largest industrial ­contract manufacturers in the pharmaceutical industry.
73
actilyse® – A 20-year strike against stroke
In addition, we conduct development and manufacturing of animal health vaccines in two ­centres
in North America. l
Biopharmaceuticals – From mind to market
tered product). With current net sales of EUR
569 million, our Biopharmaceuticals business
produces, besides for its industrial customer
­business also for its own captive use business
(CUB). We ­currently market the four biopharma-­
ceu­­ticals actilyse®, metalyse®, imukin® and
beromun®.
Biberach
At our biotechnical plant in Biberach we focus on
mammalian cell culture technologies for ­
high-volume protein therapeutics, primarily
We offer the complete value chain from process
monoclonal antibodies (mAbs). In cell culture
development to biopharmaceuticals production
fermentation we have over more than 20 years
with a one-stop-shop service.
built up economic platform technologies, which
are highly attractive for customers. Among these
technology platforms we offer the proprietary
bi-hex® high-expression system for cell line
­development and the upstream process. This
platform allows the development of a stable, high
Biopharmaceuticals
Boehringer Ingelheim is one
of the leading companies
for the development and
manufacture of biopharmaceuticals. We undertake
this with an innovative spirit
at our biopharmaceutical
facilities in Biberach,
­Germany, and in Vienna,
Austria.
expressing cell line, which is adequate for largescale manufacturing especially for mAbs.
At the Biberach site, we offer sophisticated preformulation, formulation and pharmaceutical
process development. The dosage form portfolio
ranges from solutions, highly concentrated liquid
formulations, suspensions, lyophilised or spraydried powders to inhalable presentations combined with state-of-the art proprietary ­application
systems. To improve the one-stop-shop service
for customers, we also develop ­ liquid formulations for stable biopharmaceuticals in pre-filled
syr­inges in our worldwide ­approved facilities. We
have also invested in a new aseptic filling area
with state-of-the-art isolator technology for
­double-chamber carpoules.
The site has a very good track record in regula-
As one of the pioneers in biotechnology,
tory compliance and pre-approval inspections
Boehringer Ingelheim has operated for more than
as well as during multiple-company audits by
two decades in the development and manufac-
customers as well as authorities.
turing of biologics. This has earned us a reputation as one of the most experienced contract
Vienna
manufacturing organisations (CMOs), having
Boehringer Ingelheim Regional Center Vienna
brought 14 new biologic entities (NBEs) from
produces therapeutically active proteins from
“mind to market” (i. e. initial discovery to regis-
­micro-organisms and yeast with state-of-the-art
74
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product supply and industrial customer
fermentation technologies. Areas of manufactur-
ther platform technology for the manufacturing
ing expertise include protein therapeutics, ­protein
of high-quality plasmid DNA (pDNA). To date,
subunit vaccines, protein scaffolds, antibody
the process has been constantly optimised and
fragments and plasmid DNA for gene therapy.
fermentation titers of > 3 g/l have been achieved.
Interferon beta-1b, one of the top twenty bio-
In 2008, the Vienna site and Geneart started a
pharmaceutical blockbusters, is manufactured at
cooperation comprising a value chain from DNA
this plant. A broad host range for fermentation
design up to large-scale GMP manufacturing of
from E. coli, Saccharomyces cerevisiae, Hanse­nula
pDNA therapeutics for gene therapy and vaccin­
polymorpha and Pichia pastoris is available at the
ation.
site all with high-titer processes. The ­ genome
integration system in E. coli is suitable for large,
For downstream processing, efficient harvest,
complex molecules, since the gene of interest is
high-yield, matrix-assisted refolding and purifi-
stably integrated into the genome.
cation technologies, such as crystallisation, chro-
For the production of difficult to express peptides
high-performance liquid crystallography, are in
matography, ultra/diafiltration, and large-scale
and small proteins, the proprietary Npro auto-
place. A systematically multi-stage approach for
protease technology platform can be the appro-
the development of crystallisation processes in
priate system of choice. The autoprotease of the
cell lysates, intermediates or purified bulks was
fusion protein can be used as a tag for affinity
set up and a large-scale process with 20 kg pro-
chromatography and approvable to a whole
tein per batch for crystallisation was implement-
range of protein therapeutics. It facilitates refold-
ed. Due to our very good regulatory compliance
ing and provides the correct N-terminus.
track record in launch and secured supply and
For the treatment of diseases via direct gene
folio of our Vienna site today consists of seven of
transfer, our Vienna operation developed a fur-
the top 20 pharmaceutical companies. l
our state-of-the-art technology, the client port-
Technologies (Biopharmaceuticals)
Host
Technology
Vienna, Austria
• Microorganisms and yeast • High expression systems
fermentation
• High throughput
screening in upstream and
downstream development
• Purification technologies:
e. g. crystallisation,
reversed phase HPLC
• Refolding technologies
• Pegylation
Biberach, Germany
• Mammalian cell culture
•
•
•
•
•
Biopharmaceuticals
Fill & Finish
Non-glycosylated proteins • In Biberach
Antibody fragments
Peptides
Protein scaffolds
Plasmid DNA
• High expression systems
• Glycosylated therapeutic
• High throughput
proteins
screening in upstream and • Monoclonal antibodies
downstream development • Fusion proteins
• Purification technologies
• Formulation development
for proteins
and gene therapeutics
Status as of 31 December 2008
75
Products
•
•
•
•
•
•
Aseptic filling
Lyophilisation
Liquid vials
Lyo-vials
Pre-filled syringes
Double chamber
carpoules
Pharmaceuticals Production
been achieved by using common lean production
methods and by fostering a strong performance
Pharmaceuticals Production
guarantees product availability for our internal
and external customers.
It manufactures drug
product for our Human
Pharmaceuticals business
and for external partners
for the global markets.
culture within the framework of a growing
­involvement of external production partners.
In 2008, one-third of the packing units were
produced by contract manufacturers.
An important step in this context was the sale of
our production facility in Reims, France, to a
leading European contract manufacturer. This
will provide future growth for the factory in
Reims and guarantee long-term supply for
­Boehringer Ingelheim as a customer.
Business process excellence has also resulted in
competitive cost of goods, while reliably providing our sales organisation with high-quality
Fast to the market – The launch sites
products. Innovative drugs are launched from our manufacturing sites in Germany and the USA. In 2008,
Contract manufacturing
our Ingelheim site in Germany guaranteed the
The key success factor of the contract manufac-
launch of pradaxa® for the indication preven-
turing services of Boehringer Ingelheim is its
tion of venous thrombo-embolism (VTE) after
world-class pharmaceutical production network
elective hip and knee replacement by ­supplying
enhanced by business process excellence.
drug product for the European market. In
­Ingelheim a new 10,000 m² packaging centre
The wide range of manufacturing technologies
started production. It was designed according to
established in our Pharmaceuticals Production
current material flow requirements. This
­facilities is offered in the form of contract manu-
­completed the high-tech manufacturing centre at
facturing services to external industrial clients,
the site.
as well as for captive use. Boehringer Ingelheim
provides highly valuable contract manufacturing.
The sites are well-prepared for future capacity
These are enabled by the synergies between our
needs triggered by potential new drugs, in par-
captive production and the services for our ex-
ticular flibanserin from our US site in Columbus,
ternal clients.
Ohio, and pradaxa® and spiriva® respimat®
from Germany.
Captive production has taught us for years how
to guarantee a reliable commercial supply of safe
Global presence
products with our robust quality and our compli-
Our network of sites in 2008 comprised our
ance focus.
­global export sites in Germany, the USA, Japan,
­China, Greece, Spain, Italy, Switzerland, Mexico,
Our presence on three continents, our broad set
Brazil, Colombia and Indonesia.
of manufacturing and packaging technologies
and certification by the leading regulatory agen-
Increased efficiency combined with improved
cies allow us to find the optimal solution for our
flexibility in the manufacturing network has
clients. l
76
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product supply and industrial customer
Technologies (Pharmaceuticals Production)
Non-sterile
Solids
Sterile
Semi-solids
Liquids
Inhalatives
Bedford, USA
Biberach, Germany
l
Bogor, Indonesia
l
Bogotá, Colombia
l
l
Bracknell, UK
Columbus, USA
l
l
l
l
l
l
l
l
Dortmund, Germany
l
Fukushima, Japan
l
Ingelheim, Germany
l
Itapecerica, Brazil
l
l
l
Koropi, Greece
l
l
l
Lugano, Switzerland
l
l
l
Mexico City, Mexico
l
Narita, Japan
l
Reggello, Italy
l
l
l
l
l
Sant Cugat, Spain
l
l
Shanghai, China
l
Yamagata, Japan
l
Status as of 31 December 2008
77
Injectables
Contract
manufacturing
Pharmaceuticals Production
l
activities in Ingelheim, Germany, under a single
Pharma Chemicals
roof. With our resomer® activities we keep at
At Pharma Chemicals we
benefit from the experience
and competence of the
whole Boehringer Ingelheim
group.
the cutting edge in enabling new drug delivery
approaches and new surgical ­device design.
Active pharmaceutical ingredients (API)
manufacture and new chemical entities (NCE)
development
Our Chemicals Division produces Boehringer
­Ingelheim’s own APIs in a global production
­network, as well as offering manufacturing
Contract development and manufacturing
and development services to our industrial
We take a flexible approach to the individual
­customers.
needs of pharmaceutical companies that opt to
buy rather than make their proprietary new
Our five chemical production sites in Germany,
chemical entities (NCEs). Cooperation is under-
France, Italy, Spain and the USA are operated
taken in stages, as desired, and tailored precisely
as a worldwide network. Germany, as our launch
to the customer’s requirements. We also manu-
site, has state-of-the-art facilities for the
facture and market active pharmaceutical ingre-
­development of NCEs, all the required expertise
dients (APIs) that are well-­established world-
and r­esources for launching new products and
wide – our API Classics. These cover important
­highly flexible, multi-purpose production plants.
indication areas for healthcare systems and play
Our facilities enable active ingredients to be
a major role in significant pharmaceutical mar-
­synthesised chemically or extracted and refined
kets. We are also a world leader in extracting ac-
from medicinal plants. We have the capacity
tive ingredients from medicinal plants and have
range to seamlessly upscale the production of
seamless command of the whole process chain
extremely complex chemicals from one kilo to
from plant cultivation on our own plantations to
multi-ton levels. Our Ingelheim site successfully
making marketable pharmaceuticals.
supported the 2008 launch of pradaxa® with
the development and supply of the active ingre-
Besides the supply of active ingredients, we
dient dabigatran etexilate. We complement our
also offer resorbable polymers for medical and
worldwide chemical production network with
­pharmaceutical applications. resomer® is ­firmly
strong partners for the manufacturing of starting
established in this niche market. Recently, we
materials and intermediates for our APIs. In
completed a new production and laboratory
2008, we started a strategic production alliance
building which brings our biodegradable ­polymer
in ­China. l
Technologies (Pharma Chemicals)
Synthesis
API
Phyto­
chemicals
Process
development
Regulatory
registration
support
Toxicology
process safety
l
l
l
l
l
Blanquefort, France
l
Ingelheim, Germany
l
Fornovo, Italy
l
l
Malgrat de Mar, Spain
l
l
Petersburg, USA
l
l
Status as of 31 December 2008
78
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
l
l
product supply and industrial customer
Manufacturing excellence in our centre
given it the capacity to be our global supplier of
for global animal health vaccines
porcine, bovine and equine vaccines at a time of
growing worldwide demand for preventative
­approaches.
In pursuit of our aim to
become a world leader
in vaccines for animals,
we have concentrated the
development and manufacturing of almost all of
our vaccines at our
multi-purpose US facility
in St. Joseph, Missouri.
Our strong and ever-growing presence in the
swine vaccine segment reflects a series of
­breakthroughs made at St. Joseph. ingelvac®
Aujeszky vaccine was developed there as our
first ­ innovative pig vaccine in the late 1980s,
­followed by ­i ngelvac® prrs, ingelvac® m.hyo,
­enterisol® ileitis, and only recently, ­ingelvac
­circoflex®.
Both commercial and animal welfare consider­
ations are driving this trend and our vaccine facility has had to keep up with the fast-expanding
market. From an annual 150 million vaccine
The St. Joseph plant is equipped with cutting
doses in 2001, we now produce around 400
edge technologies such as bioreactors and fer-
­million and are targeting almost 700 million
menters for cell and microbial fermentation and
doses by 2012. Our St. Joseph site currently
large freeze dryers. Furthermore, the facility
­manufactures more than 100 vaccine types. l
holds both an EU good manufacturing practice
(GMP) and a USDA licence representing the
­highest quality and compliance standard in the
animal health industry, which allows vaccine
registrations in almost all countries outside the
USA. Locating global production in the USA has
a particular advantage, as US regulations make it
difficult to import vaccines into the country – our
largest market for our Animal Health products.
The constant updating and expansion of the
highly flexible St. Joseph plant has made it one of
the leading vaccine facilities in the world and has
Core competencies in vaccine production (Boehringer Ingelheim Vetmedica. Inc)
Swine
vaccines
Guadalajara, Mexico
l
St. Joseph, USA
l
Equine
vaccines
Bovine
vaccines
l
l
l
Status as of 31 December 2008
79
Pet
vaccines
Manufacturing excellence in our centre for global animal health vaccines
Poultry
vaccines
l
l
helen lewis and mary “We saw an improvement after a week.”
80
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
animal health
My lion queen leaps again!
Mary is a 14-year-old cat who is “head of the household”
at the home she shares with Helen Lewis next to the pub
in the village of Benenden in southeast England. Helen,
a sprightly 81-year-old, explains, “I can’t remember why
we called her Mary, but she’s a very independent cat and
has always known what suits her best. But she’s a very
gentle soul and is remarkably friendly and dignified; even
our vet has commented how well behaved she is. I think she
has a sense of humour and a conscience, and I like talking
to her, but of course, friends tease me over that!” says Helen.
It was a couple of years ago when Helen, a trained
pharmacist, spotted that Mary was showing the
first signs of arthritis. “I recognised that she was
getting slower. She used to be a great leaper,
springing from tables and high up places. She
was also climbing the stairs step by step, whereas
before she would bound up them. It was and I
was checking her back legs one day and she hissed
fiercely that it became clear that she was suffering
from pain.
Mary could tell there was something slightly
­different about her when I gave her the anti­arthritis medication the vet prescribed. I would
say without a shadow of a doubt it works and we
saw an improvement in a week or so and Mary
Highlights Animal Health
ingelvac circoflex® – successful roll-out
to Europe and Asia
ingelvac circoflex®
has been our most successful
product in Animal Health in
2008. The roll-out of this
innovative vaccine for fighting PCVD was extended to
Europe and Asia.
began scampering around much more. We’re
­delighted – she is such a comfort and I’d do
ingelvac circoflex® is the first vaccine that
­anything for her.” l
protects pigs against the early and late form of
81
My lion queen leaps again!
porcine circovirus disease (PCVD) with only one
ubrolexin® – Our new mastitis treatment
injection around weaning. Other vaccines have
meets strong demand
to be given twice. This reduces stress for the animals and helps farmers to save expensive ­labour
costs. The combination of a purified circovirus
antigen (PCA) and a non-mineral oil slow release
adjuvant allows a unique synthesis of highest
efficacy and extreme safety properties. These
outstanding product characteristics have made
ingelvac circoflex® the global market leader
in its market segment, with more than
100 million doses sold in less than two years after
the first national marketing authorisation. The
global roll-out has just begun with Europe
and Asia moving into full supply in 2009. The
first convenient combinations of ingelvac
circoflex® with another core swine vaccine of
Boehringer Ingelheim Animal Health, ingelvac
As any dairy farmer can
tell, mastitis is the main
disease affecting cows today. ­
In October 2008, Boehringer
Ingelheim launched
ubrolexin®, a novel broadspectrum intramammary
treatment and a highly
effective tool in the control
of mastitis.
mycoflex®, have also just recently been licensed
in North America. l
With constant zootechnical improvement to
­increase milk yields, a large proportion of dairy
cattle suffer from mastitis, an infection of the
mammary glands. Triggered by a variety of
­pathogens, mastitis severely impacts the cow’s
health and milk quality, and reduces output.
The need for quick reaction upon occurrence of
mastitis is key to maintaining every chance for
ingelvac circoflex®
­successful cure. The availability of a first-line
treatment, which can be applied by farmers
themselves, then becomes of paramount import­
ance. Matching this need, ubrolexin® provides
farmers with exceptionally high efficacy and
safety in addition to convenience of use: infected
quarters only have to be treated twice with
ubrolexin®, leaving an interval of 24 hours
­between treatments.
ubrolexin® met exceptionally strong demand
on its initial launches in the Netherlands and the
United Kingdom in October and by early 2009
it will be available in all the main EU markets.
ingelvac circoflex® is the first one-dose
­vaccine for the reduction of the early and late
form of PCVD.
82
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
The novelty of ubrolexin® is the intelligent way
it combines two target spectrum antibiotics at a
specific ratio of concentration into a broad spectrum product. By making use of the ­synergistic
animal health
effects achieved through the combination,
Following the important launch in the USA the
­u brolexin® reaches an efficacy which by far
previous year, vetmedin® was launched in 2008
­exceeds that of the individual components. This
and very well-received in the remaining major
reduces the total amount of antibiotic ­needed for
companion animal market Japan. vetmedin® is
an effective treatment and at the same time limits
today sold in more than 30 countries around the
the risk of resistance development. Against a
world and is now market leader in the global
background of widespread criticism of the use of
­canine cardiology segment. l
antibiotics on food-producing animals, these
­effects, due to the synergistic activity in
­u brolexin®, are important contributions to
ingelvac® prrs mlv – a great success in China
the prudent use of antibiotics in mastitis treatment. l
vetmedin® reached a major
milestone in 2008 with the
publication of the longanticipated quest™ study.
During 2008, Boehringer
Ingelheim Animal Health
again provided an efficient
innovative vaccine against
outbreaks of a serious pig
disease in Asia, especially
in China.
Commissioned by Boehringer Ingelheim, the
Porcine reproductive and respiratory syndrome
study, the largest of its kind ever conducted,
(PRRS) is another major viral disease threatening
­involved pet dogs with congestive heart failure
modern pig production worldwide. Since the
quest™ – Good news for dog owners
(CHF) caused by mitral valve disease.
mid-1990s, Boehringer Ingelheim Animal Health
has been the leading supplier in this vaccine
­segment and 2008 provided additional growth,
namely in the biggest swine producing economy,
China. Starting in 2007, China suffered from a
The ­primary aim of the quest™ study (Quality of
new, highly virulent strain of PRRS which killed
Life and ­Extension of Survival Time) was to ana-
a large number of pigs and swept rapidly across
lyse the effect on survival of dogs suffering from
the country. Early on, Boehringer Ingelheim
­congestive heart failure due to mitral valve
­initiated a collaboration with the Shanghai Vet-
­insufficiency, the most common form of heart
erinary Research Institute to establish ­scientific
disease in dogs. ­Under the guidance of Professor
proof for the cross-protection of ­ ingelvac®
Jens Häggström, University of Uppsala, Sweden,
prrs mlv against these newly emerging Chinese
­32 renowned ­ cardiologists from 11 countries
strains. Results became available in mid-2008
in Europe, North America and Australia
and fostered a strong demand for our unique
­participated in the study. The success of the
­attenuated PRRS vaccine. Meanwhile, highly
quest™ study can be attributed to the close
virulent strains of PRRS have emerged in other
­cooperation between scientists from Boehringer
Asian countries and strong global demand for
Ingelheim and the most important academic
ingelvac® prrs mlv is projected for the coming
­research institutes. ­Results were presented to the
years. l
veterinary ­scientific community at two important
congresses.
83
Highlights Animal Health
Samples of the product portfolio
Branded Prescription Medicines
Respiratory diseases
Chronic obstructive pulmonary disease (COPD)
COPD is caused by noxious stimuli, such as cig­
and asthma are among the most prevalent
arette smoke or air pollution. COPD can manifest
­chronic diseases affecting the lung, and cause
itself as chronic bronchitis with cough and
­significant morbidity and premature deaths
­sputum, or as emphysema caused by destruction
worldwide.
of the lung tissue. The course of COPD is charac­
terised by occasional sudden worsening of symp­
COPD
toms called acute exacerbations.
Chronic obstructive pulmonary disease is a dis­
ease of the lung in which the airways ­become
Asthma
narrowed. This leads to a limitation of airflow
Asthma is a chronic disease involving airway in­
causing shortness of breath and other respiratory
flammation in response to exposure to asthma
symptoms. The airflow limitation is only ­partially
triggers, such as allergens. Airway inflammation
reversible and usually worsens gradually over
causes airways to narrow, mucus to increase and
time.
breathing to be more difficult. In the early stages
of disease, this airflow limitation is fully reversi­
ble and patients can be free of symptoms between
attacks.
84
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product portfolio
Indications
Brand names
Active ingredients
• Chronic obstructive
pulmonary disease (COPD)
spiriva®
tiotropium bromide
Maintenance treatment of patients with
COPD (chronic obstructive pulmonary
disease, including chronic bronchitis and
emphysema), the maintenance treatment
of associated dyspnoea and for prevention
of exacerbations.
• Bronchospasms associated
with reversible obstructive
airway diseases
combivent®
ipratropium bromide,
salbutamol
Treatment of bronchospasms associated
with reversible obstructive airway diseases
in patients requiring more than one
bronchodilator.
• Chronic obstructive
pulmonary disease (COPD)
• Chronic bronchitis
• Asthma
atrovent®
ipratropium bromide
Bronchodilator for maintenance treatment
of bronchospasm associated with chronic
obstructive pulmonary disease, including
chronic bronchitis, emphysema and
asthma.
• Bronchial asthma
• Chronic bronchitis
berodual®
bronchodual®
duovent®
fenoterol,
ipratropium bromide
For prevention and treatment of symptoms
in chronic obstructive airway disorders
with reversible bronchospasm, such as
bronchial asthma, and especially chronic
bronchitis, with or without emphysema.
• Bronchial asthma
berotec®
dosberotec®
fenoterol
Symptomatic treatment of acute asthma
attacks, prophylaxis of exercise-induced
asthma, symptomatic treatment of
bronchial asthma and other conditions
with reversible airway narrowing,
e. g. chronic obstructive bronchitis.
• Bronchial asthma
inflammide®
budesonide
Chronic control of symptoms and signs
of bronchial asthma.
85
Samples of the product portfolio Branded Prescription Medicines
Respiratory diseases (continued)
Diseases of the central nervous system
Mental and neurological diseases, such as
in the legs as well as disturbed sleep resulting in
­depression and Parkinson’s disease, significantly
daytime tiredness or sleepiness. The sensations
impact patients and their families, and are a
are felt deep within the legs and are described as
­significant burden to society.
creeping, crawling or aching.
Parkinson’s disease
Major depressive disorder
Parkinson’s disease (PD) is a degenerative dis­
Major depressive disorder (MDD) is a mental dis­
order of the central nervous system. Patients usu­
order characterised by a low mood and loss of
ally notice motor symptoms, like hand tremor
interest or pleasure in usual activities. The diag­
(shaking), as their first sign of the disease, which
nosis is based on the patient’s self-reported ex­
progresses eventually to include shaking of the
periences. MDD is a highly prevalent disease that
arms, legs or head. Other motor symptoms that
completely disrupts patients’ lives and is a major
develop over time include stiffness that often
cause of absenteeism from work worldwide.
­results in loss of facial expression and a gradual
slowing or loss of motion or “freezing”. About
Generalised anxiety disorder
30–40% of patients also suffer from non-motor
Generalised anxiety disorder (GAD) is character­
symptoms associated with PD, such as depres­
ised by excessive, uncontrollable and often
sion and sleep disorders. The primary symptoms
­irrational worry about everyday things. This
are the results of decreased stimulation of brain
­excessive worry often interferes with the patient’s
cells by lack of the neurotransmitter dopamine.
life. Patients often have physical symptoms such
as fatigue, headaches, nausea, pain, sweating or
Restless legs syndrome (RLS)
Restless legs syndrome (RLS) is a common neu­
rological disorder characterised by an uncontrol­
lable urge to move the legs, usually accompanied
by unpleasant and sometimes painful sensations
86
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
sleeping difficulties.
product portfolio
Indications
Brand names
Active ingredients
• Bronchial asthma
• Allergic rhinitis
• Allergic skin disorders
with pruritus
alesion®
flurinol®
epinastine
Indications
Brand names
Active ingredients
• Parkinson’s disease (PD)
• Restless legs syndrome
(RLS)
sifrol®
mirapex®
mirapexin®
pexola®
pramipexole
Symptomatic treatment of idiopathic
Parkinson’s disease. It may be used as
monotherapy or in combination with
levodopa. Symptomatic treatment of
idiopathic restless legs syndrome.
• Depression
• Diabetic neuropathic pain
(DNP)
• General anxiety disorder
(GAD)
cymbalta®
xeristar®
duloxetine hydrochloride
Treatment of depression.
Treatment of diabetic neuropathic
pain (DNP).
Treatment of general anxiety disorder
(GAD).
• Diabetic neuropathic pain
(DNP)
ariclaim®
duloxetine hydrochloride
Treatment of diabetic neuropathic
pain (DNP).
• Sleep disorders
lendormin®
lendorm®
lindormin®
sintonal®
brotizolam
Short-term treatment of disorders of
initiating and maintaining sleep.
87
Samples of the product portfolio Branded Prescription Medicines
Prophylactic treatment of bronchial
asthma. Prophylaxis and symptomatic
treatment of allergic rhinitis, allergic skin
disorders with pruritus, such as urticaria,
and eczema/dermatitis.
Cardiovascular diseases
Cardiovascular diseases are the leading causes of
Acute myocardial infarction
death in many countries, and are still increasing
An acute myocardial infarction, or heart attack,
in prevalence.
is an acute event that occurs when a thrombus or
clot suddenly prevents blood flow to an area of
Stroke
the heart muscle. Unless the blood flow is ­restored
Stroke is the rapidly developing loss of brain
quickly, the affected section of heart muscle
functions due to a blockage of the blood flow
­becomes permanently damaged. Heart attack is
to the affected brain tissue. This can be due to
a leading cause of death in all developed coun­
ischaemia (lack of blood supply) caused by
tries.
thrombosis or embolism, or due to a bleeding. As
a ­result, the affected area of the brain is unable
Hypertension
to function and the damage quickly becomes
Hypertension, also referred to as high blood pres­
­permanent, if untreated. Stroke is an acute event
sure, is a chronic disease in which the blood
needing emergency diagnosis and intervention.
­pressure is chronically elevated. Hypertension is
Stroke is one of the leading causes of death and
one of the major risk factors for strokes, heart
long-term disability in the developed world.
attacks, heart failure and chronic renal failure.
Symptoms of a transient ischaemic attack (TIA)
are similar to stroke, but lasting for only a few
minutes or hours. As a TIA may precede a stroke,
emergency medical care and subsequent preven­
tive treatment is necessary.
88
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product portfolio
Indications
Brand names
Active ingredients
• Hypertension
micardis®
micardisplus®
micardis® plus
micardis® hct
co-micardis®
telmisartan;
telmisartan,
hydro­chlorothiazide
Treatment of essential hypertension.
• Secondary prevention of
aggrenox®
stroke or transient ischaemic asasantin®
attacks (TIA)
asasantin® retard
persantin® plus
dipyridamole,
acetylsalicylic acid
Prevention of stroke following a first
stroke or transient ischaemic attacks.
persantin® plus as above and adjunct
to coumarin ­­anticoagulants in the
prevention of post-operative thromboembolic complications of cardiac valve
replacement.
• Hypertension
clonidine
All forms of high blood pressure, unless
caused by phaeochromocytoma.
• Acute myocardial infarction, actilyse®
acute massive pulmonary
embolism
• Acute ischaemic stroke
• Catheter clearance due to
thrombotic occlusion
alteplase
Fibrinolytic treatment of acute myocardial
infarction, acute massive pulmonary
embolism, acute ischaemic stroke and for
catheter clearance due to thrombotic
occlusion.
• Acute myocardial infarction
metalyse®
tenecteplase
Fibrinolytic treatment of acute myocardial
infarction.
• Ventricular tachycardia
mexitil®
mexitilen®
mexiletine
Serious symptomatic ventricular tachy­
cardic heart rhythm disturbances.
• Hypertension
motens®
caldine®
tens®
midotens®
lacidipine
Treatment of essential hypertension.
catapresan®
catapres®
catapressan®
atensina®
89
Samples of the product portfolio Branded Prescription Medicines
Cardiovascular diseases (continued)
Venous thrombo-embolism
Patients undergoing orthopaedic surgery are at
venous insufficiency in the lower extremity often
considerable risk of developing deep vein throm­
develops, resulting in chronic pain, venous
bosis in the legs or a potentially fatal pulmonary
­ulceration, swelling, and skin changes in the
embolism. Both are also known as venous
­affected leg. To prevent any event and its conse­
thrombo-­embolism (VTE). In the longer term,
quences, the ­ majority of patients receive some
thrombo-embolic events may recur and chronic
kind of thromboprophylaxis.
Viral diseases
Acquired immune deficiency syndrome
Acquired immune deficiency syndrome (AIDS) is
a set of symptoms and infections resulting from
the damage to the human immune system caused
by the human immunodeficiency virus (HIV). If
untreated, this condition progressively reduces
the effectiveness of the immune system and
leaves individuals susceptible to opportunistic
infections and tumours. Babies of infected
mothers are at risk of getting the virus during
pregnancy, childbirth or breastfeeding.
Urological diseases
Benign prostate hyperplasia
Benign prostate hyperplasia (BPH) refers to an
enlargement of the prostate in middle-aged and
elderly men, which can lead to problems with
urination and consequent infections of the
­urinary tract.
90
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product portfolio
Indications
Brand names
Active ingredients
• Primary prevention of
­venous thrombo-embolic
events after orthopedic
surgery
pradaxa®
pradax™
pradaxar™
dabigatran etexilate
Indications
Brand names
Active ingredients
• HIV/AIDS
viramune®
nevirapine
Available as tablets and suspension for
adults and children – for the combination
therapy of HIV-1 infection and for the
prevention of mother-to-child transmis­
sion of HIV-1 in pregnant women who are
not taking antiretroviral therapy at time
of labour.
• HIV/AIDS
aptivus®
tipranavir
Capsule and oral solution – co-adminis­
tered with 200 mg of ritonavir, is indicated
for combination antiretroviral treatment
of HIV-1-infected patients with evidence
of viral replication, who are treatmentexperienced and infected with HIV-1
strains resistant to more than one protease
inhibitor.
Indications
Brand names
Active ingredients
• Benign prostate hyperplasia
(BPH)
flomax®
alna®
josir®
pradif®
secotex®
urolosin®
mecir®
tamsulosin
Lower urinary tract symptoms (LUTS)
associated with benign prostate hyper­plasia
(BPH).
• Benign prostate hyperplasia
(BPH)
flomax® cr
alna® ocas®
pradif® t
urolosin® ocas®
tamsulosin,
orally controlled
absorption system
Lower urinary tract symptoms (LUTS)
associated with benign prostate hyper­plasia
(BPH).
91
Samples of the product portfolio Branded Prescription Medicines
Primary prevention of venous thromboembolic events (VTE) in adults after
elective total hip or knee replacement
surgery.
Samples of the product portfolio
Consumer Health Care
Cough and cold
mucosolvan® (ambroxol) and bisolvon® (brom­
clearance mechanisms of the respiratory tract,
hexine) are both indicated for secretolytic ­therapy
which play an important role in the body’s nat-
in bronchopulmonary diseases associated with
ural ­defence mechanisms. Ambroxol stimulates
abnormal mucus secretion and impaired mucus
synthesis and release of surfactant by type II
transport.
pneumocytes.
Cough is the most common symptom of clinical
bisolvon® (bromhexine), available for all age
importance and the most frequent reason to
groups, has been on the market since 1963.
­consult a doctor. The clinical symptoms of cough
­Brom­hexine is contained in various formulations
and expectoration have led to the development
of bisolvon®. There are high and low strength
of drugs that affect respiratory mucus, i.e. the
syrups 8 mg/5 ml, 4 mg/ml, tablets and soluble
mucoactive agents.
tablets (both with 8 mg bromhexine) and solu­
tion for oral use 10 mg/5 ml), adapted to the need
mucosolvan® (ambroxol), which promotes
of the patients. Bromhexine is a synthetic deriva­
­mucus clearance, facilitates expectoration and
tive of the herbal active ingredient vasicine. It has
eases productive cough, allowing patients to
been shown to increase the proportion of serous
breathe freely and deeply, is the world’s leading
bronchial secretion, making it more easily
cough brand. It is available in many different for­
­expectorated. Bromhexine also enhances mucus
mulations.
transport by reducing mucus viscosity and by
activating the ciliated epithelium.
Ambroxol is a mucoactive drug with several
properties, including secretolytic and secreto­
motoric actions that restore the physiological
Sore throat
mucoangin® (ambroxol) is the best documented
uous pain in the throat maximised when swal­
product and is well tolerated in its category of
lowing. The main goal of the treatment is thus to
pain relief in acute sore throat.
reduce pain.
Pain in sore throat is the hallmark of acute
The main property of ambroxol is the local an­
­pharyngitis, usually caused by a viral infection.
aesthetic effect, described first in the late 1970s,
The infection is self-limited and the patient
but explained and confirmed in more recent
­recovers normally in a couple of days. What is
work.
most bother some for the patient is the contin-
92
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product portfolio
Indications
Brand names
Active ingredients
• Acute and chronic
bronchopulmonary diseases
mucosolvan®
motosol®
mucosan®
surbronc®
vaksan®
lasolvan®
mucosal®
mucopect®
ambroxol
Secretolytic therapy in acute and chronic
bronchopulmonary diseases associated
with abnormal mucus secretion and
impaired mucus transport.
• Acute and chronic
bronchopulmonary diseases
bisolvon®
bromhexine
Secretolytic therapy in acute and chronic
bronchopulmonary diseases associated
with abnormal mucus secretion and
impaired mucus transport.
• Cough
silomat® dmp
dextrometorphane
Symptomatic treatment of irritable,
non-productive cough.
Indications
Brand names
Active ingredients
• Sore throat
mucoangin®
lysopadol®
ambroxol (lozenges)
93
Samples of the product portfolio Consumer Health Care
Pain relief in acute sore throat.
Gastrointestinal diseases
In our gastrointestinal portfolio, we offer
Other products within the dulcolax® m
several brands, such as dulcolax®, dulcolax®
­b alance franchise include dulcoease® (stool
m ­ balance, dulcofibre®, laxoberal® and
softener), dulcoenema® and dulcofibre®.
buscopan®, as well as the heartburn brand
­z antac®.
Abdominal cramping, pain and discomfort are
common ailments. Approximately one in four
Within the dulcolax® franchise, Boehringer
persons worldwide suffers on a regular basis.
Ingelheim markets a range of products for the
treatment, regulation and prevention of intes­
buscopan® is an antispasmodic product with
tinal irregularity and disruption. The primary
the active ingredient hyoscine butylbromide.
­ailment within this area is constipation, for
The product is basically a natural substance
which dulcolax® tablets are today the main
­extracted from Duboisia plant species as scopol-
source of treatment.
amine (hyoscine) and chemically modified to the
quaternary ammonium compound hyoscine
dulcolax® tablets have a special enteric com­
butylbromide. As an antispasmodic product,
fort coating to ensure that the active ingredient is
buscopan® acts directly on the site of abdominal
transported to work only where it is needed – in
pain by relaxing the muscles of the gastrointesti­
the large intestines. Here it stimulates the natural
nal tract.
movement of the bowels to provide gentle,
­predictable relief within 6–12 hours. One to two
This means buscopan® relieves abdominal pain
tablets taken before going to bed will still provide
by directly treating its main cause – abdominal
relief the next morning.
cramp or spasm.
The active ingredients bisacodyl (dulcolax®
Several buscopan® line extensions are available
­tablets and suppositories), sodium picosulfate
today – the mono-variant and in different com­
(dulcolax® pearls, liquid drops and syrup) and
binations with analgesics (paracetamol, ibu­
macrogol (dulcolax® m balance) are scien­
profen and metamizol/dipyrone) – and different
tifically proven to provide gentle and effective
formulations (tablets, drops, suppositories, syrup
relief.
and solutions for intravenous injection).
94
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product portfolio
Indications
Brand names
Active ingredients
• Constipation
dulcolax®
bisacodyl (tablets, suppositories),
sodium picosulfate
(drops, pearls)
Laxative for use in patients suffering from
constipation. In preparation for diagnostic
procedures, in pre- and post­-operative
treatment and in conditions, which require
defecation to be facilitated.
• Constipation
dulcolax® m balance
macrogol 4000
Symptomatic treatment of constipation
for adults and children from eight years
onwards.
• Constipation
dulcofibre®
glucomannan
Reactivation/regulation of bowel move­
ment; helps to maintain regularity.
• Constipation
laxoberal®
laxoberon®
guttalax®
sodium picosulfate
(drops, pearls, tablets)
Laxative for use in cases of constipation
and in conditions which require defecation
to be facilitated.
• Abdominal cramping
buscopan®
buscapina®
hyoscine butylbromide
Treatment for the relief of abdominal
cramping, pain and discomfort.
95
Samples of the product portfolio Consumer Health Care
Gastrointestinal (continued)
Vitamins and supplements
pharmaton® is a multivitamin and mineral
pharmaton® kiddi®, a range of products
supplements brand developed to enhance peo­
­designed for children, contains selected vitamins,
ple’s physical and mental well-being. A full range
minerals and key nutrients that are very import­
of products adapted to the needs of different
ant for growth. It is especially recommended in
target audiences has been developed that work
the preventive treatment of vitamin deficiencies.
in harmony with the body.
pharmaton® matruelle is a pre-natal multi­
pharmaton® core, a range of products for
vitamin for active planning, pregnant and lactat­
adults, contains a synergic and unique blend
ing women, containing all important micronu­
of vitamins, minerals and trace elements and
trients for mother and baby, such as vitamins,
­standardised Ginseng G115 extract. The main
minerals and omega-3 fatty acids, to cover the
target ­ indications are: exhaustion, tiredness,
increased needs for these substances in those
­decreasing ­ concentration and mental alertness.
particular periods. Moreover, it helps to protect
Numerous clinical studies have shown that a
against embryonal neural tube diseases of the
regular intake of pharmaton® has a positive
foetus and against iron and folic acids anaemia
­effect on mental and physical performance and
during pregnancy.
well-being.
96
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product portfolio
Indications
Brand names
Active ingredients
• Heartburn
zantac® (*)
ranitidine
Relieves heartburn associated with acid
indigestion and sour stomach. Prevents
heartburn associated with acid indigestion
and sour stomach brought on by certain
foods and beverages.
* only available in the USA
Indications
Brand names
Active ingredients
• Tiredness
• Decreasing concentration
pharmaton®
standardised ginseng
extract, vitamins,
minerals, trace
elements
For states of exhaustion (e. g. caused by
stress), tiredness, feeling of weakness,
decreasing concentration as well as
decreasing mental alertness.
• Children’s multivitamin
pharmaton® kiddi®
vitamins, minerals,
amino acids
Increasing demand for vitamins, minerals
and amino acids, especially during the
period of growth. Preventive treatment in
case of vitamin deficiencies, e. g. restricted
diets, convalescence, loss of appetite,
following illness, infection or surgery.
• Prophylaxis of iron and
folic acid deficiency during
pregnancy
pharmaton®
­ atruelle
m
vitamins, minerals,
trace elements,
omega-3 fatty acids
[docosahexa­enoic
acid (DHA)]
For women of child-bearing age intending
to become pregnant, already pregnant
and lactating, to cover the increased needs
for vitamins, minerals, trace elements
and DHA. To provide protection against
embryonal neural tube diseases of the
foetus, and prophylaxis of iron and folic
acid anaemia during pregnancy.
97
Samples of the product portfolio Consumer Health Care
Leg vein health
Under the brand name antistax®, Boehringer
of the described symptoms. antistax® acts to
­Ingelheim markets a range of products developed
help keep the fluid that flows out of the capillar­
for the prevention and treatment of symptoms
ies at normal levels, even when standing or sit­
attributable to known venous insufficiency. The
ting down for a long time. Red vine leaf extract
most common symptoms of venous insufficiency
AS 195, the active ingredient in antistax® prod­
observable for consumers are varicose veins,
ucts, works on the endothelium inside the veins
oedema of the lower leg, heavy or tired legs, sen­
by sealing them from the inside, thereby reduc-
sation of tension, tingling and pain. antistax®
ing the swelling and the sensation of pain and
capsules and tablets are scientifically proven to
heaviness.
help maintain healthy leg vein circulation.
Products available in the antistax® range
Heavy, aching and tired legs often occur after
­include antistax® tablets, antistax® capsules,
long periods of standing or sitting, and increase
antistax® cooling gel and antistax® cooling
at the end of the day or during the summer when
spray.
outdoor temperatures rise. antistax® tablets
and antistax® capsules offer effective treatment
Pain
The brand thomapyrin® comprises products
For this reason, the triple combination is recom­
for the treatment of acute pain of mild to inter­
mended by many national and international
mediate intensity.
medical societies as first choice acute treatment
thomapyrin® classic is the core product,
thomapyrin® is positioned as the expert treat­
which is composed of a triple combination of ace­-
ment of headache. Several line extensions are
tylic salicylic acid, paracetamol and ­caffeine. The
available: thomapyrin® classic for ­ normal
three components suppress pain synergistically
headache, thomapyrin® intensiv for stronger
via interaction with several pain-related molec­
headache, thomapyrin® medium for milder
ular mechanisms. As a result thomapyrin®
headache, and thomapyrin® Effervescent as a
­c lassic disposes of a fast and superior efficacy
galenic alternative.
for tension type headache and migraine.
compared with its single components which is,
amongst others, well proven by state-of-the-art
clinical studies.
98
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product portfolio
Indications
Brand names
Active ingredients
• Chronic venous
­insufficiency
antistax®
red vine leaf extract
Indications
Brand names
Active ingredients
• Pain
thomapyrin® classic
thomapyrin® intensiv
(*)
acetylsalicylic acid,
paracetamol, caffeine
* only available in Germany
99
Samples of the product portfolio Consumer Health Care
Prevention and treatment of symptoms
of chronic venous insufficiency; varicose
veins, leg oedema, painful swollen
legs, tingling legs, tired and heavy legs.
For adults and adolescents older than
twelve years for acute treatment of mild
to moderate headache, migraine attacks,
with and without aura, and for the
treatment of tension-type headache.
Samples of the product portfolio
Animal Health
Food producing animals – Swine
Infectious respiratory diseases
Pain and inflammatory diseases
ingelvac c ircoflex® is the first one-dose
metacam® as a member of the class of non-
­vaccine for the reduction of the early and late
­steroidal anti-inflammatory drugs (NSAID)
form of porcine circovirus disease (PCVD). This
­marries the need for maintained profitability and
vaccine provides significant reduction of mortal­
the concern for animal welfare in animal pro­
ity in the acute phase of PCVD as well as ­improved
duction.
growth rates in the chronic phase of the disease.
ingelvac circoflex® protects without causing
Due to its long-acting feature and its outstanding
systemic adverse reactions or injection site
efficacy in controlling inflammatory symptoms,
­swellings. ingelvac® prrs mlv is ­ licensed for
it helps minimising losses from inflammation
the active immunisation against the respiratory
and maintaining profitability in disease situ­
and reproductive form of porcine ­ reproductive
ations. At the same time, metacam® effectively
and respiratory syndrome (PRRS).
controls pain and supports the restoration of the
well-being in farm animals. The use of ­m etacam®
ingelvac® m. hyo and ingelvac mycoflex®
is convenient and inflicts no stress on animals
are ­licensed for the active immunisation of pigs
due to its low-volume, one-shot feature.
against enzootic pneumonia (EP) in a one-dose
regimen. Through their advanced depot-adju­
metacam® is licensed for the use in swine
vant systems they provide a long lasting and
­suffering from non-infectious locomotor dis­
­effective protection until slaughter, proven even
orders. In addition, it is used in the treatment of
in high-challenge situations.
puerperal septicaemia and toxaemia (mastitismetritis-agalactia syndrome).
Infectious enteric diseases
enterisol® ileitis is the first and only vaccine
against ileitis caused by Lawsonia intracellularis. It is licensed to improve weight gain and to
reduce growth variability associated with the
disease. enterisol® ileitis helps to reduce the
total antimicrobial use in pork production.
100
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product portfolio
Indications
Brand names
Active ingredients
• Infectious respiratory
diseases
ingelvac circoflex®
recombinant vaccine
(porcine circovirus
type 2, PCV-2)
For the active immunisation of pigs over
the age of two weeks against porcine
circovirus type 2 to reduce mortality,
clinical signs – including weight loss –
and lesions in lymphoid tissues associated
with porcine circovirus diseases (PCVD).
• Infectious respiratory
diseases
ingelvac® m.hyo
inactivated vaccine
(Mycoplasma
hyopneumoniae)
For the active immunisation of pigs from
three weeks of age to reduce lung lesions
following infection with Mycoplasma
hyopneumoniae.
• Infectious respiratory
diseases
ingelvac® prrs mlv
attenuated live vaccine
(PRRS virus)
For the active immunisation of swine from
three weeks of age against the respiratory
and reproductive form of PRRS virus
infection (porcine reproductive and
respiratory syndrome).
• Infectious enteric diseases
enterisol® ileitis
attenuated live vaccine
(Lawsonia intracellularis)
For active immunisation of pigs from
three weeks of age and older to reduce
intestinal lesions caused by Lawsonia
intracellularis infection and to reduce
growth variability and loss of weight
gain associated with the disease.
• Pain and inflammatory
diseases
metacam®
meloxicam
Non-infectious locomotor disorders.
To reduce lameness and inflammation.
Adjunctive therapy against mastitismetritis-agalactia-syndrome.
101
Samples of the product portfolio Animal Health
Food producing animals – Cattle
Mastitis
Pain and inflammatory diseases
mamyzin® Injection contains penethamate
metacam® as a member of the class of non-ster­
­hydroiodide, a prodrug of penicillin G which
oidal anti-inflammatory drugs (NSAIDs) com­
­offers a unique pharmacokinetic profile.
bines the need for maintained profitability and
the concern for animal welfare in animal pro­
Achieving very high absorption and accumula­
duction.
tion rates of its active principle in the udder,
mamyzin® is an excellent first line treatment of
Due to its long-acting feature and its outstanding
(penase negative) Staphylococcus aureus and
efficacy in controlling inflammatory symptoms,
Streptococcus spp. Highly suitable for combin­
it helps minimising losses from inflammation
ation therapy, mamyzin® is aditionally an ideal
and maintaining profitability in animals suffer­
tool in whole herd sanitation programmes where
ing from disease. At the same time metacam®
it is used to ­ control subclinical mastitis during
effectively controls pain and supports the restor­
lactation, as ­initial dry-off treatment in problem
ation of the well-being in farm animals. The use
herds, and for metaphylaxis in heifers.
of metacam® is convenient and inflicts no stress
benestermycin® is a broad spectrum and long-
­feature.
on animals due to its low-volume, one-shot
acting antibiotic preparation designed to effec­
tively treat existing infections at dry-off and to
metacam® is licensed for use in cattle suffering
prevent new infections during the dry period in
from respiratory disease. Also, it is indicated in
dairy cattle.
calves affected by diarrhoea and as adjunctive
therapy in the treatment of mastitis in lactating
ubrolexin® delivers enhanced bactericidal
­activity through a specifically designed combina­
tion of two complementary targeted antibiotics
working in synergy. ubrolexin® marks a new
quality of broad spectrum mastitis treatment
­because it achieves uncompromised efficacy on
both ends of the pathogen spectrum. This makes
ubrolexin® a simple-to-use, “no compromise”
product for the routine treatment of clinical
­mastitis.
102
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
cattle.
product portfolio
Indications
Brand names
Active ingredients
• Mastitis
mamyzin®
penethamate hydroiodide
For the treatment of mastitis in dairy
cows caused by Gram-positive pathogens.
• Mastitis
benestermycin®
penethamate hydriodide
benethamine penicillin
framycetin
sulphate
To dry out the clinical healthy udders
of milking cows when required for the
udder health of the stock.
• Mastitis
ubrolexin®
cefalexin (as monohydrate),
kanamycin
(as monosulphate)
Treatment of clinical mastitis in lactating
dairy cows for bacteria susceptible to the
combination of cefalexin and kanamycin
such as Staphylococcus aureus, Streptococ­
cus dysgalactiae, Streptococcus uberis and
Escherichia coli.
• Infectious respiratory
diseases
express® (*)
For prevention of reproductive and
attenuated live and inactivated
vaccines (IBRV, BVDV, PI3V, BRSV, respiratory diseases in cattle.
C. fetus and Lepto spp.)
*only available in Canada and USA
• Pain and inflammatory
diseases
metacam®
103
meloxicam
Samples of the product portfolio Animal Health
Acute respiratory infection with appropriate antibiotic therapy, diarrhoea in
combination with oral rehydration
therapy, adjunctive therapy of acute
mastitis in combination with antibiotic
therapy.
Companion animals – Small animals
The main small animals products of Boehringer
heart muscle, helping it to beat stronger and
Ingelheim Animal Health address major chronic
pump blood more efficiently.
diseases: heart failure and osteoarthritis.
metacam® is a non-steroidal anti-inflammatory
As the first of a new class of heart treatments
drug (NSAID). It is available as oral suspension,
termed inodilators, vetmedin® has been shown
tablets and injectable solution for dogs and as
to significantly improve the clinical signs and
oral suspension and injectable ­solution for cats.
extend the life expectancy in dogs with conges­
The indications include the ­alleviation of inflam­
tive heart failure. vetmedin® works through
mation and pain in chronic musculoskeletal
two complementary modes of action; it opens up
disorders and the reduction of ­­­ post-operative
the blood vessels taking blood to and away from
pain in dogs and cats. The variety of formula­
the heart, thereby lowering the pressure on the
tions offers veterinarians and owners the flexi­
heart and reducing the work the heart has to do
bility to use the formulations they prefer to
to pump blood around the dog’s body. At the
manage the various levels of inflammation and
same time, vetmedin® has a direct effect on the
pain associated with the licensed indications.
Companion animals – Horse
The main horse products of Boehringer Ingel­
metacam® is indicated for the alleviation of
heim Animal Health focus on the therapeutic
­inflammation and relief of pain in both acute and
areas respiratory disease, lameness and colic.
chronic musculoskeletal disorders in horses.
It is available as oral suspension and as solution
ventipulmin® is a treatment of acute and
for injection. The solution for injection is also
chronic respiratory disease where airway ob­
indicated for the relief of pain associated with
struction due to bronchospasm and/or mucus
equine colic, complementing buscopan® com­
accumulation is a contributing factor and
positum.
­improved mucociliary clearance is desirable.
ventipulmin® can be used alone or as adjunc­
In North America there is also a comprehensive
tive therapy in chronic obstructive pulmonary
range of equine vaccines available.
­disease (COPD) and in acute, sub-acute and
chronic respiratory allergic conditions.
104
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
product portfolio
Indications
Brand names
Active ingredients
• Congestive heart failure
vetmedin®
pimobendan
For the treatment of congestive heart
failure in dogs.
• Pain and inflammatory
diseases
metacam®
meloxicam
Dog, cat: alleviation of inflammation and
pain associated with acute and chronic
musculoskeletal disorders. Reduction of
post-operative pain and inflammation
following orthopaedic and soft tissue
surgery.
Indications
Brand names
Active ingredients
• Acute and chronic obstruc­
tive respiratory diseases
ventipulmin®
clenbuterol
Bronchodilator for the treatment of acute,
sub-acute and chronic obstructive airway
disease in horses.
• Pain and inflammatory
diseases
metacam®
meloxicam
Alleviation of inflammation and relief of
pain in both acute and chronic musculoskeletal disorders. Relief of pain associated
with colic.
105
Samples of the product portfolio Animal Health
Contents
} Overview of the major consolidated companies
} Consolidated balance sheet
} Consolidated profit and loss statement
} Cash flow statement
} Statement of changes in group equity
} Notes to the consolidated financial statements
} Auditor’s Report
106
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
Consolidated Financial Statements 2008
Overview of the major consolidated companies
C. H. Boehringer Sohn AG & Co. KG*
Boehringer Ingelheim
GmbH
Boehringer Ingelheim
Europe GmbH
Germany
D
P
R
Boehringer Ingelheim
Pharma GmbH & Co. KG,
Ingelheim
Boehringer Ingelheim
Vetmedica GmbH, Ingelheim
Boehringer Ingelheim
microParts GmbH, Dortmund
Austria
D
P
Boehringer Ingelheim
International GmbH
R
Boehringer Ingelheim RCV
GmbH & Co.KG, Vienna
Forschungsinstitut für
Molekulare Pathologie
Gesellschaft mbH, Vienna
Boehringer Ingelheim
Pharma Ges.m.b.H., Vienna
Czech Republic
D
D
Boehringer Ingelheim
International Trading
(Shanghai) Co. Ltd., Shanghai
China
Boehringer Ingelheim
Finland Ky, Espoo
Norway
D
Boehringer Ingelheim
Norway KS, Asker
Poland
D
Belgium
SCS Boehringer Ingelheim
Comm. V., Brussels
Boehringer Ingelheim s.r.o.,
Prague
Finland
R
Austria
D
Boehringer Ingelheim Sp.zo.o.,
Warsaw
D
Boehringer Ingelheim Shanghai
Pharmaceuticals Co. Ltd.,
Shanghai
D
Philippines
Boehringer Ingelheim
(Phil.), Inc., Manila
South Korea
D
Boehringer Ingelheim
Korea Ltd., Seoul
Boehringer Ingelheim
Vetmedica Korea Ltd., Seoul
D Distribution
P
Production
R Research
*sole general partner:
Boehringer AG
108
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
P
P
C. H. Boehringer Sohn Grundstücksverwaltung GmbH & Co. KG
Boehringer Ingelheim
Auslandsbeteiligungs GmbH
D
Argentina
Boehringer Ingelheim S.A.,
Buenos Aires
D
Boehringer Ingelheim Pty. Ltd.,
North Ryde
D
P
Boehringer Ingelheim do Brasil
Quimica e Farmaceutica Ltda.,
São Paulo
Solana Agro Pecuaria Ltda.,
Arapongas
Canada
R
D
D
Boehringer Ingelheim Ltda.,
Santiago de Chile
D
P
D
P
Boehringer Ingelheim
Danmark A/S, Copenhagen
D
Ecuador
Boehringer Ingelheim del
Ecuador Cia. Ltda., Quito
R
D
P
D
P
R
Boehringer Ingelheim
Vetmedica Japan Co. Ltd.,
Kawanishi
Boehringer Ingelheim
Seiyaku Co. Ltd., Yamagata
D
P
D
Boehringer Ingelheim
Promeco S.A. de C.V.,
Mexico City
Boehringer Ingelheim Ellas AE,
Athens
109
D
D
P
Boehringer Ingelheim
USA Corporation,
Ridgefield, Connecticut
Ben Venue Laboratories, Inc.,
Bedford, Ohio
Roxane Laboratories, Inc.,
Columbus, Ohio
Boehringer Ingelheim S.A.,
Barcelona
Europharma S.A., Barcelona
Boehringer Ingelheim
Vetmedica, Inc.,
St. Joseph, Missouri
Laboratorios Fher S.A.,
Barcelona
Boehringer Ingelheim
Roxane, Inc., Columbus, Ohio
D
Boehringer Ingelheim AB,
Stockholm
D
P
Boehringer Ingelheim
(Schweiz) GmbH, Basel
Pharmaton S.A., Lugano
D
Taiwan
D
Boehringer Ingelheim
Taiwan Ltd., Taipei
D
Boehringer Ingelheim
(Thai) Ltd., Bangkok
Boehringer Ingelheim B. V.,
Alkmaar
R
Boehringer Ingelheim
España S.A., Barcelona
Switzerland
Boehringer Ingelheim
Vetmedica S.A. de C.V.,
Guadalajara
Boehringer Ingelheim
(N.Z.) Ltd., Auckland
P
Boehringer Ingelheim
Pharmaceuticals, Inc.,
Ridgefield, Connecticut
Sweden
R
P
Unilfarma Lda., Lisbon
Spain
Nippon Boehringer Ingelheim
Co. Ltd., Tokyo
D
Boehringer Ingelheim Corp.,
Ridgefield, Connecticut
Ingelheim Pharmaceuticals
(Pty.) Ltd., Randburg
Istituto De Angeli srl,
Reggello
USA
Boehringer Ingelheim Lda.,
Lisbon
South Africa
Bidachem S.p.A.,
Fornovo S. Giovanni
New Zealand
Labso Chimie Fine S.A.R.L.,
Blanquefort
D
Portugal
Boehringer Ingelheim (Pty.) Ltd.,
Randburg
Netherlands
Boehringer Ingelheim
France S.A.S., Paris
Greece
P
Boehringer Ingelheim
Italia S.p.A., Reggello
Mexico
Boehringer Ingelheim S.A.,
Bogotá
France
D
SSP Co. Ltd., Tokyo (61%)
Chile
Denmark
Italy
Japan
Boehringer Ingelheim
(Canada) Ltd., Burlington
Colombia
P
PT Boehringer Ingelheim
Indonesia, Jakarta
Australia
Brazil
D
Indonesia
D
Thailand
D
Turkey
Boehringer Ingelheim Ilac
Ticaret A.S., Istanbul
United Kingdom
D
Boehringer Ingelheim Ltd.,
Bracknell
Overview of the major consolidated companies
P
Boehringer Ingelheim
Chemicals, Inc.,
Petersburg, Virginia
Venezuela
Boehringer Ingelheim C.A.,
Caracas
D
C. H. Boehringer Sohn AG & Co. KG, Ingelheim
Consolidated balance sheet
Assets (in millions of EUR)
Notes1)
Intangible assets
(3.1)
Tangible assets
(3.2)
3,177
2,972
Financial assets
(3.3)
1,739
1,638
Fixed assets
31.12.2008
31.12.2007
539
547
5,455
5,157
Inventories
(3.4)
1,561
1,387
Accounts receivable
(3.5)
2,659
2,165
Securities
517
162
Cash and cash equivalents
795
853
Current assets
5,532
4,567
Deferred taxes
766
691
Deferred charges and prepaid expenses
Total assets
Liabilities and equity (in millions of EUR)
Notes1)
Shareholders’ capital
Group reserves
Balance sheet currency conversion difference
71
56
11,824
10,471
31.12.2008
31.12.2007
178
178
3,326
1,670
-225
-285
Net income
1,424
1,809
Equity
4,703
3,372
190
167
4,893
3,539
Minority interests
Group equity
Provisions
(3.6)
4,952
4,567
Accounts payable
(3.7)
1,761
2,151
6,713
6,718
168
159
Liabilities
Deferred taxes
Deferred charges
Total liabilities and equity
1)
For explanation, see relevant section in the notes to the consolidated financial statements.
110
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
50
55
11,824
10,471
consolidated financial statements
C. H. Boehringer Sohn AG & Co. KG, Ingelheim
Consolidated profit and loss statement
(in millions of EUR)
Notes1)
Net sales
(4.1)
Changes in inventories
Other internal work performed and capitalised
Other operating income
Total revenues
2008
2007
11,595
10,952
59
89
4
4
690
539
12,348
11,584
Material costs
(4.2)
-1,642
-1,627
Personnel costs
(4.3)
-3,004
-2,886
Amortisation of intangible and depreciation of tangible assets
(4.4)
-524
-504
Other operating expenses
(4.5)
-5,198
-4,467
1,980
2,100
Operating income
Financial income
(4.6)
-40
262
Holding income
(4.7)
-7
0
1,933
2,362
-505
-550
1,428
1,812
-4
-3
1,424
1,809
Income before taxes
Taxes2)
(4.8)
Income after taxes
Third-party share
Net income
1)
(4.9)
For explanation, see relevant section in the Notes to the Consolidated Financial Statements.
Due to legal requirements the disclosure of the shareholder’s personal taxes arising from
consolidated business activities as tax expenses is not allowed. These taxes are shown as
withdrawals from the accrued group capital.
2)
111
Consolidated balance sheet / Consolidated profit and loss statement
C. H. Boehringer Sohn AG & Co. KG, Ingelheim
Cash flow statement
2008
2007
1,428
1,812
532
508
37
72
1,997
2,392
Change in other provisions
268
172
Other non-cash income and expenses
-20
-13
Loss/gain on disposals of fixed assets
63
8
Change in inventories
-162
-164
Change in accounts receivable and other assets not related to investing
or financing activities
-317
24
(in millions of EUR)
Income after taxes
Write-downs/write-ups on fixed assets
1)
Change in provisions for pensions
Cash flow
Change in trade accounts payable and other liabilities not related to investing
or financing activities
Cash flow from operating activities
Investments in intangible assets
72
-77
1,901
2,342
-43
-98
-665
-654
Investments in non-current financial assets1)
-51
-35
Proceeds from disposals of intangible assets
0
0
Proceeds from disposals of property, plant and equipment
21
23
Proceeds from disposals of non-current financial assets1)
7
7
Cash flow from investing activities
–731
–757
Cash payments to shareholders and minority shareholders
-434
-3,355
Investments in property, plant and equipment
Cash proceeds from borrowings/repayments of loans
-501
442
Cash flow from financing activities
–935
–2,913
235
-1,328
0
0
116
-25
Securities and liquid funds 2) as of 1. 1.
2,581
3,934
Securities and liquid funds as of 31. 12.
2,932
2,581
Change in liquid funds from cash-relevant transactions
Changes in liquid funds due to changes in scope of consolidation
Changes in liquid funds due to exchange rate movements
2)
1)
2)
excl. fixed-asset securities
liquid funds, securities within fixed and current assets
(+) = source of funds, (–) = use of funds
112
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
consolidated financial statements
C. H. Boehringer Sohn AG & Co. KG, Ingelheim
Statement of changes in group equity
(in millions of EUR)
Balance as of 31. 12. 2006
Shareholders’
capital1)
Accrued
group
capital
of which
currency
effects
Equity
Minority
interests
of which
currency
effects
Group
equity
178
4,997
-140
5,175
188
-51
5,363
Contributions
0
0
0
0
0
0
0
Withdrawals
0
-3,467
0
-3,467
0
0
-3,467
Net income
0
1,809
0
1,809
3
0
1,812
Change of scope of consolidation
0
0
0
0
0
0
0
Other changes
0
-145
-145
-145
-24
-9
-169
178
3,194
-285
3,372
167
-60
3,539
Contributions
Balance as of 31. 12. 2007
0
0
0
0
0
0
0
Withdrawals
0
-154
0
-154
0
0
-154
Net income
0
1,424
0
1,424
4
0
1,428
Change of scope of consolidation
0
0
0
0
0
0
0
Other changes
0
61
60
61
19
51
80
178
4,525
-225
4,703
190
-9
4,893
Balance as of 31. 12. 2008
T he shareholders’ capital consists of the equity of C. H. Boehringer Sohn AG & Co. KG and C. H. Boehringer
Sohn Grundstücksverwaltung GmbH & Co. KG. As of 31.12.2008 the capital consists only of the limited partners.
The shareholders’ personal taxes arising from consolidated business activities are shown as withdrawals
from the accrued group capital.
1)
113
Cash flow statement / Statement of changes in group equity
C. H. Boehringer Sohn AG & Co. KG, Ingelheim
Notes to the consolidated financial statements
1 Principles and methods
1.1 General principles
The consolidated financial statements of Boehringer Ingelheim for the fiscal year 2008 have
been prepared pursuant to section 264a German Commercial Code (HGB) by applying the group
accounting regulations of section 290 to 314 HGB.
In accordance with section 297, paragraph 1 HGB, the consolidated financial statements are
composed of the consolidated balance sheet, the consolidated profit and loss statement, notes to
the consolidated financial statements, the consolidated cash flow statement and the statement
on changes in equity.
1.2 Companies included in the consolidation
The ultimate parent of the Boehringer Ingelheim group is C. H. Boehringer Sohn AG & Co. KG.
Boehringer AG is the sole unlimited managing partner of this company.
Besides C. H. Boehringer Sohn AG & Co. KG there is C. H. Boehringer Sohn Grundstücksverwaltung
GmbH & Co. KG whose unlimited partner is under the unified management of C. H. Boehringer
Sohn AG & Co. KG.
The Boehringer Ingelheim group of companies consists of 138 affiliated companies in and outside
Germany. In addition to C. H. Boehringer Sohn AG & Co. KG and C. H. Boehringer Sohn Grundstücksverwaltung GmbH & Co. KG, a further 108 companies in which C. H. Boehringer Sohn AG &
Co. KG holds directly or indirectly the majority of voting shares are included in the consolidated
financial statements.
Twenty-six companies were not consolidated in the reporting year, as the net assets, financial
position and results of operations of these companies were insignificant to Boehringer Ingelheim.
Combined they represent less than 1 % of the group’s net sales, equity and net profit. A further
two companies are subject to bylaws containing enduring restrictions.
Compared to the previous year, the total number of affiliated companies was increased by three:
• one company was liquidated,
• four companies were established.
114
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
consolidated financial statements
A separate statement of interests held by Boehringer Ingelheim will be submitted to the authority
operating the German Federal Gazette in order to place it in the Register of Companies.
The following subsidiaries were exempted from the reporting and disclosure obligations in
­accordance with section 264, paragraph 3 HGB:
• Boehringer Ingelheim GmbH, Ingelheim
• Boehringer Ingelheim International GmbH, Ingelheim
• Dr. Karl Thomae GmbH, Biberach
• Dr. Karl Thomae Wohnungsbau GmbH, Biberach
• Boehringer Ingelheim Europe GmbH, Ingelheim
• Boehringer Ingelheim Vetmedica GmbH, Ingelheim
• Boehringer Ingelheim Secura Versicherungsvermittlungs GmbH, Ingelheim
• Boehringer Ingelheim Grundstücks-GmbH, Ingelheim
• Boehringer Ingelheim Finanzierungs GmbH, Ingelheim
• Boehringer Ingelheim R&D Beteiligungs GmbH, Ingelheim
Exempted from reporting and disclosure obligations of annual financial statements according to
HGB regulations for joint stock companies under section 264b HGB are:
• C. H. Boehringer Sohn AG & Co. KG, Ingelheim
• C. H. Boehringer Sohn Grundstücksverwaltung GmbH & Co. KG, Ingelheim
• Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim
• Boehringer Ingelheim Veterinary Research Center GmbH & Co. KG, Hannover
1.3 Consolidation methods
For inventories, accounts receivable and payable, and the income and expense items, business
transactions among the consolidated companies were eliminated as part of the debt consolidation,
according to section 303 HGB, the elimination of inter-company profits according to section
304 HGB, and the income and expense consolidation according to section 305 HGB.
The purchase method of accounting was used for the capital consolidation of those subsidiaries that
were included for the first time in the consolidated financial statements. First-time consolidation
takes place at the time of the respective company becoming a subsidiary.
115
Notes to the consolidated financial statements
1.4 Currency conversions
The financial statements prepared in foreign currencies were translated into euros, the functional
currency of the group parent company, C. H. Boehringer Sohn AG & Co. KG, according to the
modified closing rate concept.
All assets and liabilities have been converted at the year-end rate. The profit and loss statement
and, consequently, net income, were converted at the average annual rate for the reporting year.
The shareholders’ capital and the group reserves are calculated using historical exchange rates.
Translation differences due to the conversion of foreign currencies are shown as a balancing item
in the equity without impact on income.
In general the functional currency of subsidiaries is the respective local currency. Annual financial
statements in high inflation countries are in principle drawn up in accordance with German
Accounting Standard 14 (GAS 14); in the financial year 2008, no group company was affected by
high inflation accounting.
The most important currencies for Boehringer Ingelheim reflect the following changes in the
reporting year (base 1 euro):
year-end rate
31.12.2008
US dollar
Japanese yen
average annual rate
31.12.2007
2008
2007
1.39
1.47
1.47
1.37
126.14
164.93
152.27
161.24
Pound sterling
0.95
0.73
0.79
0.68
Canadian dollar
1.69
1.44
1.55
1.47
116
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
consolidated financial statements
2 Accounting and evaluation methods
2.1 Fixed assets
Intangible and tangible assets are shown at purchase or manufacturing cost, net of regular
straight-line depreciation, according to the technical and economic situation. The following periods
of use were applied:
Intangible assets
3 to 15 years
Buildings
20 years
Technical facilities and machinery
Other facilities, operating and business equipment
10 years
3 to 10 years
In the consolidated financial statements the standard method of depreciation is the straight-line
method. Anticipated long-term losses in the value of investments were accounted for by
unscheduled write-offs. Cost of direct material and production as well as appropriate portions
of material and production overheads were taken into consideration for the determination of the
manufacturing costs. Fully amortised goodwill that is more than five years old, or is materially
insignificant, is shown under disposals.
All capitalised intangible assets have a limited useful life.
Goodwill resulting from the consolidation of the purchase of shares of Boehringer Ingelheim Korea
Ltd. and Baiksu Pharmaceutical Co. Ltd. is being amortised according to plan over ten years.
Financial assets were valued at the lower of either purchase cost or fair market value. The valuation
of securities in case of temporary diminution in value is made at the lower current value.
2.2 Current assets
Inventories are valued at the lower of either purchase or manufacturing cost using the weighted
average cost flow method as the group-wide uniform method of measurement, or fair market value,
whereas C. H. Boehringer Sohn AG & Co. KG applies the LIFO Method in its individual financial
statements. The cost of direct material and production as well as appropriate portions of material
and production overheads were taken into consideration for the determination of the manufacturing
costs. Necessary reductions were made for inventory risks.
Accounts receivable were stated at their purchase cost net of any individual valuation allowances
required. The general credit risk was covered by a general valuation allowance for bad debt.
Other assets, securities and liquid funds were stated at the lower of either purchase cost, present
­value or fair market value.
Short-term foreign currency items were recorded at the year-end rate of exchange.
117
Notes to the consolidated financial statements
2.3 Group reserves
Group reserves include the retained earnings of the consolidated subsidiaries from prior years,
consolidation entries that affect earnings and credit balances arising from capital consolidation,
where they respectively relate to prior years.
2.4 Provisions
Provisions include amounts necessary to cover any perceptible obligations and risks that require
­recognition in the accounts, including provisions for contingent losses from pending contracts.
The valuation is made on the basis of reasonable commercial judgement. Provisions with an implied
interest are shown on a discounted basis (e. g. certain personnel provisions).
2.5 Liabilities
Liabilities are shown in the balance sheet at the repayable amount. Liabilities in foreign currencies
were recorded at the year-end rate of exchange.
2.6 Deferred taxes
Deferred tax assets and liabilities represent the tax deferral in accordance with sections 274 and
306 HGB, which arise because of temporary differences between the tax balance sheets of the
individual companies and the consolidated balance sheet (including differences arising from adjustments for conformity in group-wide reporting and evaluation as well as consolidation measures).
Quasi-permanent differences between the consolidated balance sheet and the tax balance sheet are
treated as temporary differences in accordance with German Accounting Standard 10 (GAS 10).
In the individual balance sheets (i. e. the financial statements II) the consolidated companies made
use of their option to capitalise assets to the amount of probable tax relief in the following years
in accordance with section 274, paragraph 2 HGB. The calculation of deferred taxes is based on the
tax rates that are expected to be valid at the time of their realisation.
The capitalisation of deferred tax assets on tax loss carry-forwards is carried out if it is sufficiently
probable that the tax benefits can be realised.
118
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
consolidated financial statements
3 Notes to the consolidated balance sheet
3.1 Intangible assets
Concessions/
similar rights
Goodwill
Advance
payments
Total
Balance as of 1. 1. 2007
975
806
11
1,792
Currency conversion difference
-46
0
0
-46
(in millions of EUR)
Procurement/manufacturing costs
Additions due to first consolidation
0
0
0
0
Additions
43
48
7
98
Disposals
-17
-285
0
-302
11
0
-6
5
966
569
12
1,547
27
0
1
28
0
0
0
0
Additions
27
0
16
43
Disposals
-14
0
0
-14
Reclassifications
Balance as of 31. 12. 2007
Currency conversion difference
Additions due to first consolidation
Reclassifications
Balance as of 31. 12. 2008
14
0
-8
6
1,020
569
21
1,610
432
806
0
1,238
-8
0
0
-8
0
0
0
0
65
7
0
72
Accumulated depreciations
Balance as of 1. 1. 2007
Currency conversion difference
Additions due to first consolidation
Additions
Write-ups
0
0
0
0
Disposals
-17
-285
0
-302
Reclassifications
0
0
0
0
472
528
0
1,000
Currency conversion difference
8
-1
0
7
Additions due to first consolidation
0
0
0
0
Additions
67
5
0
72
Write-ups
0
0
0
0
Disposals
-8
0
0
-8
0
0
0
0
Balance as of 31. 12. 2008
539
532
0
1,071
Book value as of 31. 12. 2007
494
41
12
547
Book value as of 31. 12. 2008
481
37
21
539
Balance as of 31. 12. 2007
Reclassifications
119
Notes to the consolidated financial statements
3.2 Tangible assets
Land and
buildings
(in millions of EUR)
Technical
facilities
and
machines
Procurement/manufacturing costs
Balance as of 1. 1. 2007
Currency conversion difference
Additions due to first consolidation
Other
Advance
facilities/
payments/
operating construction
equipment in progress
Total
2,110
2,238
1,590
375
6,313
-80
-64
-52
-21
-217
0
0
0
0
0
Additions
75
97
158
324
654
Disposals
-17
-47
-98
-5
-167
Reclassifications
Balance as of 31. 12. 2007
Currency conversion difference
Additions due to first consolidation
89
98
66
-258
-5
2,177
2,322
1,664
415
6,578
97
32
10
18
157
0
0
0
0
0
Additions
62
113
149
341
665
Disposals
-68
-107
-88
-6
-269
89
76
38
-209
-6
2,357
2,436
1,773
559
7,125
1,076
1,277
1,074
0
3,427
-39
-37
-36
0
-112
0
0
0
0
0
Additions
83
176
173
0
432
Write-ups
0
-1
0
0
-1
Disposals
-11
-43
-86
0
-140
0
-7
7
0
0
1,109
1,365
1,132
0
3,606
55
16
9
0
80
Reclassifications
Balance as of 31. 12. 2008
Accumulated depreciations
Balance as of 1. 1. 2007
Currency conversion difference
Additions due to first consolidation
Reclassifications
Balance as of 31. 12. 2007
Currency conversion difference
Additions due to first consolidation
Additions
0
0
0
0
0
93
182
178
0
453
Write-ups
0
0
0
0
0
Disposals
-31
-82
-78
0
-191
Reclassifications
0
0
0
0
0
Balance as of 31. 12. 2008
1,226
1,481
1,241
0
3,948
Book value as of 31. 12. 2007
1,068
957
532
415
2,972
Book value as of 31. 12. 2008
1,131
955
532
559
3,177
120
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
consolidated financial statements
3.3 Financial assets
Investments
in affiliated
companies
Loans
to affiliated
companies
Investments
in related
companies
Loans to
related
companies
Investment
securities
Other loans
Total
Balance as of 1. 1. 2007
18
8
10
6
3,039
23
3,104
Currency conversion difference
-1
0
0
0
-5
0
-6
Additions due to first consolidation
0
0
0
0
0
0
0
Additions
1
0
30
0
257
4
292
Disposals
-6
-1
0
-3
-1,672
-7
-1,689
0
0
0
0
0
0
0
12
7
40
3
1,619
20
1,701
7
2
-1
0
10
0
18
(in millions of EUR)
Procurement/manufacturing costs
Reclassifications
Balance as of 31. 12. 2007
Currency conversion difference
0
0
0
0
0
0
0
Additions
Additions due to first consolidation
17
0
29
0
175
5
226
Disposals
0
-1
-1
0
-141
-6
-149
Reclassifications
0
0
0
0
0
0
0
36
8
67
3
1,663
19
1,796
Balance as of 1. 1. 2007
3
0
2
3
50
3
61
Currency conversion difference
0
0
0
0
0
0
0
Additions due to first consolidation
0
0
0
0
0
0
0
Additions
0
0
5
0
12
0
17
Write-ups
0
0
0
0
-2
0
-2
Disposals
Balance as of 31. 12. 2008
Accumulated depreciations
-3
0
0
-3
-7
0
-13
Reclassifications
0
0
0
0
0
0
0
Balance as of 31. 12. 2007
0
0
7
0
53
3
63
Currency conversion difference
0
0
-1
0
0
-1
-2
Additions due to first consolidation
0
0
0
0
0
0
0
Additions
0
0
7
0
31
0
38
Write-ups
0
0
0
0
-37
0
-37
Disposals
0
0
-1
0
-4
0
-5
Reclassifications
0
0
0
0
0
0
0
Balance as of 31. 12. 2008
0
0
12
0
43
2
57
Book value as of 31. 12. 2007
12
7
33
3
1,566
17
1,638
Book value as of 31. 12. 2008
36
8
55
3
1,620
17
1,739
As in the previous year, the item other loans includes no loans to shareholders.
121
Notes to the consolidated financial statements
3.4 Inventories
(in millions of EUR)
31.12.2008
31.12.2007
350
242
Unfinished products
624
598
Finished products and goods for resale
576
540
11
7
1,561
1,387
Raw materials and supplies
Advance payments to suppliers
3.5 Accounts receivable
(in millions of EUR)
Trade accounts receivable
Receivables from affiliated companies
Receivables from related companies
Other assets
31.12.2008
Residual term
over 1 year
31.12.2007
Residual term
over 1 year
1,977
4
1,797
6
4
0
3
0
6
0
3
0
672
23
362
20
2,659
27
2,165
26
The item other assets contains receivables from shareholders amounting to EUR 189 million
(2007: EUR 1 million).
3.6 Provisions (in millions of EUR)
31.12.2008
31.12.2007
Pension provisions
2,170
2,110
Tax provisions
Other provisions
122
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
492
486
2,290
1,971
4,952
4,567
consolidated financial statements
Pension provisions
Boehringer Ingelheim’s pension schemes are based on various defined contribution plans as well
as defined benefit plans.
Pension obligations arising from direct or indirect defined benefit plans are determined on the basis
of actuarial calculations in accordance with the projected unit credit method, taking future salary
and pension increases into consideration.
The actuarial calculation of the pension obligation from defined benefit plans is based on countryspecific biometric data (e. g. in Germany the “generation tables” issued in 2005 by Professor Klaus
Heubeck) and actuarial assumptions. The main countries applied the following parameters:
Germany
Parameter (in % as of 31 December)
USA
Japan
2008
2007
2008
2007
2008
2007
Discount rate
5.3
5.3
5.8
5.8
1.5
1.5
Expected return on plan assets
6.0
6.0
8.0
8.0
2.2–3.0
2.2–3.0
Salary increase
4.0
4.0
5.5
5.5
0.0–3.0
0.0–3.0
Pension increase
2.0
2.0
3.0
3.0
0.0
0.0
At the balance sheet date, the present value of the expected pension obligation was netted with
the fair value of the respective pension plan assets (funded status).
Based on this, pension provisions are determined by deducting unrealised transition amounts as
well as unrealised actuarial gains and losses from the funded status. Actuarial gains and losses,
inasmuch as they surpass 10 % of the higher value of either the present value of the expected
pension obligation or the fair value of the plan assets, are to be spread over the expected average
service period of the active employees.
On the balance sheet date, pension commitments (including total unrealised transition amounts
and actuarial gains and losses) amounted to EUR 594 million (2007: EUR 332 million). Further
pension commitments did not exist at year-end.
In conjunction with defined contribution plans, group companies paid contributions to state or
private insurers on the basis of legal or contractual regulations. On payment of the contributions
the companies no longer have any performance obligations. Contributions are recognised as
personnel costs.
123
Notes to the consolidated financial statements
3.7 Accounts payable
Residual term
less than 1 year
Residual term
1–5 years
Residual term
over 5 years
31.12.2008
174
117
17
308
800
649
1,239
5
209
1,453
1,351
1,185
751
1
0
752
704
702
29
0
31
60
68
32
0
0
0
0
5
5
– Accounts payable to
affiliated companies
12
0
0
12
11
11
– Accounts payable to
related companies
1
0
0
1
1
1
(in millions of EUR)
Bank loans
Other accounts payable
of which:
– Trade accounts payable
– Advance payments
– Notes payable
– Other liabilities *
Residual term
31.12.2007 less than 1 year
446
4
178
628
562
434
1,413
122
226
1,761
2,151
1,834
31
39
2
8
*of which:
– taxes
– social security contributions
There were no liabilities secured by mortgages or similar rights on the balance sheet date consistent
with the previous year.
At year-end liabilities due to shareholders amounted to EUR 3 million (2007: EUR 64 million).
124
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
consolidated financial statements
4 Notes to the consolidated profit and loss statement
The consolidated profit and loss statement is presented in line with the total cost method.
4.1 Net sales by business and business segment (in millions of EUR)
Human Pharmaceuticals
2008
2007
11,128
10,544
of which:
Prescription Medicines
9,111
8,660
Consumer Health Care
1,190
1,141
Industrial Customer
819
739
Other sales
8
4
467
408
11,595
10,952
by geographic region (in millions of EUR)
2008
2007
Europe
3,877
3,578
Animal Health
of which: Germany
Americas
980
853
5,560
5,463
of which: USA/Canada/Mexico
5,107
5,050
Asia/Australasia/Africa
2,158
1,911
of which: Japan
1,338
1,193
11,595
10,952
(in millions of EUR)
2008
2007
Costs of raw material, supplies and goods for resale
1,287
1,314
355
313
1,642
1,627
(in millions of EUR)
2008
2007
Salaries and wages
2,411
2,291
Social benefits and retirement benefits
593
595
of which: retirement benefits
185
197
3,004
2,886
4.2 Material costs
Expenditure on services
4.3 Personnel costs
125
Notes to the consolidated financial statements
The interest component with respect to the increase in pensions and similar obligations is included
in financial income rather than in personnel costs and is, therefore, not included in the operating
result of the company.
Average headcount
Production
Administration
Marketing and sales
Research and development
Apprentices
2008
2007
12,600
12,502
5,299
5,095
15,909
15,095
6,788
6,405
704
703
41,300
39,800
4.4 Amortisation of intangible and depreciation of tangible assets
The amortisation of intangible assets and depreciation of tangible assets include unscheduled
write-offs of EUR 6 million (2007: EUR 8 million).
4.5 Other operating expenses
Other operating expenses include third-party services in research, development, medicine, and
marketing, further administration costs, fees, contributions, non-income-related taxes, commissions, rents, freight costs, and expenses for third-party repairs as well as expenses incurred by
restructuring measures.
4.6 Financial income
(in millions of EUR)
2008
2007
Interest expense relating to pensions and similar obligations
-121
-107
Other interest expense and similar expenditure
Interest expense and similar expenditure
-85
-51
-206
-158
Amortisation of other financial assets and short-term investments
-32
-13
Income from other investment securities and from long-term loans
96
346
Other interest income and similar proceeds
126
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
102
87
-40
262
consolidated financial statements
4.7 Holding income
2008
2007
0
5
-7
-5
-7
0
2008
2007
Income taxes
539
554
Deferred taxes
-34
-4
505
550
(in millions of EUR)
Gains from the sale of investments
Amortisation of financial assets
4.8 Taxes
(in millions of EUR)
By concluding profit transfer agreements, significant German companies have since 1 January 2004
belonged to the trade and corporate taxation group of integrated companies of the parent company
C. H. Boehringer Sohn AG & Co. KG. As income tax levied on taxable income allocated to the
­shareholders of C. H. Boehringer Sohn AG & Co. KG may not be shown in the consolidated profit
and loss statement, only the trade tax of the relevant companies is shown as a tax expense.
In the effective tax-rate reconciliation the expected tax expense for Boehringer Ingelheim is
calculated on the profit tax rate for corporations (corporate tax, solidarity levy and trade tax).
As in the profit and loss statement tax expenses related to the income tax for partnerships and
­integrated companies of C. H. Boehringer Sohn AG & Co. KG are limited to showing trade tax, the
­expected tax expense in the effective tax-rate reconciliation is in this respect adjusted for fictive
current and deferred ­corporate tax expenses in order to link to the profit tax expense shown in
the profit and loss statement. This ­elimination of fictive corporate tax (including the solidarity levy)
is shown in the items Fictive Corporation.
127
Notes to the consolidated financial statements
The expected tax expense derived by using a fictive tax rate of 27.5 % (average tax rate for a German
corporation at a municipal trade tax levy rate of 332 %; 2007: 340 %) can be reconciled to the actual
tax expense as follows:
(in millions of EUR)
Income before taxes
2008
2007
1,933
Expected tax expense (current and deferred)
532
Decrease/increase in expected tax expense by
– Fictive Corporation current taxes
2,362
27.5 %
876
37.1 %
-136
-7.0 %
-317
-13.4 %
– Fictive Corporation deferred taxes
-16
-0.8 %
-25
-1.1 %
– Local tax rate divergences
110
5.7 %
-72
-3.0 %
– Non-taxable income
-25
-1.3 %
-54
-2.3 %
– Non-tax-deductible expenses
10
0.5 %
58
2.5 %
– Taxes related to prior periods
-8
-0.4 %
2
0.1 %
1
0.1 %
2
0.1 %
22
1.1 %
83
3.5 %
8
0.4 %
7
0.3 %
-46
-2.4 %
-52
-2.2 %
53
2.7 %
42
1.7 %
505
26.1 %
550
23.3 %
– Amortisation of goodwill
– Changes in applicable tax rates
– Withholding taxes not subject to tax credits
– Tax credits for research activities
– Other effects
Actual tax expense (current and deferred)
The deferred taxes can be attributed to the following balance sheet items:
31.12.2008
(in millions of EUR)
31.12.2007
Assets
Liabilities
Assets
Liabilities
Intangible assets
20
2
7
2
Tangible assets
33
105
29
90
Financial assets
15
19
22
17
Inventories
116
14
106
14
Receivables
17
14
19
11
Provisions
529
14
469
24
Liabilities
25
0
23
1
Tax loss carryforwards and tax credits
128
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
11
0
16
0
766
168
691
159
consolidated financial statements
Other disclosure requirements according to GAS 10.39:
(in millions of EUR)
Deferred tax expense from changes in law
Deferred tax expense relating to the write-off of deferred tax assets
in fiscal year
2008
2007
22
83
2
1
The absence of changes in accounting and evaluation methods results, as in the previous year, in
no deferred tax income.
The valuation allowances relating to deferred tax assets amount to EUR 5 million.
Unused tax loss carryforwards, on which no deferred tax assets are recognised in the balance sheet,
amount to EUR 21 million at year-end, of which EUR 11 million expire in five years and EUR 3
million expire in 10 years at the latest.
4.9 Net income
Net income for the year 2008 includes operating income unrelated to the accounting period
(mainly the release of other provisions) in the amount of EUR 135 million (2007: EUR 125 million).
Operating expenditure unrelated to the accounting period amounted to EUR 66 million (2007:
EUR 53 million).
5 Notes to the cash flow statement
The cash flow statement shows how the total liquid funds (liquid assets and securities in fixed and
current assets) of the Boehringer Ingelheim group have changed during the reporting year through
inflow and outflow of cash and cash equivalents. In accordance with German Accounting Standard
No. 2 (GAS 2), Cash Flow Statements, cash flows are classified by operating, investing or financing
activities.
Changes reported by consolidated companies are converted at the average annual rate. Liquid funds
are converted, as shown in the balance sheet, according to the year-end rate method. The influence
of exchange rate changes on liquid funds is provided separately.
129
Notes to the consolidated financial statements
6 Other information
6.1 Derivative financial instruments
Boehringer Ingelheim is, due to its extensive international structure, highly dependent on
­developments in the major world currencies and interest rates. In order to hedge against the risks,
particularly those inherent in supplies and services and financial funding, use is generally made
of foreign exchange forward contracts in the case of currency risks. Regarding interest rate risks,
use is made of interest rate swaps and interest rate options.
The use of derivative financial instruments and the organisational procedure are laid down in
internal guidelines. Trade, processing, documentation, and control are kept strictly separate.
The risk positions are recorded, analysed and assessed regularly in a special consolidated financial
report. The items are periodically re-evaluated and monitored. The fair market value of derivative
financial instruments on the balance sheet date is determined by taking year-end market data into
consideration while applying prevailing evaluation methods (foreign exchange forward contracts and
interest swaps with the net present value method, foreign exchange options and interest options with
accredited option pricing models).
Foreign exchange options and interest options are recorded at the lower of fair market value or paid
or received option premium. They will be taken out of the books at their respective expiry date.
Derivative financial instruments at year-end were as follows:
Nominal value
(in millions of EUR)
Market value
31.12.2008
31.12.2007
31.12.2008
31.12.2007
Foreign exchange forward contracts
2,562
1,871
51
49
Foreign exchange options
1,126
1,217
-13
90
201
157
0
0
9
21
0
0
Interest options
Interest swaps
In sum, the foreign exchange forward contracts recorded positive fair market values on the balance
sheet date in the amount of EUR 51 million. A provision, which has been included in other provisions
and accruals, was set up for those open items with a negative fair market value within one currency
on the balance sheet date. As far as a positive balance of the open items resulted within one currency,
this was not applied in accordance with the imparity principle.
130
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
consolidated financial statements
The foreign exchange option contracts recorded negative fair market values on the balance sheet
date in the amount of EUR 13 million. The purchased foreign exchange options are shown in other
assets. The sold foreign exchange options are recorded in other liabilities.
6.2 Contingent liabilities to the benefit of third parties (in millions of EUR)
31.12.2008
31.12.2007
24
19
31.12.2008
31.12.2007
966
1,192
Liabilities from guarantees, guarantees for bills and cheques,
warranties and provisions of collateral for third-party liabilities
6.3 Other financial obligations
(in millions of EUR)
To third parties
At year-end, other financial obligations included capital investments of EUR 603 million (2007:
EUR 657 million). Furthermore, EUR 245 million (2007: EUR 196 million) from renting and leasing
contracts are included, of which EUR 70 million (2007: EUR 75 million) concern long-term rent
contracts with subsidiaries not included in the consolidation.
6.4 Research and development expenses
(in millions of EUR)
2008
2007
Expenses for research and development
2,109
1,900
Starting with reporting year 2008, phase IV clinical trial costs, among others, are included in the
expenses for research and development. The figure for 2007 was adjusted accordingly.
131
Notes to the consolidated financial statements
Auditor’s Report
We have audited the consolidated financial
We conducted our audit of the consolidated
statements prepared by C. H. Boehringer Sohn
financial statements in accordance with §317
AG & Co. KG, Ingelheim – comprising the
HGB (German Commercial Code) and German
balance sheet, the income statement, statement
generally accepted standards for the audit of
of changes in equity, cash flow statement and
financial statements promulgated by the Institut
the notes to the consolidated financial state-
der Wirtschaftsprüfer (Institute of Public
ments – together with the group management
Auditors in Germany) (IDW). Those standards
report for the business year from 1 January
require that we plan and perform the audit such
to 31 December 2008. The preparation of the
that misstatements materially affecting the
consolidated financial statements and the group
presentation of the net assets, financial position
management report in accordance with German
and results of operations in the consolidated
commercial law is the responsibility of the
financial statements in accordance with
Managing Directors of the managing corporate
(German) principles of proper accounting and
general partner. Our responsibility is to express
in the group management report are detected
an opinion on the consolidated financial state-
with reasonable assurance. Knowledge of
ments and the group management report based
the business activities and the economic and
on our audit.
legal environment of the Group and expectations as to possible misstatements are taken
into account in the determination of audit
procedures. The effectiveness of the accounting-related internal control system and the
evidence supporting the disclosures in the
­consolidated financial statements and the group
management report are examined primarily on
a test basis within the framework of the audit.
The audit includes assessing the annual financial statements of the companies included in
consolidation, the determination of the com­
panies to be included in consolidation, the
accounting and consolidation principles used
and significant estimates made by the Managing Directors of the managing corporate general
partner, as well as evaluating the overall
­presentation of the consolidated financial
­statements and the group management report.
We believe that our audit provides a reasonable
basis for our opinion.
132
Boehringer Ingelheim A n n u a l R e p o r t 2 0 0 8
consolidated financial statements
With the following exception, our audit has not
led to any reservations: Contrary to §314
­paragraph 1 number 6 HGB compensation of
the members and the former members of the
board of managing directors and loans granted
to these persons have not been disclosed.
In our opinion, based on the findings of our
audit, the consolidated financial statements
with the exception mentioned comply with the
legal requirements. The consolidated financial
statements give a true and fair view of the net
assets, financial position and results of operations of the Group in accordance with German
principles of proper accounting. The group
management report is consistent with consolidated financial statements that comply with the
legal requirements and as a whole provides a
suitable view of the Group‘s position and suitably
presents the opportunities and risks of future
development.
Frankfurt am Main, 12 February 2009
PricewaterhouseCoopers
Aktiengesellschaft
Wirtschaftsprüfungsgesellschaft
(Philip Marshall)
(Klaus Höfer)
Wirtschaftsprüfer
Wirtschaftsprüfer
(German Certified
(German Certified
Public Accountant)
Public Accountant)
133
Auditor’s Report
If you have any queries or comments,
please contact us.
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim
Germany
Telephone + 49 6132 77-0
Fax + 49 6132 72-3000
Contact
CD Communications
Dr Bernd Mann
Telephone + 49 6132 77-92300
Fax + 49 6132 72-92300
E-mail [email protected]
Internet www.boehringer-ingelheim.com
Issued by
Boehringer Ingelheim GmbH
Design and layout
Neufrankfurt Corporate Design GmbH, Offenbach am Main
[email protected]
Photos
Markus Hildebrand (page 3), Frank Ossenbrink (page 5),
Jens Wunderlich (page 28, 34, 44, 70, 80), Chris Gomersall/RSPB Images (page 33),
Peter Pulkowski (page 59), Eugenio Goulart (page 62), Boehringer Ingelheim (all others)
Printed by
Süddeutsche Verlagsgesellschaft, Ulm
Copyright
© Boehringer Ingelheim GmbH, 2009
All rights reserved. No part of this Annual Report 2008 may be reproduced or
transmitted in any form or by any means, electronic or photocopy, without permission
in writing from Boehringer Ingelheim GmbH.
Figures from third parties used in the annual report are based on data available at the
time the financial statement was drawn up.
Contents
2 The shareholders’ perspective
4 Key aspects 2008
8 Corporate bodies
Corporate
Responsibility
The ethical principles that guide
our company have created a
culture of corporate responsibility
and commitment. page 28
10 Group Management Report
Comparison of balance sheets/
financial data 1999—2008 (in millions of EUR)
30 Corporate Responsibility
30 Caring for our neighbours – “We care”
32 Environmental protection and occupational safety
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
400
344
322
302
242
267
233
554
547
539
1,992
2,217
2,467
2,840
2,767
2,712
2,900
2,886
2,972
3,177
849
1,135
1,008
1,689
2,462
2,756
3,396
3,043
1,638
1,739
3,241
3,696
3,797
4,831
5,471
5,735
6,529
6,483
5,157
5,455
944
1,021
1,014
971
1,000
1,085
1,229
1,280
1,387
1,561
1,870
1,938
2,314
2,360
2,537
2,477
3,013
3,137
2,912
3,496
459
477
1,002
1,055
1,134
1,333
1,247
945
1,015
1,312
Current assets
3,273
3,436
4,330
4,386
4,671
4,895
5,489
5,362
5,314
6,369
Total assets
6,514
7,132
8,127
9,217
10,142
10,630
12,018
11,845
10,471
11,824
Liabilities and equity (as of 31.12.)
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
Financial assets
Fixed assets
Inventories
Accounts receivable (incl. deferred charges and deferred taxes)
Our own research and
development continues to be
the major driver of innovative,
new medicines. page 44
30 Caring for patients – The viramune® Donation Programme
Intangible assets
Tangible assets
Research & Development
Corporate Responsibility
Assets (as of 31.12.)
Cash and cash equivalents (incl. securities)
39 Our people
Research & Development
46 Our R&D strategy
48 Our R&D sites
51 Non-clinical research and development
53 From test tube to bioreactor – A seamless path for biopharmaceuticals
53 Clinical development
56 2008 – The year of landmark trials
58 Bridge to academia
Human
Pharmaceuticals
Shareholders’ capital
332
211
200
178
178
178
178
178
178
178
1,982
2,362
2,753
2,818
3,139
3,297
2,940
3,275
1,385
3,101
Net income
320
379
401
537
529
888
1,491
1,722
1,809
1,424
Total equity
2,634
2,952
3,354
3,533
3,846
4,363
4,609
5,175
3,372
4,703
0
0
1
203
188
193
216
188
167
190
Group equity
2,634
2,952
3,355
3,736
4,034
4,556
4,825
5,363
3,539
4,893
Provisions (incl. deferred taxes)
2,631
2,932
3,150
3,568
3,963
4,172
4,958
4,641
4,726
5,120
Reserves (incl. currency conversion difference)
We are committed to the goal
of serving humankind through
new drugs and therapies. page 62
Minority interests
60 Our business
Human Pharmaceuticals
64 Highlights Branded Prescription Medicines*
67 Highlights Generic Prescription Medicines
68 Highlights Consumer Health Care
Liabilities (incl. deferred charges)
1,249
1,248
1,622
1,913
2,145
1,902
2,235
1,841
2,206
1,811
Total liabilities
3,880
4,180
4,772
5,481
6,108
6,074
7,193
6,482
6,932
6,931
Total liabilities and equity
6,514
7,132
8,127
9,217
10,142
10,630
12,018
11,845
10,471
11,824
Product Supply and Industrial Customer
74 Biopharmaceuticals
Product supply and
Industrial Customer
76 Pharmaceuticals Production
78 Pharma Chemicals
79 Manufacturing excellence in our centre for global animal health vaccines
Animal Health
81 Highlights Animal Health
84 Samples of the product portfolio
106 Consolidated Financial Statements 2008
108 Overview of the major consolidated companies
110 Consolidated balance sheet
Animal Health
With innovative veterinary
medicines that accommodate the
needs of both man and animal,
we are a reliable partner for ­animal
owners and veterinarians. page 80
We produce drugs for our own Human
­Pharmaceuticals business in a globally
coordinated production network.
Furthermore we offer customised
manufacturing services to our indus­trial
customers. page 70
Summary of selected financial data
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
Net sales
5,086
6,188
6,694
7,580
7,382
8,157
9,535
10,574
10,952
11,595
Operating income
655
800
980
1,082
901
1,372
1,923
2,140
2,100
1,980
Operating income as % of net sales
12.9
12.9
14.6
14.3
12.2
16.8
20.2
20.2
19.2
17.1
Income after taxes
320
379
401
551
537
908
1,514
1,729
1,812
1,428
Income after taxes as % of net sales
6.3
6.1
6.0
7.3
7.3
11.1
15.9
16.4
16.5
12.3
Return on shareholders’ equity (in %)
13.8
14.4
13.6
16.0
15.0
23.1
34.2
37.4
35.0
42.2
Equity ratio (in %)
40.4
41.4
41.3
38.3
37.9
41.0
38.4
43.7
32.2
39.8
Cash flow
111 Consolidated profit and loss statement
737
791
1,117
1,049
1,059
1,430
2,069
2,317
2,392
1,997
Financial funds
1,055
1,094
1,645
2,645
3,516
4,015
4,585
3,934
2,581
2,932
Personnel costs
1,527
1,749
1,916
2,175
2,252
2,443
2,671
2,836
2,886
3,004
30.5
29.9
28.0
26.8
26.4
25.9
34,221 35,529
37,406
38,428
39,800
41,300
112 Cash flow statement
Personnel costs as % of net sales
113 Statement of changes in group equity
Average number of employees
114 Notes to the consolidated financial statements
Research and development costs*
132 Auditor’s Report
R&D as % of net sales
Flap Comparison of balance sheets / financial data 1999–2008
* The patient reports are authentic reports which refer to personal
experience only. Please note that other patients may experience
different treatment results. Individual treatment regimes have always
to be discussed between patient and physician case by case.
28.3
28.6
28.7
27,325
27,980
31,843
826
968
1,019
1,304
1,176
1,232
1,360
1,574
1,900
2,109
16.2
15.6
15.2
17.2
15.9
15.1
14.3
14.9
17.3
18.2
Investments in tangible assets
377
497
548
634
516
427
532
596
654
665
Depreciation of tangible assets
256
288
305
340
354
377
439
419
432
453
* As���������������������������������������
of the year 2008, costs for phase IV clinical
����������������
trials
are included in R&D costs, among other expenses.
The 2007 figure was adjusted accordingly.
please turn over
30.0
26,448
Financial Highlights
Boehringer Ingelheim group of companies
2008
2007
change
11,595
10,952
6 %
Europe
33 %
33 %
Americas
48 %
50 %
Asia, Australasia, Africa
19 %
17 %
96 %
96 %
4 %
4 %
Research and development
2,109
1,900
11 %
Personnel costs
3,004
2,886
4 %
41,300
39,800
4 %
Operating income
1,980
2,100
- 6 %
Operating income as % of sales
17.1%
19.2 %
Amounts in millions of EUR, unless otherwise indicated
Net sales
by region
by business
Human Pharmaceuticals
Boehringer Ingelheim
Animal Health
Annual Report 2008
Income after taxes
Annual Report 2008
www.boehringer-ingelheim.com
Average number of employees
1,428
1,812
12.3 %
16.5 %
4,703
3,372
42.2 %
35.0 %
1,997
2,392
-17 %
Investments in tangible assets
665
654
2 %
Depreciation of tangible assets
453
432
5 %
Income after taxes as % of sales
Shareholders’ equity
Return on shareholders’ equity
Cash flow
-21 %
39 %
Value through Innovation
Value through Innovation
Top 5 products — Prescription Medicines
30234/03/09
Net sales 2008
nopq
Top 5 products — Consumer Health Care
in millions of EUR
change
Net sales 2008
in millions of EUR
change
spiriva®
2,070
+16 %
micardis®
1,219
+15 %
dulcolax®
134
+7 %
mucosolvan®
125
+7 %
flomax®/alna®
pharmaton®
1,075
+5 %
115
+21 %
mirapex®/sifrol®
752
+17 %
buscopan®
99
+24 %
combivent®
553
-15 %
zantac®
92
-17 %